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PREFACE 
 
The property of an object to be distinguishable from its mirror image, the chirality, has intrigued 
scientists, and distinctively chemists, since the earlier studies of Pasteur on the tartrate crystals. 
The term "chirality" is derived from the Greek, χειρ, "hand", the most notorious chiral object. 
 
In nature many biologically active molecules are chiral, and often form homochiral groups. A 
system is homochiral if all the constituent molecules feature the same chiral form. In biology, 
homochirality is commonly observed in aminoacids, that present L- chirality, and sugars, that are 
mostly D-enantiomers. Consequently, nucleosides, the building blocks of DNA and RNA, that are 
composed by D-ribose and D-deoxyribose, are homochiral. The origin of this phenomenon, that is 
the breaking mirror-symmetry, is not clearly understood and is subject of much debate. Most 
scientists believe that Earth life's "choice" of chirality was purely random, and that possible 
carbon-based life forms elsewhere in the universe would exist with both the chiral forms. However, 
there is some suggestion that early aminoacids would have formed in comet dust. In this case, 
circularly polarized radiation might be the cause for the selective development of one chirality of 
aminoacids, leading to a selection bias, which ultimately resulted in all life on Earth being 
homochiral. 
Generally, biochemical pathways involve just one enantiomer of a chiral molecule. In 
particular, in living systems just one of the two enantiomers take part in metabolic cycles, while 
the other is ignored and may even be dangerous. This is true especially for drugs. One of the most 
famous cases of toxicity is given by thalidomide (Figure 1), a racemic antiemetic approved and 
marketed in 1956. While (R)-enantiomer is a sedative, the (S)-enantiomer has teratogenic effects. 
In the early sixties, the use of medications during pregnancy was not strictly controlled, and drugs 
were not thoroughly tested for potential harm to the fetus1. Thousands of pregnant women took 
the drug to relieve their symptoms. At the time of the drug's development, scientists did not believe 
any drug taken by a pregnant woman could pass across the placental barrier and harm the 
developing fetus. Indeed, soon appeared reports on abnormalities in children born form mothers 
who assumed thalidomide during pregnancy. Hence, while initially considered safe, the drug 
proved to be responsible for teratogenic deformities in children, if assumed by the mother prior to 
the third trimester of pregnancy. In November 1961, thalidomide was taken off the market due to 
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massive pressure from the press and public opinion. Experts estimate that the drug thalidomide led 
to the death of approximately 2,000 children and serious birth defects in more than 10,000 children. 
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(S)-thalidomide (D)-thalidomide
 
Figure 1: Enantiomers of thalidomide. 
 
These side effects observed in thalidomide therapy are associated with its interaction with the 
cellular biological systems. Indeed, at the molecular level, chirality often has a profound impact 
on recognition and interaction events and has thus a relevant role in biochemistry and 
pharmacology. In fact, the biomolecular recognition is mostly based on the conformation, 
structural order and chirality of molecules. For example, madangamine A (1, Figure 2), a chiral 
bioactive marine sponge alkaloid isolated for the first time by Andersen and co-workers in 19902, 
with his unique structure and conformation has shown significant in vitro cytotoxic activity against 
a large number of tumour cell lines3.  
Enzymes, which are chiral structures, often distinguish the two enantiomeric forms of a chiral 
substrate. For example, L-forms of aminoacids tend to be tasteless, whereas D-forms tend to taste 
sweet. Spearmint leaves contain the L-enantiomer of the chemical carvone or R-(–)-carvone and 
caraway seeds contain the D-enantiomer or S-(+)-carvone4. These smell dissimilar to most people 
because our olfactory receptors also contain chiral molecules that respond differently in the 
presence of different enantiomers. 
Distinction between different enantiomers is not a general rule in biological processes, as 
witnessed by some important drugs targeting chiral biological macromolecules. 
For example, 3TC (lamivudine, 2) and FTC (emtricitabine, 3), two chiral antiviral nucleosidic 
agents approved by FDA in drug therapies against AIDS, are recognized and phosphorylated by 
the human deoxycytidine kinase independently from their chirality. The picture changes when 
looking at the deoxycytidine deaminase catalysed deamination. Indeed, this strictly 
enantioselective enzyme5 does recognize 3TC and FTC (both L- enantiomers) but is inactive 
toward their D-enantiomers (Figure 2).  
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Figure 2: Bioactive chiral drugs. 
 
The enzyme substrate interaction is even more complicated and may result in a better fitting of 
the active sites of the enzymes by those enantiomers that are not the natural substrates. For 
example, although glycosides belonging to D-series are the natural substrates for all glycosidases 
(except L-fucosidases), an L-enantiomer could own a structure that fits better the active site.  
 
The iminosugars are an important class of glycosidase inhibitors and are witnessing a great 
interest as potential therapeutic agents. An example is given by deoxy-L-allonojirimycin (4), a 
much better inhibitor of α-D-mannosidase than deoxy-D-mannojirimycin6 (Figure 3).  
 
 
Figure 3: Glycosidase iminosugar inhibitors. 
 
In light of these findings, in the last decades the development of new methodologies for the 
enantioselective synthesis of chiral compounds has experienced a huge evolution, carrying this 
topic from the status of a curiosity to a central issue in academia and in the life science industry.  
In chemical synthesis, much effort has been directed towards developing asymmetric synthesis 
strategies that yield product molecules with a significant excess of either the left-handed or the 
right-handed enantiomer. This is usually achieved by making use of chiral auxiliaries or catalysts 
that influence the course of a reaction, with the enantiomeric excess (ee) of the product linearly 
related to the ee of the auxiliary or catalyst used. In recent years, however, an increasing number 
of asymmetric reactions have been documented where this relationship is nonlinear7, suggesting 
the existence of effects that can lead to "asymmetric amplification". Theoretical models8 have long 
suggested that autocatalytic processes can result in kinetically controlled "asymmetric 
amplification", a prediction that has now been verified experimentally9 and rationalized 
mechanistically10 in the case of autocatalytic alkylation reaction. It was observed that such 
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"asymmetric amplification" could explain the development of high enantiomeric excess in 
biomolecules from a presumably racemic prebiotic world. 
 
In this context, this thesis is focused on the study of the central role of chirality in different kind 
of molecular structures; in particular, new synthetic pathways have been developed to improve the 
synthesis of already existing drugs, exploring at the same time the relationship between the 
chirality and the pharmacological properties of these compounds. Moreover, new enantiomeric 
systems have been synthetized and their pharmacological properties will be tested to verify the 
potential bioactivity and use as drugs.  
The thesis is organized in three major sections focusing on the different molecule typology 
investigated (nucleosides, iminosugars, alkaloids). The studies on nucleosides and iminosugars 
have been carried out at the department of Chemical Sciences of University of Naples “Federico 
II”, while the synthesis of alkaloids has been accomplished at the department of Organic Chemistry 
of the Faculty of Pharmacy of the University of Barcelona.  
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1. INTRODUCTION 
 
 
Development of antiviral drugs entails combined competences in chemistry and biology. 
Nucleoside analogues (NAs) can play the role of antiviral and anticancer prodrugs owing to their 
ability of mimicking natural nucleosides in structural and functional terms. Consequently, they can 
interact with viral and/or cellular enzymes and inhibit critical processes in the metabolism of 
nucleic acids, such as the binding to host human cells1, the transcription of genomic RNA2 or the 
gene expression3. 
For this reason, NAs have been the most representative antivirals therapeutically adopted over 
the last decades and a large plethora of strategies for their synthesis has been surveyed. They play 
a prominent role among the drugs currently adopted against acquired immunodeficiency syndrome 
(AIDS). In particular, they work by interacting with human immunodeficiency virus type-1 reverse 
transcriptase (HIV-1 RT)4, the viral RNA-dependent DNA polymerase. The inhibitory action 
towards HIV-1 replication is dependent on the following stages: 1) the cellular uptake of the 
analogue, 2) its phosphorylation mediated by cellular kinases, 3) the extent of competitive 
inhibition achieved, and 4) its binding to RT and subsequent incorporation into elongating viral 
DNA5. For this reason, the design and the synthesis of these active NAs has always been a 
challenge for chemist and biologist, also in view of the virus ability to develop easily a drug 
resistance. 
 
 
1.1. HUMAN IMMUNODEFICIENCY VIRUS AND ACQUIRED 
IMMUNODEFICIENCY SYNDROME (HIV/AIDS) 
 
Over the last decades new therapies for acquired immunodeficiency syndrome (AIDS) have 
been developed, providing much improved tools in the treatment of this pandemic disease. 
Unfortunately, even nowadays there is not a definitive therapeutic protocol and in 2014 AIDS still 
caused an estimated 1.2 million fatalities with about 36.9 million people infected by human 
immunodeficiency virus (HIV) worldwide6. At present, there are more drugs approved for the 
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treatment of HIV than for all other viral infections collected together. In absence of an effective 
vaccine, these drugs are the only therapeutic tools available for the treatment of human 
immunodeficiency virus type 1 (HIV-1) infections. Unfortunately, these drugs cannot heal HIV 
infections, so that drug therapy, once initiated for a patient, must be continued all life long. This 
represents a demanding limitation, and anti-HIV drugs are thereby required to be relatively 
nontoxic so to be used in a long-term therapy7.  
AIDS is caused by human immunodeficiency virus, a highly mutable lentivirus roughly 
spherical of 120 nm, a member of retrovirus family Retroviriadae, whose genome is encoded in 
RNA (Figure 1.1).  
 
 
Figure 1.1: HIV virus. 
 
Two copies of positive single-stranded RNA are present in the virus; they encode nine genes of 
the virus and are coated by a conical capsid made of 2,000 copies of the viral protein p24. The  
RNA strands are bound to nucleocapsid proteins, p7, and some enzymes necessary for the of the 
virion development: reverse transcriptase (RT), ribonuclease (RNase), proteases (PR) and 
integrase (IN). The reverse transcriptase, an enzyme found just in retroviruses, is the most 
important therapeutic target in AIDS treatment. RT transcribes retroviral RNA into DNA, which 
is then integrated into the host genome and expressed by the infected host cell under the control of 
viral genes. The viral RNase catalyzes the degradation of RNA into smaller fragments after the 
transcription into viral DNA mediated by RT. PR is essential for maturation and infectivity of the 
virus. Indeed, budded, immature viral particles possess catalytically inactive protease, and this 
immature form is not infective8. IN is instead involved at the stage in which viral DNA is inserted 
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into the host chromosomal DNA, an essential event for HIV replication. This is an irreversible 
step causing the cell to be a permanent carrier of the viral genome (provirus). 
HIV has the 5'-gag-pol-env-3' gene organization typical of other retroviruses9. Gag, pol and env 
are three major genes encoding major structural proteins and essential enzymes: gag encodes 
proteins of the virion interior; pol (pol, polymerase) encodes viral enzymes; env (envelope) 
encodes the virion glycoproteins. The integrity of the virion particle is ensured by a matrix 
composed of the viral protein p17 surrounding the capsid. The matrix is in turn surrounded by the 
viral envelope, featuring a lipid bilayer (taken from the membrane of the host cell), proteins from 
the host cell, and a few copies of HIV Envelope protein. In particular, outside of the membrane 
are exposed several caps composed of three copies of a glycoprotein (gp) known as gp120, 
anchored to the envelope through a stem composed of three gp41 copies. The Envelop protein is 
responsible for the viral attack to the target cells, the fusion of the viral envelope with the cell 
membrane, and the release of the viral content into the invaded cell. Overall, these events represent 
the start of the infectious cycle, and not casually the Envelope protein is a major target for vaccine 
efforts addressed against HIV. 
HIV is highly capable of both evading the host immune system and developing resistance to all 
available drugs10. This is a consequence of the error amenability of HIV replication combined with 
the rapidity of this latter process. Consequently, the only way to stop the development of resistance 
is to block completely viral replication; this, in turn, stops the evolution of resistance. 
The currently approved anti-HIV drugs can be divided into seven groups: nucleoside reverse 
transcriptase inhibitors (NRTIs), nucleotide reverse transcriptase inhibitors (NtRTIs), non-
nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors 
(FIs), co-receptor inhibitors (CRIs), and integrase inhibitors (INIs). Current treatments are 
typically involving a combination of three drugs, and nowadays AIDS can be regarded as a 
chronic, manageable disease11 after a long period in which a high mortality rate was sadly 
associated with the diagnosis of this disease. Of the approved drugs, most target the reverse 
transcriptase and the protease.  
 The earliest drugs developed in the fight against AIDS were NRTIs; specifically, they 
terminate further insertion of nucleotides into the elongating viral DNA chain carried out by the 
enzyme reverse transcriptase. The favourable effect of these drugs in AIDS patients has confirmed 
the importance of inhibiting RT, and led to the development and clinical use of another class of 
RT inhibitors that are not nucleosides, the NNRTIs. NNRTIs inhibit RT by binding to an allosteric 
site of the enzyme. Finally, the intense effort by scientists covering a wide spectrum of disciplines 
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has produced the other distinct mechanistic class of drugs in the fight against AIDS. These drugs 
have been designed to block the action of the PR, and their synergy with RT inhibitors has brought 
to the market place new and efficacious combination therapies for the treatment of this disease. 
Successful development of PR inhibitors as drugs was based on the early comprehension of its 
pivotal role in viral maturation as well as its structure and function. Indeed, many reviews have 
been published on the protease and the discovery and development of its inhibitors12. Furthermore, 
a new drug, raltegravir, which targets the IN, has recently been approved and shows good efficacy 
for resistant HIV infections13. 
However, the use of these drugs has been relatively limited by their toxicity14, drug resistance 
insurgence15, and more worryingly, the inherent resistance of some newly HIV-infected patients 
even to the currently approved AIDS treatments16. Combination of these issues with undesired 
side effects, and a possible poor tolerability of the drugs strongly spurs the research for new anti-
HIV agemts with an acceptable toxicity and resistance profile and, more importantly, with novel 
mechanisms of action.  
. 
 
1.1.1. HIV LIFE CYCLE 
 
Before explaining the mechanism of action of these antiviral drugs, the HIV life cycle have to 
be outlined in few crucial steps, as summarized in Figure 1.2.  
The first step is the specific interaction between the virion glycoprotein gp120 on the outer 
membrane and the CD4 (cluster of differentiation 4) receptor on the host cell surface. This reaction 
cause a change of conformation, allowing the interaction of gp120 with the chemokine coreceptor 
CXCR4 or CCR5. This is then followed by further conformational changes that expose a fusogenic 
peptide (gp41), which anchors into the host cell membrane. Once the viral envelope and cell 
membrane have fused, the virion is decapsidated releasing the viral RNA (the virion has two copies 
of a single-stranded RNA genome and viral proteins) into the host cell’s cytoplasm.  
18 
 
Figure 1.2: HIV life cycle. 
 
The viral RNA is transcribed to viral double-stranded DNA with the reverse transcription. This 
process is catalysed by the reverse transcriptase, a RNA-dependent DNA polymerase, which is 
encoded by the viral genome. RT exhibits enzymatic activity in two ways: 1) it can act as a DNA 
polymerase, copying either a DNA or an RNA template; 2) it can serve as a RNase H, cleaving 
RNA when this latter is incorporated into an RNA/DNA duplex. Both these activities bring to the 
conversion of RNA into a double stranded linear DNA, a process occurring in the cytoplasm of 
the infected cell. As DNA synthesis proceeds, RNase H degrades the RNA strand. Upon 
completion of DNA synthesis, the produced linear double-stranded viral DNA is translocated to 
the nucleus where it is inserted into the host genome by integrase (IN). This inserted DNA copy, 
called a provirus, is the source of both viral genomic and viral messenger RNAs, which are 
generated by the host DNA-dependent RNA polymerase. RT is endowed with all enzymatic 
activity the necessary for the conversion of viral RNA into DNA; nonetheless it can be helped for 
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the goal by other viral proteins (notably the nucleic acid chaperone nucleocapsid, and perhaps IN), 
and probably some cellular factors. After transcription (helped by regulatory proteins tat and rev, 
which are themselves viral gene products) and translation into viral proteins using the cells’ 
apparatus, the assembly of the gag and gag-pol polyproteins occurs near the cell membrane17,18. 
During viral assembly, two copies of single-stranded viral RNA are incorporated into the virion, 
which then buds off from the cell, taking with it part of the host cell membrane. Soon after budding, 
viral protease cleaves the gag-pol polyprotein to generate a mature, functional virion18.  
A question arises, why virions contain two copies of the viral RNA genome instead of one, if 
in theory, the reactions could be carried out with only one copy of the viral RNA genome The 
answer is that, with only one copy of the viral RNA in a virion, a single break in the RNA would 
be fatal, as the synthesis of a complete DNA copy would be prevented. Indeed, if there is a second 
copy of the RNA, and minus-strand DNA synthesis is blocked by a break in the RNA template, 
synthesis can be continued if minus-strand DNA synthesis is transferred to the second RNA 
genome. In fact, with two copies of genomic RNA present, a complete DNA copy can be made 
even when both RNA genomes are extensively nicked, unless both RNA copies are nicked at the 
same site. If a virion is generated by a cell bearing only one integrated DNA genome, the two RNA 
copies will be identical (unless RNA polymerase makes an error), and the fact that, during minus-
strand DNA synthesis, RT often shifts back and forth between the two RNA templates will have 
no significant consequence. However, if a host cell contains two different integrated viral DNA 
genomes, then virions can be produced that contain two related RNA genomes that have different 
sequences. This sets the stage for the generation of viral recombinants. If RT makes a double-
stranded viral DNA by copying from two different RNA genomes, the resulting DNA will contain 
sequences that are derived from both of the parental genomes. In HIV-1, recombination during 
reverse transcription is a routine, rather than unusual, process. This can have important 
consequences. For example, recombination can lead to the generation of viruses that are resistant 
to multiple drugs from parental viruses that are each resistant to only a single drug. 
Generally, antiviral drugs could be targeted at either viral proteins or cellular proteins. The 
former strategy provides more specific and less toxic compounds, albeit with a limited spectrum 
of activity and a higher amenability to induce viral drug resistance. The latter strategy, instead, 
affords anti-HIV drugs with a broader activity spectrum and a lower resistance, but a higher 
probability of toxicity17. 
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1.2.   NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS) 
 
As seen above, reverse transcriptase is essential in the replicative cycle of retroviruses, because 
it synthesizes the proviral DNA, which will then be integrated into the host cell genome and passed 
on to all of the progeny cells. The substrate (dNTP) binding site of HIV reverse transcriptase turned 
out to be an attractive target for nucleosidic HIV inhibitors. In fact, the first anti-HIV drug that 
was approved in 1987 for the treatment of AIDS was the nucleoside reverse transcriptase inhibitor 
3’-azido-2’,3’-dideoxythymidine19 (zidovudine, ZDV or AZT, I), which is a nucleoside analogue 
that inhibits the HIV reverse transcriptase. In the following years the research has been focused on 
the synthesis of other nucleoside-based compounds with good inhibitory activities of RT. For this 
reason, six more NRTIs, 2’,3’-dideoxynucleosides, have been identified and approved by the Food 
and Drug Administration (FDA) for treating HIV patients: 2′,3′-didehydro-2′,3′-
dideoxythymidine20 (stavudine, d4T, II), 2′,3′-dideoxycytidine20 (zalcitabine, ddc, III), 2′,3′-
dideoxyinosine21 (didanosine, ddI, IV), (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-
yl]-2cyclopentene-1-methanol22 (abacavir, ABC, V), (-)-2′,3′-dideoxy-5-fluoro-3’-thiacytidine23 
(emtricitabine, FTC, VI), and (-)-2′,3′-dideoxy-3′-thiacytidine24 (lamivudine, 3TC, VII) (Figure 
1.3).  
 
  
Figure 1.3: Zidovudine (I), stavudine (II), zalcitabine (III), didanosine (IV),  
abacavir (V), emtricitabine (VI), lamivudine (VII). 
 
To overcome insurgence of virus drug resistance, they were also used in combination of two or 
three, but unfortunately even in combination they proved unable for a long term suppression of 
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viral activity and patients inevitably died25. To distinguish new advanced therapeutic approaches 
from this early anti-retroviral therapy (ART), the term highly active anti-retroviral therapy 
(HAART) was coined. The HAART relies on the use of multiple drugs acting on different viral 
targets. In 1996, sequential publications in The New England Journal of Medicine by Hammer and 
colleagues26 and Gulick and coinvestigators27 pointed out the beneficial effect of the combination 
of two NRTIs with the protease inhibitors. This concept of three-drug therapy quickly entered the 
clinical practice and proved successful within short times, with a 60% to 80% decline in rates of 
AIDS, death, and hospitalization28 
These nucleosides are classified according to the structural differences with the natural 
substrates. In particular, they are divided in three different groups featuring: 1) modifications in 
the sugar moiety, 2) modifications in the nucleic base moiety and 3) modifications in both the 
sugar and base moieties. Generally, the main modifications are the configuration inversion of 
carbinol sites, their elimination (leading to dideoxy- or dideoxy-didehydro-nucleosides), their 
substitution or refunctionalization, or cleavage of the sugar ring (leading to acyclic nucleosides). 
Other structural modifications have also been attempted such as replacement of the endocyclic 
oxygen with a methylene group or a sulfur atom, transposition of the endocyclic heteroatom and/or 
additional insertion of a second heteroatom in the sugar moiety. 
NRTIs are prodrugs; in order to serve as chain terminators in the reverse transcription 
(RNA→DNA), they need to be phosphorylated inside the host cell to their triphosphate 
derivatives29 under the agency of three kinases. As all NRTIs follow the same inhibition pathway 
against HIV, an example of inhibitory mechanism is illustrated only for VII (Figure 1.4)17 . 
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Figure 1.4: Mechanism of phosphorylation for lamivudine (VII). 
 
Lamivudine (VII) is sequentially phosphorylated by deoxycytidine kinase, deoxycytidine 
monophosphate kinase and nucleoside diphosphate kinase to form the monophosphate, 
diphosphate, and the active triphosphate derivative of VII, respectively (for more informations on 
kinases, an interesting review has been published by Cellular and Molecular Life Sciences30).  
All NRTIs are analogs of normal nucleosides, but not always NRTIs prove to be good substrates 
for the cellular kinases31. For example, low amounts of AZTTP are accessible because of the 
limited addition of the second and third phosphate32. However, for other NRTIs, the addition of 
the first phosphate is the limiting step in the overall metabolic pathway leading to the active 5′-
triphosphate metabolites. Poor phosphorylation at the nucleoside-kinase level can account for the 
low anti-HIV activity displayed by some dideoxynucleoside analogues (for example, 2′,3′-
dideoxyuridine) under conditions in which other derivatives are active. This issue has spurred the 
search of 2′,3′-dideoxynucleoside-5′-monophosphate pro-drugs prone to be elaborated in the host 
cell to the corresponding 5′-di- and 5′-triphosphate derivatives, in a strategy aimed at overcoming 
the initial nucleoside-kinase dependency. 
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The active triphosphate moiety is then incorporated into the growing DNA by cellular DNA 
polymerases and it causes the termination of the elongation of the growing DNA double strand. 
This happens because all NRTIs lack the 3′-hydroxyl group; therefore, they prevent the 
incorporation of the incoming nucleotide. A possible mechanism underlying the viral resistance is 
likely based on a pyrophosphorolysis repair reaction, removing the chain-terminating residue 
through a process that is substantially the reverse of the transcriptase-catalysed elongation17. 
 Besides the seven NRTIs approved so far (Figure 1.3), further six derivatives advanced to 
either phase II or phase III clinical trials (Figure 1.5): apricitabine33 (VIII), racivir34 (IX), 
amdoxovir35 (X), elvucitabine36 (XI), reverset37 (XII) and alovudine4 (XIII).  
 
 
Figure 1.5: NRTIs currently undergoing either phase II or phase III of clinical trials. 
 
Compound VIII is the most advanced in clinical trials, showing potent anti-HIV activity both 
in vivo38 and in vitro39, and probably FDA will approve it for clinical use soon. Racivir (IX) is a 
50:50 mixture of VI and its enantiomer, and possesses a high anti-HIV activity in vivo34 and in 
vitro40. Others compounds are showing an interesting potent activity in vitro, alone or in 
combination with other NRTIs, also against wild-type and HIV resistant to several other 
nucleoside analogues41.  
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1.3. L-NUCLEOSIDES: LAMIVUDINE AND EMTRICITABINE 
 
Enzymes are enantiomerically pure catalysts largely responsible for the conservation of 
chirality in living organisms. Enzyme-catalyzed reactions are generally highly stereoselective and 
often their kinetic outcome is strongly dependent by the chirality of the substrates: for instance, 
many enzymes are selective towards D-nucleosides and L-aminoacids. The enantioselectivity in 
enzymatic catalysis has been exploited in organic synthesis, for example in kinetic resolution of 
racemic mixtures as well as in the synthesis of chiral building blocks from achiral precursors. 
However, it was probed that the selectivity of enzymes used in synthesis with large series of 
substrate is not so strict, depending on the structure of the candidate substrate42. For this reason, 
the conviction that enzymes catalyze the transformation, for example, of just D-nucleosides and 
their analogues is absolutely wrong.  
L- and D-nucleosides are (of course) displaying identical physical and chemical properties with 
the exception of optical rotation. However, the pharmacological properties in chiral environment 
can be differentiated for each isomer. The origin of these differences may be rooted in: 1) delivery 
of nucleosides into the cells, 2) anabolic and catabolic enzymes that act on these compounds, 3) 
interaction with the viral and/or cellular target enzymes.  
L-nucleosides have an inverted configuration at all chiral centers, preserving the β-orientation 
(cis) of the nucleobase and the 4′-hydroxymethyl group. Atom at the position X, R1 and R2 may 
be oxygen, methylene group, sulfur or another single heteroatom (Figure 1.6).  
 
 
Figure 1.6: D- and L-nucleosides. 
 
Although the first synthesis of L-nucleoside was reported in the 1960s43, a little interest has 
been addressed to L-nucleosides until the emergence of 3TC. Belleau et al. first described the 
synthesis and anti-HIV activity of an unusual nucleoside analog, (±)-2,3′-dideoxy-3′-thiacytidine 
(BCH-189, XIV)44, a compound in which the 3′-carbon with the hydroxyl function of the furanose 
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sugar moiety is replaced by a sulfur atom. Subsequently, it was found rather surprisingly that the 
L-isomer of BCH-189 (3TC, VII) was more powerful against HIV-1 and less toxic than its D-
isomer (XV)24,45 (Figure 1.7). 3TC and its D-enantiomer were found to possess comparable anti 
HIV-2, activities. 3TC displays a poor cytotoxicity, whereas (+)-BCH-189 proved to cytotoxic 
(IC50 = 2.7 µM) against human PBM cells. 
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Figure 1.7: Isomers of BCH-189. 
 
Since then, the synthesis and the biological evaluation of a large array of L-nucleosides analogs 
highlighted the importance of chirality and its influence on antiviral activity of the L-nucleosides. 
These properties are not always predictable: L-AZT, the L-isomer of I was synthesized using L-
arabinose as a starting material46. The anti-HIV activity of L -AZT was reported to be about 10000 
times lower than that of AZT. 
However, the most surprising aspect in the related subject lies in some instances of cellular 
kinases capable of phosphorylating the L-nucleosides to their triphosphates, and thereby endowing 
them with various biological activities. For example, it was found that deoxycytidine kinase is the 
enzyme responsible for the monophosphorylation of 3TC47 and that 3TC is a better substrate for 
this enzyme than the D-enantiomer48. Deoxycytidylate kinase and nucleoside diphosphate kinases 
are the enzymes that phosphorylate the monophosphate of 3TC to its di- and triphosphate, 
respectively. 3TC is resistant to deamination by deoxycytidine deaminase, whereas the D-
enantiomer is deaminated to 2′-deoxy-3′-thiauridine by the same enzyme49. The half-life of 3TC 
triphosphate was 12–15.5 h in mock-infected cells, and 10.5–13 h in HIV-1-infected cells, whereas 
a significantly shorter half-life was recorded with the D-enantiomer (3.5 h in mock-infected cells 
and 5–7 h in HIV-1 infected cells)50. The better substrate specificity for deoxycytidine kinase, the 
resistance to deamination as well as the longer half-life of the triphosphate of 3TC may explain 
the observation that 3TC is more potent than its D-enantiomer against HIV-1 in vitro.  
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(−)-2′,3′-dideoxy-5-fluoro-3′-thiacytidine (FTC, VI), a 5-fluoro analog of 3TC, also showed 
potent antiretroviral activity against HIV- 1 and HIV-234 (Figure 1.8). 
 
 
Figure 1.8: Isomers of FTC and their activity. 
 
Like 3TC, (−)-β-L-FTC exhibits more potent anti-HIV-1 and HIV-2 activity than its D- 
enantiomer respectively in PBM cells and in vitro. It is also significantly less toxic than D-FTC, 
and both enantiomers are less cytotoxic than both BCH-18951: in fact, when the triphosphate form 
of emtricitabine (E-TP) was compared with 3TC triphosphate, the activity against mitochondrial 
DNA polymerases (pol γ) of E-TP was 24 times lower than that of 3TC52. As with 3TC, (+)-FTC 
was found to be a suitable substrate for deoxycytidine deaminase, whereas the enantiomer, (−)-
FTC, was resistant to deamination mediated by the enzyme53.   
Biological studies suggested that like 3TC, deoxycytidine kinase, deoxycytidylate kinase and 
possibly nucleoside diphosphate kinases are the enzymes that phosphorylate L-FTC to 
emtricitabine 5′-triphosphate. E-TP is incorporated by RT into the elongating proviral DNA chain, 
causing termination of DNA synthesis because of the impossible incorporation of the next 
nucleotide at the E-TP 3′ position (Figure 1.4)48,54. Both D- and L-enantiomers of FTC 
triphosphates were equipotent inhibitors for RT, but L-FTC proved to be anabolized more 
efficiently and to be a better substrate for the deoxycytidine kinase than the corresponding D-
enantiomer55. Intracellular concentrations of the D- and L-FTC triphosphates were compared 
following incubation with racemic FTC and there were 30 times more L-FTC triphosphate than 
the corresponding D-FTC triphosphate. Therefore, the potent anti-HIV activity of L-FTC and 3TC 
is caused by their selective phosphorylation steps together with the stereoselective deaminations 
of the D- enantiomers56. However, 1:1 racemic FTC (racivir, IX), is in phase II clinical trial and 
probably will be soon approved by FDA for its anti-HIV-1 activity. 
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Unfortunately, both 3TC and FTC could develop rapidly drug resistance. After few weeks of 
initiation of monotherapy, they cause a single point mutation at position 184 of RT57. The point 
mutation causes a replace of methionine by valine or isoleucine (M184V, M184I mutations). As 
expected, this mutation confers cross-resistance to 3TC, but other nucleoside agents retain their 
activity58, so the combination of different antivirals of the HAART can avoid the problem4. 
 
 
1.3.1. PREVIOUS SYNTHETIC APPROACHES TO 3TC AND FTC 
 
The first synthetic approach to (±)-BCH-189 reported by Belleau et al.44 utilized an oxathiolane 
intermediate obtained as a 1:1 mixture of anomers by reaction of benzoyl oxyacetaldehyde (XVII) 
with protected mercaptoacetaldehyde XVIII. The intermediate XIX was then coupled with 
silylated cytosine by TiCl4 promoted reaction to give a 1:1 mixture of α and β nucleosides. After 
separation by chromatography and following deprotection, (±)-BCH-189 (XIV) was obtained 
(Scheme 1.1).  
 
 
Scheme 1.1: First synthesis of racemic BCH-189. 
 
Various approaches for the synthesis of 3TC have been reported, especially in nineties. Liotta 
et al. first reported the synthesis of 3TC using SnCl4 as promoter obtaining the β-anomer as the 
major product (selectivity >300:1), and following the 3TC after enzyme resolution59 (Scheme 1.2).  
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Scheme 1.2: (a) HSCH2CO2H; (b) DIBAL-H; (c) Ac2O; (d) TMS-cytosine/SnCl4 (e) TBAF; (f) enzyme. 
 
Chu and co-workers reported an asymmetric synthesis of the enantiomeric pure isomers of D-
oxathiolane nucleosides (enantiomers of 3TC and FTC included) starting from D-mannose and D-
galactose60 or L-gulose to finally get L-oxathiolane nucleosides (3TC and FTC included) 61,62 using 
TMSOTf (with a low ratio α:β = 1:2) and SnCl4 (Scheme 1.3).  
 
 
 
Scheme 1.3: (a) TsCl; (b) Ac2O; (c) HBr/AcOH; (d) KEX; (e) NH4OH/MeOH; (f) NaIO4; (g) NaBH4; (h) p-TsOH; 
(i) TBDPSCl; (j) p-TsOH/MeOH (k) Pb(OAc)4; (l) PDC; (m) Pb(OAc)4; (n) TMS-cytosine/SnCl4 or TMSOTf; (o) 
NH3/MeOH; (p) TBAF. 
 
Goodyear et al.63 in 1995 did a breakthrough in the synthesis of these oxathiolane derivatives, 
using the menthyl group as inductor of chirality and the TMSI as promoter of the N-glycosylation, 
obtaining a good α:β selectivity of 1:23 (Scheme 1.4).  
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Scheme 1.4: (a) glyoxylic acid hydrate/t-BuOMe; (b) (i) Ac2O/MeSO3H; (ii) recrystallization; (c) (i) (-)-L-
menthol/DCC/DMAP; (ii) recrystallization; (d) (TBDMS)2-cytosine/TMSI; (e) LiAlH4. 
 
After then, several papers and patents then described the synthesis of 3TC and FTC64, but 
another substantial contribution in this field came from the Glaxo-Wellcome group65 in the 
synthesis of the single enantiomer lamivudine. Indeed, condensation of L-menthyl glyoxate 
hydrate XXV with 1,4-dithiane-2,5-diol XX yielded an intermediate (XXVI) that was chlorinated 
with SOCl2. The addition of silylated nucleobase in presence of TMSOTf gave the 3TC precursor 
XXVII (Scheme 1.5). 
 
 
Scheme 1.5: (a) AcOH; (b) SOCl2; (c) TMS-cytosine/TMSOTf; (d) (i) K2HPO4/NaBH4 (ii) recrystallization. 
 
Other chiral precursors66 and chromatographic processing67 have been described. For example, 
5-fluorocytosine can be obtained via direct fluorination of cytosine using trifluoromethyl 
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hypofluorite and fluorotrichloromethane as solvent, or alternatively from fluoroacetic acid68, but 
its production is the step with the largest price. 
A last patent has been published in 2013 by Roy et al.69, where the synthetic strategy is really 
similar to the Glaxo-Wellcome one except for the N-glycosylation, that starts from an acetylated 
intermediate and is promoted by ZrCl4. The obtained β-product is >97% (Scheme 1.6).  
 
 
Scheme 1.6: (a) AcOH; (b) Ac2O; (c) TMS-cytosine/ZrCl4; (d) (i) K2HPO4/NaBH4 (ii) recrystallization. 
 
Every explored strategy presents common drawbacks, in particular in the N-glycosylation step. 
The reaction is promoted by unwieldy and unstable promoters, which involves little reproducibility 
of the reaction, both in terms of yield and stereoselectivity. These two factors are very important 
for the large production of 3TC and FTC and for minimizing their contamination with undesired 
cytotoxic isomers.  
 
 
1.4. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
In spite of all the worldwide efforts, AIDS remains a pandemic disease because the rapid 
evolution of the HIV virus and the development of drug resistance. However, a large number of 
antivirals has been licensed, most of them NRTIs, which can turn in most of cases this disease 
from mortal to chronical. In particular, L-nucleosides represent a good compromise between 
activity and toxicity, for their almost exclusive interaction with RT rather than human DNA 
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polymerase. Within this class of nucleosides, 3TC and FTC are the most representative drugs 
approved by FDA, showing a potent antiviral activity and a low cytotoxicity in vitro and in vivo. 
Their preparation still constitute a challenge for scientist for the difficult of obtaining at the same 
time good yields and stereoselectivity, enclosed to a practical, cheap and safe synthesis. Indeed, a 
new synthetic approach is requested, to avoid the use of unwieldy and unstable promoters of N-
glycosylation and to obtain a higher selectivity.  
More importantly, new anti-HIV agents featuring novel mechanisms of action and capable of 
minimizing the insurgence of resistance are still needed. 
  
32 
 
2. OBJECTIVES AND SYNTHETIC STRATEGY 
 
 
This section of the thesis is addressed to the development of a convenient, cheap, safe and 
stereoselective synthesis of 3TC and FTC, using a stable promoter system in the key N-
glycosylation step. Furthermore, on pursuing the search for new anti-HIV agents able to avoid the 
evolution of resistance, new derivatives of 3TC have been synthesized to be tested for their 
potential biological activity. 
 
The stepwise strategy can be outlined in few critical points: 
• The construction of new 3TC derivatives corresponding to the diastereoisomeric 
sulfoxides obtained from a racemic mixture of lamivudine and its D enantiomer via a 
kinetic resolution (Figure 2.1). 
 
 
Figure 2.1: Construction of sulfoxides of 3TC and its enantiomer. 
 
• The construction of 3TC sulfoxides starting from commercial Zeffix®, in case of an 
unsuccessful kinetic resolution (Figure 2.2). 
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Figure 2.2: Construction of sulfoxides of 3TC starting from commercial drug. 
 
• The synthesis of D enantiomers of 3TC and FTC with the silane/iodine combined 
reagent as the promoter of the N-glycosylation reaction (Figure 2.3). 
 
 
Figure 2.3: Employment of the silane/iodine system in N-glycosylation. 
 
• The construction of D-sulfoxides from the synthetized (+)-BCH-189 (D-isomer of 
3TC) (Figure 2.4). 
 
 
Figure 2.4: Construction of D-sulfoxides. 
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3. RESULTS AND DISCUSSION 
 
 
3.1. CONSTRUCTION OF 3TC DERIVATIVES 
 
As described in the introduction, the NRTIs feature modification in the sugar and/or nucleic 
base moieties to interact with RT and operate as chain terminators in the viral reverse transcription 
reaction (Figure 1.4)17. 3TC (1), in spite of its L-configuration, exhibits potent anti-HIV-1 and 
HIV-2 activity, that is expected to be amplified with structural modifications making it more 
similar to the cytidine (Scheme 3.1). 
 
 
Scheme 3.1: Project of construction of 3TC sulfoxides. 
 
The introduction of an oxygen linked to the sulfur mimics the hydroxyl group attached to 
cytosine C-3′, and could better deceive the RT. At the same time, the impossible condensation 
reaction between the sulfoxide and the phosphate group of other triphosphate nucleotides prevents 
the elongation of the viral DNA chain. The preparation of both the sulfoxides starting from 3TC 
and its enantiomer was planned, considering that the biological activity and the toxicity of 
molecules is not easily predictable and every isomer could be a potential antiviral drug.  
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3.1.1. KINETIC RESOLUTION OF SULFOXIDE RACEMIC MIXTURE 
 
In a previous work of the research group where this section of the thesis was carried out, the 
commercially 3TC (Zeffix®) was oxidized after a protection of the exocyclic amine group of the 
cytosine, to permit the chromatographic separation of the two isomeric sulfoxides. 
Among the numerous existing methods70 of sulfoxidation, the group selected the Kagan71 and 
the Modena72 oxidations. Both methods contemplate the use of diethyl tartrate (DET) and 
titanium(IV) isopropoxide (Ti(Oi-Pr)4) for the asymmetric induction and a hydroperoxide as 
oxidizing agent (in particular, the research group used the cumene hydroperoxide, CuOOH). The 
Kagan method involves a 1:2:1 of Ti(Oi-Pr)4/DET/H2O ratio, with the surprising presence of the 
water that give a strong increase in the optical yield; the Modena method instead contemplates a 
1:4 ratio of Ti(Oi-Pr)4/DET alone, but both the sulfoxidations shows similar results.  
Protected 3TC 7 was oxidized with both D and L-DET under conditions of Kagan and Modena 
trying to mimic the different reactivity of the two enantiomers 7 and 8 with the only D-DET in the 
formation of four stereoisomeric sulfoxides 9, 10, 11, and 12 (Scheme 3.2). 
 
 
Scheme 3.2: Previous work of the research group: stereoselective sulfoxidation of 3TC under Kagan conditions. 
 
Analysis of these results indicated the potential applicability of a kinetic resolution approach 
starting from a racemic mixture of 7 and 8. Indeed, this strategy was supported by combining the 
following observations: 1) the low diastereoisomeric ratio (dr) obtained by treatment of 7 with L-
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DET (4:6) corresponds to that obtainable on exposure of 8 to D-DET; 2) oxidation of 7 with D-
DET is not only more diastereoselective, but is also faster than with L-DET. 
 
The synthesis of racemic mixture of 3TC and its enantiomer started from compound 14, 
previously obtained by the condensation of benzoyl oxyacetaldehyde with 1,4-dithiane-2,5-diol 
(dimeric mercaptoacetaldehyde), in a synthetic route similar to that described by Belleau et al.44 
(Scheme 3.3). 
 
 
Scheme 3.3: Condensation and protection leading to compound 14. 
 
Next step has been the glycosylation of 14 with a protected cytosine (as seen above, the 
exocyclic amine group of the cytosine needs a benzoyl to permit the chromatographic separation 
of isomeric sulfoxides). In the first step of the reaction N,O-bis(trimethylsilyl)acetamide was added 
to the reaction mixture to silylate the nucleic base in order to minimize the undesired O-
glycosylation process competing with desired N-functionalization. Then SnCl4 was added into the 
flask via cannula to serve as the glycosylation promoter (Scheme 3.4). 
 
 
Scheme 3.4: N-glycosylation promoted by SnCl4. 
 
Use of an aged commercial sample of SnCl4, probably for the presence of HCl, led to the 
formation of 15 as a 1:1 α/β mixture of anomers (α refers to the 2,5-trans isomers and β to the 2,5-
cis isomers) in an overall 55% yield (28% for the β-anomer alone). Furthermore, the 
chromatographical separation did not allow a complete separation of the anomeric mixture, and 
just a low percentage of β isomers was recovered, underlining the need of a stable promoter 
system.  
A further attempt was carried out with ZrCl4 as reported by Roy et al.69 but only the starting 
product was recovered, in spite of application of extended reaction times and high temperatures. 
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The deprotection of the hydroxyl moiety was easily achieved in presence of NaOH, affording 
the starting product for the sulfoxidation 16, namely a mixture of nucleosides 7 and 8 (Scheme 
3.5). 
 
 
Scheme 3.5: Basic hydrolysis of benzoyloxy moiety of nucleosides 15. 
 
A large number of sulfoxidation experiments was carried out on 16 (Table 3.1) testing both 
Kagan and Modena methods under a variety of experimental conditions, but unfortunately the 
kinetic resolution gave disappointing results. In fact, the sulfoxides were always recovered as two 
racemic couples (in red in Scheme 3.6), also when the reaction was stopped after a few hours 
(entry 2). The recovered starting product never showed a significant enrichment of either 
enantiomer 7 or 8.  
 
 
Scheme 3.6: Sulfoxidation of racemic mixture 16. 
 
Entries Ti(Oi-Pr)4 
equivalents 
D-DET 
equivalents 
L-DET 
equivalents 
H2O 
equivalents 
CuOOH 
equivalents Temperature (°C) Time 
1 1 2  1 2 -10 to 0 24 h 
2 1 1 1  2 0 to rt 4 h 
3 1 2  1 2 + 2 -10 to rt 8 days 
38 
 
4 1 + 1 4   2 -20 24 h 
5 1 4   2 -20 to 0 6 days 
6 0.5 2   1 -20 to 0 3 days 
7 1  4  2 -20 to 0 2 days 
Table 3.1: Tested conditions for the attempted kinetic resolution via sulfoxidation. 
 
 
The enantiomeric pairs of sulfoxides were hard to separate and for this reason unusable. A 
different strategy was then developed to obtain the desired product. 
 
 
3.1.2. SYNTHESIS OF L-SULFOXIDES 
 
The sulfoxides obtained by the research group during the evaluation of the model system 
previously described belong to the L- steric series, because were obtained from the commercial 
3TC. For this reason, a difficult chromatographic separation was accomplished on about one gram 
of mixture, recovering 50 mg of each isomer, and the sulfoxides 9 and 10 were deprotected in 
presence of a solution of ammonia and methanol 6 M (Scheme 3.7). 
 
 
Scheme 3.7: Deprotection of L-sulfoxides. 
 
Crystallization of the products permitted to obtain 10 mg of each isomer, that will be tested in 
vitro for their antiviral activity. 
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To obtain the D-sulfoxides a total synthesis of (+)-BCH-189 (D-isomer of 3TC) was 
accomplished, with a previous research of a better promoter system for the N-glycosylation. This 
promoter was also tested in the synthesis of D-FTC 
 
 
3.2. SYNTHESIS OF (+)-BCH-189 AND D-FTC: THE EMPLOYMENT OF 
SILANE/IODINE SYSTEM AS A NEW N-GLYCOSYLATION PROMOTER 
 
As seen in the introduction, the most recent and employed methods for the synthesis of 3TC 
and FTC (Glaxo-Wellcome group65, Roy et al.69) involve the use of the menthyl ester group as 
chiral inductor. The new developed synthetic route, unlike the previous ones, takes advantage of 
(+)-menthol instead of the (-)-menthol to obtain the desired enantiomers of the commercial drugs. 
 
 
3.2.1. SYNTHESIS OF ACETYLATED STARTING PRODUCT FOR N-GLYCOSYLATION 
 
The first step of the route is already reported in literature65,69,73 for the synthesis of 3TC and 
FTC, and consists of a condensation between D-menthylglyoxylate and 1,4-dithiane-2,5-diol. The 
reaction was carried out with L-menthylglyoxylate to obtain the enantiomeric products (Scheme 
3.8). 
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Scheme 3.8: Construction of oxathiolane ring. 
 
The condensation lead to the formation of four diastereoisomers (17-20) because the creation 
of two chiral centers, in ratio 35:35:15:15 (where the two most abundant are the trans isomers, as 
determined by NMR). Crystallization in hexane at 0 °C in presence of triethylamine, that permits 
the opening of the new-formed oxathiolane rings and the rapid interconversion of the stereocenters, 
afforded pure hemiacetals 17 and 18 in a 60% overall yield without the need of further 
purifications. These results are in contrast to what described in literature73, where the generation 
of the four diastereoisomers is reported to occur with a different ratio (hemiacetals with R 
configuration at C-2 are present with a 35% rate) and crystallization with hexane and triethylamine 
led to the formation of the 18 alone. This discrepancy has proved to be of little importance, because 
the subsequent acetylation was carried out in presence of pyridine, that promoted a second 
interconversion of the chiral centers and the formation of the four acetylated products in the same 
35:35:15:15 ratio (Scheme 3.9).  
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Scheme 3.9: Acetylation of hemiacetals 17-18. 
 
Crystallization in hexane and triethylamine, carried out at -20 °C for three days, led to the 
formation of the sole desired trans product 22, used as the starting product in the subsequent N-
glycosylation studies. 
 
 
3.2.2. STUDIES OF N-GLYCOSYLATION 
 
On the basis of previous literature, the N-glycosylation system that gave the best results was 
relying on the unstable and expensive TMSI63; on pursuing the search for a cheaper, more stable 
and easier to handle promoter, the efforts in this thesis have been focused on a silane/iodine 
combined system. In particular, two different silanes proved useful for this purpose, triethylsilane 
(Et3SiH) and polymethylhydrosiloxane (PMHS). 
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The combination of Et3SiH and I2, largely explored and used in organic synthesis (especially in 
carbohydrate chemistry), generates in DCM the species Et3SiI, that presents lower but still 
significant reactivity in comparison with TMSI, and HI, otherwise difficult to be obtained in a  
anhydrous form. This system claims a large plethora of applications, including anomeric 
iodination, a reaction that often precedes the introduction of a large number of functional groups74, 
the regioselective debenzylation of densely benzylated polyols, when the removal of the protecting 
group leads to a steric relief75, O-glycosylation, where the combined reagent can activate 
haloacetimidate leaving groups76, or allylic rearrangement of glycals, where the promoter entails 
a catalytic amount of iodine in combination with an excess of silane77 (Figure 3.1). 
 
 
Figure 3.1: Examples of applications of the Et3SiH/I2 system. 
 
In this study a particular interest was focused on the possible replacement of Et3SiH with PMHS 
in the reagent system. This latter is a polymer synthetized for the first time in 1946, but employed 
in organic synthesis only recently; this polysilane is convenient for large-scale application, because 
is less expensive and more stable than other silanes and can be stored for larger periods. In 
combination with iodine, PMHS has been used in a large number of anomeric iodinations, where 
it showed a reactivity similar to Et3SiH. Resulting glycosyl iodides can be quickly converted into 
alternative derivatives without an intermediate chromatographical purification78. In addition, 
PMHS can be employed in reductive processes for its ability to serve as stable hydride donor under 
acidic conditions, avoiding the use of boranes and aluminum hydrides that could cause problems 
of selectivity and the generation of toxic salts as byproducts79. Examples of these applications are 
the reductive dihydroxylation of benzylic alcohols, in combination with Lewis acids of iron80 and 
one-pot reductive amination, in combination with TFA, allowing the alkylation of amines with 
aldehydes and ketones81 (Figure 3.2). 
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Figure 3.2: Examples of synthetic applications of the PMHS. 
 
 
The N-glycosylation studies also explored the effect of the nucleobases protecting group on 
yields and stereoselectivity. For this reason the commercial cytosine, 5-fluorocytosine, 
acetylcytosine and benzoylcytosine have been employed, together with benzylcytosine, 
synthetized with a procedure reported in literature82, and benzoyl 5-fluorocytosine, synthetized by 
an N-benzoylation with BzCl (Scheme 3.10). 
 
 
Scheme 3.10: Synthesis of benzoyl 5-fluorocytosine. 
 
N-glycosylation reaction consists of the iodination of starting acetyl oxathiolane 22 and its 
coupling with a presilylated nucleobase (Scheme 3.11). 
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Scheme 3.11: N-glycosylation reaction. 
 
As detailed below, the explored N-glycosylation methodology generally gave a satisfying β-
selectivity which may be accounted for by the following mechanistic picture. Treatment of starting 
22 with a pre-mixed solution of silane and iodine leads to the formation of an oxonium ion 26, 
stabilized through anchimeric assistance by the menthyl ester function, as confirmed in literature73. 
Iodination then occurs in the most accessible α-face, affording the trans iodinated product 27. In 
a separate flask the nucleobase was silylated with BSA to avoid the participation of either the 
oxygen or the exocyclic amine in the reaction with the oxathiolane ring. Attack of this protected 
base via an SN2 reaction gives the β nucleoside (cis) as final product (28-33) with a small amount 
of the inseparable α (trans) isomer. 
Results of the experiments with the different nucleobases are summarized in Table 3.2. 
 
Entry Silane R base X base Product Yield (%) Selectivitya,b (de,%)  
1 Et3SiH H H 28 98 88  
2 PMHS H H 28 86 88  
3 Et3SiHc Bz H 29 72 95  
4 PMHSc Bz H 29 73 95  
5 Et3SiHd Bz H 29 87 98  
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6 PMHSd Bz H 29 94 99  
7 Et3SiH Ac H 30 95 97  
8 PMHS Ac H 30 80 98  
9 Et3SiHd Bn H 31 62c 86  
10 Et3SiH H F 32 91 94  
11 PMHS H F 32 84 94  
12 Et3SiH Bz F 33 85 98  
13 PMHS Bz F 33 90 99  
Table 3.2: N-glycosylation reaction study.  
aDetermined by 1H NMR analysis (400−600 MHz). bThe structure of β- and α-nucleosides was determined by 
reduction of the menthyl ester group and NMR comparison with literature data61. cSilane/I2 addition to the reaction 
mixture immediately after premixing of the two reagents. dSilane/I2 addition to the reaction mixture carried out 15 
min after premixing of the two reagents. eMixture of regioisomeric N1 and N3 nucleosides (from NMR analysis). 
 
Application of standard conditions to unprotected cytosine (entries 1-2) and 5-fluorocytosine 
(entries 10-11) gave satisfying yields and anomeric selectivity with both Et3SiH and PMHS, 
although lower than with other described results. Conversely, when the cytosine was protected 
with benzoyl group (entries 3-6) a remarkable improvement of selectivity was reported, in 
particular when the addition of the silane/iodine system was carried out after 15 minutes after 
premixing of the two reagents. The trend was confirmed by reaction with acetylcytosine and 
benzoyl 5-fluorocytosine, that displayed the best results in terms of selectivity. PMHS gave 
generally higher selectivity for all the substrates, while Et3SiH afforded better yields except for 
benzoyl cytosines (entries 6 and 13). When cytosine was protected with a benzyl group (entry 9), 
a dramatic decrease of yield and selectivity was reported, with the formation of an inseparable 
mixture of N1 and N3 nucleosides as products. 
Rationalization of these results can be supported by the HSAB theory (Scheme 3.12). 
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Scheme 3.12: HSAB theory applied to the N-glycosylation reaction. 
 
Considering that an equilibrium is established between the oxonium ion and the iodinated 
oxathiolane, the latter being reasonably the prevalent intermediate, the silylated nucleobase can 
attack both the species through an SN2 pathway, leading to the formation of two anomers. Indeed, 
an α nucleoside is obtained starting from the oxonium ion, whereas a β nucleoside derives from 
the nucleobase attack to the β face of the iodinated intermediate. The oxonium ion is a harder 
species than the iodide. As to nucleobases, if an electron withdrawing group (EWG) is present at 
the N-4 position, the N-1 will be electron poorer and, for this reason, softer. These bases will have 
a preference for an attack to the soft iodinated intermediate from the β-face, leading to the desired 
cis nucleoside. Conversely, an electron releasing group (ERG) like the benzyl group makes the N-
1 position harder, leading to a lower β selectivity, as well as a reduced yield. Furthermore, the 
presence of the fluorine atom at C-5 makes the N-1 position even softer for inductive effect, 
resulting in the highest β:α ratio in the attack. 
 
 
3.2.3. REDUCTION OF MENTHYL ESTER GROUP 
 
The last step to obtain (+)-BCH-189 and D-FTC was the reduction of the menthyl group. This 
reaction was easily accomplished with nucleosides bearing an unprotected cytosine, following the 
Goodyear et al.63 procedure, which contemplates the use of LiAlH4 in THF (Scheme 3.13). 
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Scheme 3.13: Reduction of menthyl group with LiAlH4. 
 
The reduction of nucleoside bearing the 5-fluorocytosine did not show satisfying yields, and 
consequently the reaction was accomplished with NaBH4 as described in latest procedures63,65,69, 
obtaining excellent results (Scheme 3.14). 
 
 
Scheme 3.14: Reduction of menthyl group with NaBH4. 
 
When the reduction reactions were carried out on nucleosides with protected cytosines, the most 
interesting substrates, the final products were recovered in low (58% from acetylcytosine) or even 
negligible amounts (<10% from benzoylcytosine). In the light of these results, a new route was 
explored, involving the superheated methanol83 to remove in a first step the protecting group 
bonded with an amide function to cytosine, and then a reduction of the menthyl ester group in 
presence of LiAlH4 or NaBH4 (Scheme 3.15). 
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Scheme 3.15: Reduction of menthyl group with a two-steps reaction involving MeOH and NaBH4. 
 
Following the procedures described by Robins et al.83 that involves MeOH at 100 °C, a large 
amount of epimerization products at C2 was recovered, along with transesterification products 37 
and 38 (where a methoxy group replaces the menthyloxy group). Lowering the temperature down 
to 40 °C and extending the reaction time from one hour to two days, the epimerization and the 
transesterification were reduced (epimerization: at 100 °C 35:37=2.2:1, at 50 °C 35:37=24:1, at 
40 °C 35:37=60:1). The presence of the transesterification products did not affect the final yield, 
because the methyl ester is reduced under the same condition as the menthyloxy moiety. Addition 
to the mixture of LiAlH4 or NaBH4 led to the formation of desired products in a good anomeric 
selectivity (4: β:α > 50:1, 34: β:α > 40:1). 
 
 
3.3. COMING BACK TO THE CONSTRUCTION OF SULFOXIDES 
 
With (+)-BCH-189 in hand, the first step on the route to sulfoxide has been an easy selective 
benzoylation of the exocyclic nitrogen, that was carried out with a temporary protection of the 
oxygen with a silyl group, removed during the work-up of the reaction (Scheme 3.16). 
 
 
Scheme 3.16: Protection of the exocyclic amine with a benzoyl group. 
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Oxidation of 8 was carried out with m-CPBA, being avoided in this case the problem of the 
dynamic resolution of products (Scheme 3.17). 
 
 
Scheme 3.17: Construction of protected sulfoxides. 
 
Unfortunately, the separation of the sulfoxides was not accomplished in spite of many and 
different attempts (flash chromatography, preparative TLC and HPLC were tried). To obtain the 
same results as L-sulfoxides (10 mg of final products), one gram of the mixture of sulfoxides is 
needed, which means that 30 g of menthyl glyoxylate should be employed in the first reaction. For 
this reason this strategy was discarded. 
 
 
3.4. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
The synthesis of the sulfoxide derivatives of 3TC was accomplished and the products will be 
tested for their biological activity. Nevertheless, the high cost of the production of these substrates 
probably will not permit a large scale production, discouraged by the laborious synthesis and low 
yielding isolation observed for the D-enantiomers; on the other hand, in case of especially 
favourable activities and low toxicity, the reported approaches may represent a useful 
methodological reference for designing more effective pathways.  
.The silane/iodine system proved to be an optimal N-glycosylation promoter, and in particular 
the PMHS, for its low cost, stability, reproducibility and easy of handling, has been the reagent of 
choice. This strategy opened a new route to antiviral drugs 3TC and FTC that ensure high 
stereoselectivity and yields. 
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Furthermore, the critical role played by nucleobase protecting groups in influencing yields and 
selectivity of the reactions was unveiled, and a rationalization based on the HSAB theory was put 
forward.  
In addition, an efficient one-pot reduction was developed, allowing the removal under mild 
conditions of both the cytosine protecting group and the menthyl ester moiety, by minimizing the 
epimerization of the reducing chiral centre. Overall, this study sets new perspectives for the 
synthesis of β nucleosides, pointing to the suitable combination of an effective activation system 
(the silane/iodine system), the nature of nucleobase protecting groups and the anchimeric 
assistance provided by the menthyl ester group, linked to the saccharide moiety. 
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4. EXPERIMENTAL SECTION 
 
 
All air sensitive manipulations were carried out under dry nitrogen atmosphere. Solvents and 
all standard reagents were purchased from Sigma Aldrich, Alfa Aesar of VWR and were used 
without further purification. 
Analytical thin-layer chromatography was performed on SiO2 (Merck silica gel 60 F254), and 
the spots were located with ultraviolet radiation, iodine vapor and chromic mixture. 
Chromatography refers to flash chromatography and was carried out on SiO2 (Merck Kieselgel 60, 
230-400 mesh). Drying of organic extracts during workup of reactions was performed over 
anhydrous Na2SO4. Evaporation of solvent was accomplished with a rotary evaporator. NMR 
spectra were recorded at 400 MHz (1H) and 100.6 MHz (13C) (Bruker DRX, Bruker Avance), at 
500 MHz (1H) and 125.7 MHz (13C) (Varian Inova equipped with a VnmrJ 4.0 software) and at 
600 MHz (1H) (Bruker DRX equipped with a CryoProbe), and chemical shifts are reported in 
δ values downfield from TMS or relative to residual chloroform (7.26 ppm, 77.0 ppm) as an 
internal standard. Data are reported in the following manner: chemical shift, integrated intensity, 
multiplicity, coupling constant (J) in Hertz (Hz), and assignment (when possible). The 
determination of β/α ratios in the N-glycosylation reactions was performed by integration of 1H 
NMR anomeric signals (H-5) of each pair of diastereoisomers at the given spectrometer (detection 
limit: down to 10-6 g). Combustion analyses were performed using a CHNS analyzer. Melting 
points are uncorrected and were determined with a capillary apparatus. Optical rotations were 
measured at 25 ± in the stated solvent. [α]D values are given in 10-1 deg cm2 g-1. 
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2-(Benzoyloxymethyl)-5-(4-benzamido-2-oxo-1,2-dihydropyrimidine)-1’-yl-1,3-oxathiolane 
(15). 
 
Oxathiolane derivative 14 (2.101 g, 7.450 mmol) was charged in a flask with benzoyl cytosine 
(2.085 g, 9.688 mmol) and the products were suspended in MeCN (95 ml) under nitrogen 
atmosphere. BSA (8.379 ml, 49.506 mmol) was then added, and the mixture was heated to 60 °C 
for 90 minutes. The reaction was cooled to 0 °C and SnCl4 (1.828 ml, 15.648 mmol), suspended 
in MeCN (25 ml), was cannulated in the flask. The temperature was allowed to raise to rt and after 
two hours the reaction was quenched with pyridine and concentrated under reduced pressure. Flash 
chromatography (9:1 EtOAc-hexane) of the residue afforded α and β anomers of product 15 (55% 
of total conversion, 137 mg of anomers α, 211 mg of anomers β (15) and 1.454 g of mixture of 
α/β anomers). 
 
NMR data not avaible. 
 
 
 
 
2-(Hydroxymethyl)-5-(4-benzamido-2-oxo-1,2-dihydropyrimidine)-1’-yl-1,3-oxathiolane 
(16). 
 
Protected compounds 15 (104 mg, 0.238 mmol) were dissolved in a mixture of THF/MeOH/H2O 
(1.6 ml/0.7 ml/0.1 ml) and cooled to 0 °C. A solution 2 N of NaOH (2.4 ml) was added, and after 
stirring for one hour the reaction was neutralized with HCl and concentrated under reduced 
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pressure. The crude was chromatographed (DCM to 7:3 DCM-MeOH) affording products 16 (72 
mg, 91%). 
 
1H NMR (400 MHz, CDCl3): δ 3.29 (dd, J = 12.4, 3.6 Hz, 1H, H-4), 3.67 (dd, J = 12.4, 5.3 Hz, 
1H, H-4), 3.99 (dd, J = 12.7, 3.5 Hz, 1H, CH2OH), 4.18 (dd, J = 12.6, 2.6 Hz, 1H, CH2OH), 5.39 
(t, J = 3.2 Hz, 1H, H-2), 6.39 (dd, J = 5.2, 3.6 Hz, 1H, H-5), 7.52 (t, J = 7.9 Hz, 2H, H-m Ar), 7.58-
7.64 (m, 2H, H-5’, H-p Ar), 8.11 d, J = 7.2 Hz, 2H, H-o Ar), 8.42 (d, J = 7.5 Hz, 1H, H-6’). 
 
13C NMR (100.6 MHz, CDCl3): δ 29.7 (C-4), 39.0 (CH2OH), 87.9 (C-2), 88.2 (C-5), 127.9 (C-5’), 
128.4 (C-m or o Ar), 129.0 (C-m or o Ar), 130.2 (C-p Ar), 133.2 (C-6’), 133.5 (C-i Ar), 145.2 (C-
4’), 163.0 (C-2’), 178.4 (C=O benzoyl). 
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2(R)-(Hydroxymethyl)-5(S)-(4-benzamido-2-oxo-1,2-dihydropyrimidine)-1’-yl-3-oxido-1,3-
oxathiolane (9 and 10). 
 
Nucleosides 9 and 10 were obtained via flash chromatography (98:2 DCM-MeOH to 96:4 DCM-
MeOH) from studies of sulfoxidation carried out under Kagan71 and Modena72 conditions. 1 g of 
crude afforded 53 mg of sulfoxide with higher Rf, 60 mg of sulfoxide with lower Rf and 825 mg 
of mixture.  
 
Compound with higher Rf:  
 
1H NMR (400 MHz, MeOD): δ 3.20 (d, J = 3.5 Hz, 2H, H-2’), 3.23-3.26 (m, 1H, H-4), 3.60 (dd, 
J = 13.7, 3.3 Hz, 1H, H-4), 3.84-3.87 (m, 1H, H-4 other isomer), 4.03 (br d, J = 12.4 Hz, 1H, H-4 
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other isomer), 4.16 (app d, J = 4.1 Hz, 1H, CH2OH), 4.87 (br s, 1H, CH2OH), 5.60 (br s, 1H, H-
2), 6.77 (dd, J = 9.6, 4.4 Hz, 1H, H-5), 7.43 (br d, J = 6.4 Hz, 1H, H-5’), 7.56 (t, J = 7.0 Hz, 2H, 
H-m Ar), 7.67 (app t, J = 8.4 Hz, 1H, H-p Ar), 8.05 (d, J = 8.0 Hz, 2H, H-o Ar), 8.31 (d, J = 6.4 
Hz, 1H, H-6’), 11.45 (s, 1H, NH). 
 
 
 
Compound with lower Rf:  
 
1H NMR (400 MHz, MeOD): δ 3.47 (d, J = 15.3 Hz, 1H, H-4), 3.73 (dd, J = 15.4, 8.4 Hz, 1H, H-
4), 3.86-3.90 (m, 1H, CH2OH), 4.81 (app t, J = 5.6 Hz, 1H, CH2OH), 5.54 (t, J = 5.0 Hz, 1H, H-
2), 6.68 (app d, J = 8.4 Hz, 1H, H-5), 7.34 (br d, J = 7.6 Hz, 1H, H-5’), 7.50 (t, J = 7.8 Hz, 2H, H-
m Ar), 7.61 (t, J = 7.3 Hz, 1H, H-p Ar), 7.99 (d, J = 8.0 Hz, 2H, H-o Ar), 8.25 (d, J = 7.6 Hz, 1H, 
H-6’), 11.33 (s, 1H, NH). 
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2(R)-(Hydroxymethyl)-5(S)-(4-amino-2-oxo-1,2-dihydropyrimidine)-1’-yl-3-oxido-1,3-
oxathiolane (2 and 3). 
 
5 ml of NH3/MeOH solution (6 M) was added at 0 °C to starting products 9 and 10 (50 mg, 0.143 
mmol), and the resulting mixture was stirred at rt overnight. Then, the crude was concentrated 
under reduced pressure. Flash chromatography (9:1 to 8:2 DCM-MeOH) of the residue afforded 2 
and 3 (35 mg, 99% yield). 
 
NMR data not avaible. 
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(1'S,2’R,5'S)-2-Isopropyl-5-methylcyclohexyl (2R,5R)-5-hydroxy-1,3-oxathiolane-2-
carboxylate (17). 
 (1'S,2’R,5'S)-2-Isopropyl-5-methylcyclohexyl (2S,5S)-5-hydroxy-1,3-oxathiolane-2-
carboxylate (18). 
 
L-Menthyl glyoxylate monohydrate (2.5 g, 10.86 mmol), toluene (12.5 mL) and acetic acid (0.25 
mL) were mixed under stirring and the resulting mixture was heated to 120 °C, removing water 
azeotropically with a Dean-Stark trap. The resulting solution was concentrated to collect 5 mL of 
distillate, and cooled to rt; then 1,4-dithiane-2,5-diol (826 mg, 5.43 mmol) was added. The reaction 
mixture was refluxed for 4 h; then it was cooled to 80 °C and clarified. The filtrate was cooled to 
0 °C, and a solution of triethylamine (150 μL) in n-hexane (15 mL) was added dropwise. The 
mixture was stirred at 0 °C for 16 h, observing the formation of a precipitate. The isolated solid 
was filtered, washed with a mixture of toluene and n-hexane (1:3 v/v) and dried to give the 
hemiacetals 17 and 18 (1.86 g, 60% o.y.) as a mixture of two trans stereoisomers. 
 
1H NMR (400 MHz, DMSO, mixture of two isomers): δ 0.69 (d, J = 6.9 Hz, 3H, CH3 menthyl 17), 
0.70 (d, J = 6.9 Hz, 3H, CH3 menthyl 18), 0.76-0.90 (m, 14H, H menthyl 17 and 18), 0.90-1.09 
(m, 4H, H menthyl 17 and 18), 1.31-1.52 (m, 4H, H menthyl 17 and 18), 1.57-1.65 (m, 4H, H 
menthyl 17 and 18), 1.77-1.94 (m, 4H, H menthyl 17 and 18), 2.85 (br d, J = 10.6 Hz, 2H, H-4 17 
and 18), 3.11 (dd, J = 10.0, 4.5, 1H, H-4 17), 3.12 (dd, J = 10.0, 4.7 Hz, 1H, H-4 18), 4.59 (dt, J = 
11.1, 4.2 Hz, 1H, H-1’ 17), 4.62 (dt, J = 11.1, 4.2 Hz, 1H, H-1’ 18), 5.54 (s, 1H, H-2 17), 5.55 (s, 
1H, H-2 18), 5.82-5.87 (m, 2H, H-5 17, H-5 18), 7.02 (d, J = 8.4, 1H, OH 17), 7.03 (d, J = 8.4, 
1H, OH 18). 
 
13C NMR (100.6 MHz, DMSO, mixture of two isomers): δ 16.5, 16.6, 20.8, 20.9, 22.2, 23.2, 23.3, 
26.0, 26.1, 31.1, 31.2, 33.4 (C menthyl), 38.0 (C-4 17), 38.1 (C-4 18), 40.6, 46.6, 46.7 (C menthyl), 
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74.9 (C-1’ 17), 75.0 (C-1’ 18), 76.4 (C-2 17), 76.6 (C-2 18), 101.2 (C-5 17), 101.5 (C-5 18), 169.4 
(COO 17), 169.5 (COO 18). 
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(1'S,2’R,5'S)-2-Isopropyl-5-methylcyclohexyl (2S,5S)-5-methylcarbonyloxy-1,3-oxathiolane-
2-carboxylate (22). 
 
A solution of 17 and 18 (1.86 g, 6.52 mmol), acetic anhydride (3.75 mL, 39.75 mmol) and 
dichloromethane (10 mL) were mixed under nitrogen atmosphere. The solution was cooled to 0 
°C and pyridine (0.95 mL, 18.20 mmol) was added dropwise under stirring. The reaction mixture 
was warmed to room temperature and stirred for 4 h; after completion, it was quenched by addition 
of water at 0 °C. The organic layer was washed with diluted HCl, dried over Na2SO4 and 
concentrated under reduced pressure. Flash chromatography of the crude residue (95:5 hexane-
EtOAc) gave a mixture of four cis and trans diastereoisomers (2.34 g, 91% yield). A sample of 
1.2 g was dissolved in 40 mL of hexane with 200 µL of TEA, and after 72 h at -20 °C the only 
desired trans-(2S,5S) stereoisomer 22 precipitated  as white crystal (0.50 g, 42% of the acetylated 
product). 
 
 [α]25D  = –56.0 (c 3.1, CHCl3). 
 
1H NMR (400 MHz, CDCl3): δ 0.74 (d, J = 7.0 Hz, 3H, CH3 menthyl), 0.81-0.92 (m, 7H, H 
menthyl), 0.92-1.10 (m, 2H, H menthyl), 1.39 (br t, J = 11.3 Hz, 1H, H menthyl), 1.44-1.55 (m, 
1H, H menthyl), 1.67 (br d, J = 11.4 Hz, 2H, H menthyl), 1.87-1.95 (m, 1H, H menthyl), 1.99 (br 
d, J = 11.7 Hz, 1H, H menthyl), 2.09 (s, 3H, OC=OCH3), 3.15 (d, J = 11.7 Hz, 1H, H-4), 3.43 (dd, 
J = 11.7, 4.2 Hz, 1H, H-4), 4.71 (dt, J = 10.9, 4.4 Hz, 1H, H-1’), 5.60 (s, 1H, H-2), 6.77 (d, J = 4.2 
Hz, 1H, H-5). 
 
13C NMR (100.6 MHz, CDCl3): δ 16.0, 20.6, 21.0 (C menthyl), 21.9 (O-C=O-CH3), 23.2, 26.0, 
31.3, 34.0 (C menthyl), 37.1 (C-4), 40.5, 47.0 (C menthyl), 76.0 (C-1’), 79.8 (C-2), 99.7 (C-5), 
168.5 (O-C=O-CH3), 169.6 (C=OO-menthyl). 
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m.p. 99-103 °C.  
 
Elemental analysis calcd (%) for [C16H26O5S]: C 58.16, H 7.93, S, 9.70. Found: C 58.01, H 7.96, 
S, 9.74. 
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5-Fluoro-2-oxo-4-(benzamido)-1,2-dihydropyrimidine (25). 
 
5-Fluorocytosine (0.2 g, 1.5 mmol) was suspended in pyridine (10 mL) and the resulting mixture 
was cooled to 0 °C. Benzoyl chloride (1.04 mL, 9 mmol) was added dropwise and the suspension 
was stirred at rt for 16 h. The reaction mixture was cooled with an ice bath, treated with NH4OH 
(1 mL) for 90 min and concentrated under reduced pressure. Flash chromatography of the crude 
residue over silica gel (85:15 DCM-MeOH) provided the pure nucleobase 25 (0.36 g, 99%). 
 
1H NMR (400 MHz, DMSO): δ 7.49 (t, J = 7.7 Hz, 2H, H-m benzoyl), 7.60 (t, J = 7.4 Hz, 1H, H-
p benzoyl), 8.01 (br d, J = 7.4 Hz, 3H, H-6, H-o benzoyl). 
 
13C NMR (100.6 MHz, DMSO): δ 128.9 (C-o benzoyl), 129.4 (C-m benzoyl), 133.2 (C-p benzoyl), 
135.0 (C-i benzoyl), 139.5, (d, J = 225.9 Hz, C-5), 152.3 (d, J = 21.2 Hz, C-6), 162.0 (C-4), 164.9 
(C-2), 168.5 (C=O benzoyl). 
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N-glycosylation: general procedure. 
 
First step: Iodine (1.2 eq) was suspended in anhydrous dichloromethane (7.50 mL) under nitrogen 
atmosphere and the silane (1.2 eq) was added. After 15 min, the resulting mixture was cooled to 0 
°C and cannulated dropwise into a solution of oxathiolane 22 (1 mmol) in anhydrous 
dichloromethane (0.75 mL), using additional dichloromethane (7.50 mL) for rinsing. The reaction 
was then stirred at the same temperature for 1 h. (b) BSA (3.25 eq when reacting with cytosine or 
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5-fluorocytosine; 2 eq when reacting with benzoylcytosine, benzylcytosine or 25) was added to a 
suspension of the nucleobase (1.3 eq) in anhydrous dichloromethane (7.50 mL) under nitrogen 
atmosphere. The resulting mixture was warmed to 40 °C until a clear solution was observed. The 
mixture (a) was cannulated dropwise into solution (b) under stirring at 0 °C, using additional 
dichloromethane (7.50 mL) for rinsing. The reaction mixture was then warmed to rt and stirred for 
1 h. Afterwards, the reaction was quenched with few drops of saturated NaHCO3 solution. The 
emulsion was washed with a 1 N Na2S2O3 solution and brine and extracted with dichloromethane. 
The organic layer was dried (Na2SO4) and concentrated under reduced pressure. Flash 
chromatography of the crude residue over silica gel (28, 32: 95:5 DCM-MeOH; 29, 30, 33: 1:1 
hexane-EtOAc) provided the pure nucleoside (28: 86-98%; 29: 87-94%; 30: 80-95%; 32: 84-91%; 
33: 85-91% with Et3SiH and PMHS respectively). 
 
 
 
 
(1'S,2’R,5'S)-2-Isopropyl-5-methylcyclohexyl (2S,5R)-5-(4-amido-2-oxo-1,2-
dihydropyrimidine)-1”-yl-1,3-oxathiolane (28). 
 
1H NMR (400 MHz, CDCl3):δ 0.77 (d, J = 7.0 Hz, 3H, CH3 menthyl), 0.84-0.96 (m, 7H, H 
menthyl), 0.98-1.11 (m, 2H, H menthyl), 1.43 (br t, J = 12.0 Hz, 1H, H menthyl), 1.48-1.57 (m, 
1H, H menthyl), 1.71 (br d, J = 11.3 Hz, 2H, H menthyl), 1.88-1.99 (m, 1H, H menthyl), 2.01-2.09 
(m, 1H, H menthyl), 3.13 (dd, J = 12.1, 6.6 Hz, 1H, H-4), 3.56 (dd, J = 12.1, 4.7 Hz, 1H, H-4), 
4.76 (td, J = 11.1, 4.4 Hz, 1H, H-1’), 5.46 (s, 1H, H-2), 5.73 (d, J = 7.5 Hz, 1H, H-5”), 6.47 (dd, J 
= 6.5, 4.7 Hz, 1H, H-5), 8.40 (d, J = 7.5 Hz, 1H, H-6”).  
 
13C NMR (100.6 MHz, CDCl3): δ 16.1, 20.7, 21.9, 23.2, 26.1, 31.5, 34.1 (C menthyl), 36.6 (C-4), 
40.8, 47.1 (C menthyl), 76.7 (C-1’), 78.6 (C-2), 90.4 (C-5”), 93.8 (C-5), 142.4 (C-6”), 155.5 (C-
2”), 165.5 (C-4”), 169.8 (C=OO-menthyl). 
. 
64 
 
Elemental analysis calcd (%) for [C18H27N3O4S]: C 56.67; H 7.13; N 11.01; S 8.41. Found: C 
56.56; H 7.16; N 11.05; S 8.44. 
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(1'S,2’R,5'S)-2-Isopropyl-5-methylcyclohexyl (2S,5R)-5-(4-benzamido-2-oxo-1,2-
dihydropyrimidine)-1’-yl-1,3-oxathiolane (29). 
 
1H NMR (600 MHz, CDCl3):δ 0.78 (d, J = 6.9 Hz, 3H, CH3 menthyl), 0.82-0.98 (m, 7H, H 
menthyl), 0.99-1.15 (m, 2H, H menthyl), 1.45 (br t, J = 11.5 Hz, 1H, H menthyl), 1.49-1.59 (m, 
1H, H menthyl), 1.62-1.76 (m, 2H, H menthyl), 1.87-1.99 (m, 1H, H menthyl), 2.02-2.12 (m, 1H, 
H menthyl), 3.24 (dd, J = 12.3, 5.9 Hz, 1H, H-4), 3.69 (dd, J = 12.3, 4.7 Hz, 1H, H-4), 4.80 (td, J 
= 10.9, 4.2 Hz, 1H, H-1’), 5.54 (s, 1H, H-2), 6.42 (t, J = 5.3 Hz, 1H, H-5), 7.52 (t, J = 7.8 Hz, 2H, 
H-m Ar), 7.62 (t, J = 7.4 Hz, 1H, H-p Ar), 7.89 (d, J = 7.5 Hz, 3H, H-5”, H-o Ar), 8.69 (br s, 1H, 
NH), 8.79 (d, J = 7.5 Hz, 1H, H-6”).  
 
13C NMR (100.6 MHz, CDCl3): δ 16.1, 20.7, 21.9, 23.2, 26.2, 31.5, 34.0 (C menthyl), 37.1 (C-4), 
40.8, 47.1 (C menthyl), 77.0 (C-1’), 79.7 (C-2), 90.7 (C-5”), 96.6 (C-5), 127.5 (C-o Ar), 129.1 (C-
m Ar), 133.0 (C-p Ar), 133.2 (C-i Ar), 143.6 (C-6”), 154.9 (C-4”), 162.6 (C-2”), 166.4 (C=O 
benzoyl), 169.3 (C=OO-menthyl). 
 
Elemental analysis calcd (%) for [C25H31N3O5S]: C 61.83; H 6.43; N 8.65; S 6.60. Found: C 61.97; 
H 6.41; N 8.62; S 6.57. 
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(1'S,2’R,5'S)-2-Isopropyl-5-methylcyclohexyl (2S,5R)-5-(4-acetamido-2-oxo-1,2-
dihydropyrimidine)-1’-yl-1,3-oxathiolane (30). 
 
1H NMR (500 MHz, CDCl3): δ 0.74 (d, J = 6.9 Hz, 3H, CH3 menthyl), 0.80-0.95 (m, 7H, H 
menthyl), 0.96-1.11 (m, 2H, H menthyl), 1.41 (br t, J = 11.7 Hz, 1H, H menthyl), 1.46-1.56 (m, 
1H, H menthyl), 1.68 (br d, J = 11.4 Hz, 2H, H menthyl), 1.83-1.94 (m, 1H, H menthyl), 2.03 (br 
d, J = 11.6 Hz, 1H, H menthyl), 2.19 (s, 3H, C=OCH3), 3.18 (dd, J = 12.3, 5.8 Hz, 1H, H-4), 3.65 
(dd, J = 12.3, 4.6 Hz, 1H, H-4), 4.75 (td, J = 11.1, 4.4 Hz, 1H, H-1’), 5.55 (s, 1H, H-2), 6.40 (br t, 
J = 5.4 Hz, 1H, H-5), 7.41 (d, J = 7.3 Hz, 1H, H-5”), 8.13 (br s, 1H, NH), 8.71 (d, J = 7.3 Hz, 1H, 
H-6”).  
 
13C NMR (100.6 MHz, CDCl3) : δ 16.0, 20.6, 21.8, 23.1 (C menthyl), 24.9 (C=OCH3), 26.0, 31.3 
(C menthyl), 33.9 (C menthyl), 37.0 (C-4), 40.6, 46.9 (C menthyl), 76.8 (C-1’), 79.6 (C-2), 90.6 
(C-5”), 96.6 (C-5), 145.4 (C-6”), 154.9 (C-4”), 162.9 (C-2”), 169.2 (C=OCH3), 169.9 (C=OO-
menthyl). 
 
Elemental analysis calcd (%) for [C20H29N3O5S]: C 56.72; H 6.90; N 9.92; S 7.57. Found: C 56.88; 
H 6.87; N 9.88; S 7.54. 
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(1'S,2’R,5'S)-2-Isopropyl-5-methylcyclohexyl (2S,5R)-5-(4-amido-5-fluoro-2-oxo-1,2-
dihydropyrimidine)-1’-yl-1,3-oxathiolane (32). 
 
1H NMR (400 MHz, CDCl3):δ 0.76 (d, J = 6.9 Hz, 3H, CH3 menthyl), 0.80-0.95 (m, 7H, H 
menthyl), 0.96-1.12 (m, 2H, H menthyl), 1.43 (bt, J = 11.4 Hz, 1H, H menthyl), 1.47-1.58 (m, 1H, 
H menthyl), 1.69 (br d, J = 11.4 Hz, 2H, H menthyl), 1.87-1.98 (m, 1H, H menthyl), 2.04-2.08 (m, 
1H, H menthyl), 3.11 (dd, J = 12.1, 6.6 Hz, 1H, H-4), 3.51 (dd, J = 12.1, 4.7 Hz, 1H, H-4), 4.78 
(td, J = 11.0, 4.4 Hz, 1H, H-1’), 5.44 (s, 1H, H-2), 5.82 (br s, 1H), 6.40 (ddd, J = 6.4, 4.8, 1.6 Hz, 
1H, H-5), 8.36 (br s, 1H, NH2), 8.46 (d, J = 6.6 Hz, 1H, H-6”).  
 
13C NMR (100.6 MHz, CDCl3): δ 16.0, 20.6, 21.8, 23.1, 26.0, 31.4, 34.0 (C menthyl), 36.2 (C-4), 
40.6, 47.0 (C menthyl), 76.7 (C-1’), 78.6 (C-2), 90.3 (C-5), 125.7 (d, J = 33.2 Hz, C-6”), 136.5 (d, 
J = 242.0 Hz, C-5”), 153.8 (C-2”), 158.3 (d, J = 14.2 Hz, C-4”), 169.7 (C=OO-menthyl). 
 
Elemental analysis calcd (%) for [C18H26FN3O4S]: C 54.12; H 6.56; N 10.52; S 8.03. Found: C 
53.97; H 6.58; N 10.55; S 8.06. 
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(1'S,2’R,5'S)-2-Isopropyl-5-methylcyclohexyl (2S,5R)-5-(4-benzamido-5-fluoro-2-oxo-1,2-
dihydropyrimidine)-1’-yl-1,3-oxathiolane (33). 
 
1H NMR (600 MHz, CDCl3): δ 0.78 (d, J = 7.0 Hz, 3H, CH3 menthyl), 0.83-0.97 (m, 7H, H 
menthyl), 0.99-1.15 (m, 2H, H menthyl), 1.46 (br t, J = 12.2 Hz, 1H, H menthyl), 1.48-1.60 (m, 
1H, H menthyl), 1.72 (br d, J = 11.3 Hz, 2H, H menthyl), 1.87-1.98 (m, 1H, H menthyl), 2.02-2.11 
(m, 1H, H menthyl), 3.20 (dd, J = 12.2, 6.9 Hz, 1H, H-4), 3.50 (dd, J = 12.2, 4.7 Hz, 1H, H-4), 
4.82 (dt, J = 11.0, 4.3 Hz, 1H, H-1’), 5.48 (s, 1H, H-2), 6.43 (br t, J = 5.6 Hz, 1H, H-5), 7.46 (t, J 
= 7.6 Hz, 2H, H-m Ar), 7.56 (t, J = 7.6 Hz, 1H, H-p Ar), 8.27 (d, J = 7.6 Hz, 3H, H-5”, H-o Ar), 
8.70 (d, J = 6.3 Hz, 1H, H-6”). 
 
13C NMR (100.6 MHz, CDCl3): δ 16.0, 20.6, 21.8, 23.1, 26.0, 31.4, 33.9 (C menthyl), 35.6 (C-4), 
40.6, 47.0 (C menthyl), 77.0 (C-1’), 78.6 (C-2), 89.7 (C-5), 126.2 (d, J = 41.3 Hz, C-6”), 128.3 
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(C-o Ar), 129.9 (C-m Ar), 133.0 (C-p Ar), 135.6 (C-i Ar), 139.7 (d, J = 241.7 Hz, C-5”), 147.1 (C-
2”), 152.6 (d, J = 19.4 Hz, C-4”), 162.1 (C=O benzoyl), 169.5 (C=OO-menthyl). 
 
Elemental analysis calcd (%) for [C25H30FN3O5S]: C 59.63; H 6.00; N 8.34; S 6.37. Found: C 
59.73; H 6.02; N 8.32; S 6.35. 
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(2S,5R)-2-(Hydroxymethyl)-5-(4-amido-2-oxo-1,2-dihydropyrimidine)-1’-yl-1,3-oxathiolane 
(4, (+)-BCH-189). 
 
Protected nucleoside 28 (24 mg, 0.0630 mmol) was dissolved in anhydrous THF (1.5 mL) under 
nitrogen atmosphere, and LiAlH4, suspended in THF (800 µl), was added at 0 °C. After an hour, 
the reaction was quenched with MeOH, was filtered through a celite pad and concentrated under 
reduced pressure. Chromatography of the crude residue over silica gel (95:5 DCM-MeOH) gave 
the pure nucleoside 4 (12 mg, 83%). 
 
1H NMR (500 MHz, MeOD): δ 3.12 (dd, J = 12.0, 4.1 Hz, 1H, H-4), 3.50 (dd, J = 12.0, 5.4 Hz, 
1H, H-4), 3.86 (dd, J = 12.5, 4.0 Hz, 1H, CH2OH), 3.94 (dd, J = 12.5, 2.8 Hz, 1H, CH2OH), 5.27 
(br s, 1H, H-2), 5.88 (d, J = 7.5 Hz, 1H, H-5’), 6.28 (br t, J = 4.6 Hz, 1H, H-5), 8.05 (d, J = 7.5 
Hz, 1H, H-6’). 
 
13C NMR (100.6 MHz, MeOD): δ 37.2 (C-4), 62.5 (CH2OH), 86.3 (C-2), 86.6 (C-5), 94.2 (C-5’), 
141.6 (C-6’), 156.6 (C-4’), 166.3 (C-2’). 
 
Elemental analysis calcd (%) for [C8H11N3O3S]: C 41.91; H 4.84; N 18.33; S 13.99. Found: C 
42.03; H 4.82; N 18.27; S 14.02. 
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(2S,5R)-2-(Hydroxymethyl)-5-(4-amido-5-fluoro-2-oxo-1,2-dihydropyrimidine)-1’-yl-1,3-
oxathiolane (34, D-FTC). 
 
A solution of K2HPO4 (111 mg, 0.639 mmol) in H2O (500 µL) was added to a suspension of 
protected nucleoside 32 (65 mg, 0.162 mmol) in ethanol (1 mL). Hence a solution of NaBH4 (16 
mg, 0.426 mmol) in H2O (600 µL) containing 25% w/w NaOH was added to the reaction mixture. 
After 1 h, the reaction was quenched with diluted HCl, adjusting the pH to 4-4.5 and then to pH 7 
using a saturated solution of NaHCO3. The mixture was filtered through a celite pad and 
concentrated under reduced pressure. Chromatography of the crude residue over silica gel (9:1 to 
85:15 DCM-MeOH) gave the pure nucleoside 34 (40 mg, 99%). 
 
1H NMR (400 MHz, DMSO): δ 3.10 (dd, J = 11.9, 4.4 Hz, 1H, H-4), 3.40 (dd, J = 11.9, 5.6 Hz, 
1H, H-4), 3.72 (dd, J = 12.3, 4.1 Hz, 1H, CH2OH), 3.77 (dd, J = 12.3, 3.8 Hz, 1H, CH2OH), 5.17 
(t, J = 3.9 Hz, 1H, H-2), 6.12 (ddd, J = 5.6, 4.8, 1.8 Hz, 1H, H-5), 7.54 (br s, 1H), 7.78 (br s, 1H), 
8.17 (d, J = 7.2 Hz, 1H, H-6’). 
74 
 
 
13C NMR (100.6 MHz, DMSO): δ 36.6 (C-4), 62.2 (CH2OH), 86.4 (C-2), 86.5 (C-5), 125.6, (d, J 
= 32.6 Hz, C-6’), 136.2 (d, J = 240.6 Hz, C-5’), 152.9 (C-2’), 157.5 (d, J = 13.4 Hz, C-4’). 
 
Elemental analysis calcd (%) for [C8H10FN3O3S]: C 38.86; H 4.08; N 17.00; S 12.97. Found: C 
38.74; H 4.10; N 17.05; S 13.01 
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Reduction of benzoyl nucleosides: general procedure. 
 
A suspension of protected nucleoside 29 or 33 (1 mmol) in anhydrous methanol (20 mL) was 
heated to 40 °C and left under stirring at the same temperature for 48h (29) or 72 h (33). The 
reaction mixture (containing menthyl nucleoside 35 or 36 as the main products) was then cooled 
to room temperature and a solution of K2HPO4 (3 eq) in H2O (2 mL) was added. Hence a solution 
of NaBH4 (2 eq) in H2O (2 mL) containing 25% w/w NaOH was added to the reaction mixture. 
After 1 h, the reaction was quenched with diluted HCl, adjusting the pH to 4-4.5 and then to pH 7 
using a saturated solution of NaHCO3. The mixture was filtered through a celite pad and 
concentrated under reduced pressure. Chromatography of the crude residue over silica gel gave 
the pure nucleoside (4: 95% o.y.; 34: 75% o.y.). 
 
 
 
 
2(S)-(Hydroxymethyl)-5(R)-(4-benzamide-2-oxo-1,2-dihydropyrimidine)-1’-yl-1,3-
oxathiolane (8). 
 
To a solution of (+)-BCH-189 (4, 75 mg, 0.328 mmol) in pyridine (7 ml) was added under nitrogen 
atmosphere TMSCl (360 µl, 2.84 mmol). After 30 minutes, benzoyl chloride (82 µl, 0.710 mmol) 
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was added at 0 °C and the solution was stirred at room temperature overnight. The reaction was 
quenched at 0 °C with 800 µl of H2O and 800 µl of NH3 (aq). The mixture, after stirring for one 
hour, was dried under reduced pressure. Flash chromatography of the crude (97:3 DCM–MeOH 
to 8:2 DCM MeOH) afforded protected product 8 (108 mg, 99%). 
 
1H NMR (400 MHz, CDCl3): δ 3.29 (dd, J = 12.4, 3.6 Hz, 1H, H-4), 3.67 (dd, J = 12.4, 5.3 Hz, 
1H, H-4), 3.99 (dd, J = 12.7, 3.5 Hz, 1H, CH2OH), 4.18 (dd, J = 12.6, 2.6 Hz, 1H, CH2OH), 5.39 
(t, J = 3.2 Hz, 1H, H-2), 6.39 (dd, J = 5.2, 3.6 Hz, 1H, H-5), 7.52 (t, J = 7.9 Hz, 2H, H-m Ar), 7.58-
7.64 (m, 2H, H-5’, H-p Ar), 8.11 d, J = 7.2 Hz, 2H, H-o Ar), 8.42 (d, J = 7.5 Hz, 1H, H-6’). 
 
13C NMR (100.6 MHz, CDCl3): δ 29.7 (C-4), 39.0 (CH2OH), 87.9 (C-2), 88.2 (C-5), 127.9 (C-5’), 
128.4 (C-m or o Ar), 129.0 (C-m or o Ar), 130.2 (C-p Ar), 133.2 (C-6’), 133.5 (C-i Ar), 145.2 (C-
4’), 163.0 (C-2’), 178.4 (C=O benzoyl). 
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2(S)-(Hydroxymethyl)-5(R)-(4-benzamide-2-oxo-1,2-dihydropyrimidine)-1’-yl-3-oxido-1,3-
oxathiolane (11 and 12). 
 
Nucleoside 8 (169 mg, 0.484 mmol) was dissolved in anhydrous DCM (6 ml) under nitrogen 
atmosphere, and the mixture was cooled to -78 °C. A suspension of m-CPBA (108 mg, 0.629 
mmol) in DCM (1 ml) was added to the starting product, and the reaction was stirred for 30 
minutes. A solution of NaHCO3 was then added, and the mixture was concentrated under reduced 
pressure. Flash chromatography (95:5 DCM-MeOH to 9:1 DCM-MeOH), preparative TLC, HPLC 
of the residue could not separate the sulfoxides 11 and 12. 
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1. INTRODUCTION 
 
 
Iminosugars are carbohydrate derivatives having the endocyclic oxygen replaced by a nitrogen 
atom. This substitution makes iminosugars compounds of difficult preparation and profoundly 
changes their biological properties. In particular, iminosugars are the most interesting 
carbohydrate mimics, especially for their ability to act as glycosidase inhibitions, arising from their 
resemblance to sugars. Glycosidases are found in a number of important biological processes, such 
as intestinal digestion, post-translational processing of glycoproteins and the lysosomal catabolism 
of glycoconjugates; for this reason sugar mimics might have enormous therapeutic potential in 
many diseases such as diabetes, viral infection and lysosomal storage disorders.  
The inherited metabolic disorders of glycosphingolipid (GSL) metabolism are a rare group of 
diseases that cause different dysfunctions, often neurodegenerative. Generally, problems in 
catabolic enzyme activity lead to lysosomal storage of GSL substrates and, in many diseases, other 
glycoconjugates. Today there are not cures for lysosomal storage diseases, and treatment is mostly 
symptomatic, although bone marrow transplantation and enzyme replacement therapy have been 
tried with some success. An approach to treating these diseases could be the substrate reduction 
therapy (SRT), in this regard there is the discovery and development of N-alkylated iminosugars, 
more lipophilic and, consequently, better absorbed, as effective drugs. 
 
 
1.1. IMINOSUGARS 
 
For many years iminosugars were also denominated “azasugars” to distinguish them from 
general amino sugars, such as glucosamine derivatives or other carbohydrate analogues, but 
commonly the term aza is used when a nitrogen replaces a carbon, not an oxygen. They can also 
be defined polyhydroxylated alkaloids, but their biogenetic pathway is completely different: the 
starting product of the route is always a carbohydrate1. 
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Iminosugars are classified in five classes, according to their structure: polyhydroxylated 
piperidines, pyrrolidines, indolizidines, pyrrolizidines and nortropanes (Figure 1.1). They can also 
occur in a glycosylated form. 
 
 
Figure 1.1: The five classes of iminosugars. 
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The study of the iminosugars led to a noteworthy progress in glycobiology, especially after the 
investigation of their inhibition mechanisms on glycosyltransferases2, glycogen phosphorylases3, 
nucleoside-processing enzymes4 and metalloproteinases5. New therapies for numerous diseases 
have been developed thanks to the ability of iminosugars to influence the folding of abnormal 
glycosidases, avoiding their degradation, and their resemblance, in the protonated form, to the 
transition state of the glycosidic bond hydrolysis. Because of these properties, iminosugars are 
among the most powerful inhibitors of glycosydases6 (Figure 1.2). Although the lack of the sp2 
character in the nitrogen-C-1 bond affects the mimicking of transition state, iminosugars bind the 
active sites of glycosidases 103 times better than carbohydrates, probably because nitrogen 
participates to interaction. 
 
NH2
HO
HO
HO
OH
Protonated DNJ
Hydrolysis transition state
O OR
H
O H
H
HO
HO
HO
OH
 
Figure 1.2: Resemblance between protonated DNJ and carbohydrate hydrolysis transition state. 
 
Nojirimycin (NJ, I), an analog of glucose, is the first discovered iminosugar, isolated from 
Streptomyces roseochromogenes R-468 in 19667, and is characterized by the presence of a 
nitrogen atom in place of the endocyclic oxygen. NJ is a strong inhibitor of α- and β-glucosidases8 
with IC50 = 9 and 19 µM respectively. However, NJ was never approved as antibiotic because of 
the instability of the hydroxyl group at C-1. Its reduction with NaBH4 lead to 1-deoxynojirimycin 
(DNJ, II)7, isolated in 1966 from the roots of mulberry trees as fagomine (III), but also produced 
by many strains in the genera Bacillus and Streptomyces9. DNJ displayed α-glucosidase inhibitory 
activity in vitro but not in vivo10, and for this reason a large number of its derivatives (as Emiglitate 
or Miglitol) was synthetized trying to increase the in vivo activity. From mulberry trees was also 
isolated DAB (VI), a potent inhibitor of α-glucosidases and α-mannosidase, while α-
homonojirimycin (α-HNJ, IV), isolated from the neotropical liana Omphalea diandra, the first 
natural substituted DNJ at C-1, is a specific strong inhibitor of only α-glucosidases.  
Swainsonine (X) can inhibit lysosomal and Golgi α-mannosidases, and castanospermine (IX), 
casuarine (XIV) and DMDP (V) show potent inhibitory activity against α-glucosidases, but, 
curiously, the L-enantiomer of DMDP is more powerful and specific than the D-enantiomer11. 
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Many D-iminosugars are competitive inhibitors of D-glycohydrolases, but their L-enantiomers are 
noncompetitive inhibitors of the enzymes11,12. 
Recently, L-iminosugars were synthetized and tested in a large number of diseases; although 
the active site of enzymes generally accepts only the D-enantiomer, L-enantiomers can inhibit 
glycosidases with different mechanisms of action and a comparable potency13. 
 
 
1.1.1. APPLICATIONS OF N-ALKYLATED IMINOSUGARS 
 
As seen above, the strong inhibitory activity of DNJ in vitro attracted the attention of many 
chemists who focused on production of its N-alkylated derivatives, in an attempt to increase their 
activity in vivo. N-alkylated iminosugars present an amphiphilic character that increases the 
inhibitory potency because the carbon chain takes part in the recognition of the active site of 
glucosylceramidase14 and the protonated nitrogen forms an ion pair with a carboxylate present in 
the active site. Deoxynojirimycin derivatives (Figure 1.3) are endowed with the highest activity 
among N-alkylated iminosugars and the elongation of the alkyl chain brings about an improvement 
in the activity.  
 
 
Figure 1.3: N-substituted DNJ derivatives. 
 
Iminosugars can prevent the glycosylation of N-linked glycoproteins or alter the structure of 
carbohydrates, affecting cell functions. DNJ, HNJ strongly inhibit α-glucosidases II, their 
alkylation shifts their effect on α-glucosidases I, but their activity is lower than castanospermine, 
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probably because IX has a fixed axial position of the C-1 group, that correspond to the C-6 group 
of DNJ and HNJ15. The C-6 OH group of II and C-1 OH group of IV are in equatorial position, 
and the NH···O-6 in DNJ or NH···O-1 in HNJ intramolecular interaction stabilizes the C-6—O-6 
or C-1—O-1 conformation. The N-alkylation increases the efficiency of DNJ or HNJ derivatives 
favoring the C-6 OH and C-1 OH axial conformation, breaking the intramolecular interactions16. 
 
 
Figure 1.4: Preferred conformation of II, IX, XXIII and N-substituted HNJ (IV). 
 
In 1996 FDA approved N-hydroxyethyl-deoxynojirimycin (Miglitol, XXI, Figure 1.3) as a 
second generation α-glucosidase inhibitor for its potent activity associated with a few intestinal 
side effects17, due to the complete absorption of the drug. In fact, Miglitol is able to reduce the 
postprandial elevation of blood glucose by 50% and is metabolized (absorbed from the intestinal 
tract), in contrast to Acarbose (another α-glucosidase inhibitor approved in 1990 as anti-diabetes 
drug). It was introduced in the market in 1999 for the treatment of type 2 diabetes mellitus, and is 
prescribed also for heart diseases due to diabetic complications. Emiglitate (XXII), as DAB (VI) 
or isofagomine, showed similar activities with a long lasting effect in vivo, caused by a quasi-
irreversible binding to α-glucosidases18. The higher reactivity of Emiglitate over Miglitol is due to 
its greater lipophilicity of the former, which can reach lysosomes more easily than Miglitate19. 
Some iminosugars as DNJ (II), N-butyl-DNJ (NB-DNJ, XXIII) or castanospermine (IX) can 
feature antiviral activity for their capacity to interfere in glycosylation processes, and viral 
envelope glycoproteins are essential for virion assembly. These iminosugars can inhibit HIV 
replication, a property probably related to the potent inhibitor activity of α-glucosidases I. 
Unfortunately, despite their good anti-HIV activity in vitro, the in vivo activity is not comparable 
to zidovudine20 (EC50 = 560, 56 and 29 µM for II, XXIII and IX against 0.1 µM for AZT), and 
high concentration of the drugs are needed, but side effects can occur.  
Conversely, NB-DNJ, and in particular N-nonyl-DNJ (NN-DNJ, XXIV) are good in vitro 
inhibitors of N-linked glycosylations involved in the transport of HBV virus out of the cell21 and 
their administration results in a high percentage of virus particles retained in the host cell. They 
93 
 
also feature interesting activity against bovine viral diarrhea virus (BVDV), a culture surrogate of 
hepatitis C virus (HCV). 
Owing to the important role of membrane-anchored oligosaccharides in tumor growth, 
substrates as iminosugars, capable of altering the glycosidase and glycosyltransferase structures, 
could be employed in tumor treatments. Castanospermine and N-methyl-DNJ (Me-DNJ, XXV) 
inhibit platelet aggregation of metastatic cells and cellular transformation by altering oncogene 
glycosylation, and reduce the adhesion of cancer cells to the vascular endothelium22. 
 
 
1.2. LYSOSOMAL STORAGE DISORDERS 
 
1.2.1. GLYCOSPHINGOLIPIDS METABOLISM 
 
Glycosphingolipids (GSLs) are composed of the hydrophobic amino alcohol sphingosine or 
ceramide, situated ubiquitously in the lipid bilayer of the cellular membrane, linked to a 
hydrophilic carbohydrate, with about 300 known structural variants23. Their function is to shield 
eukaryotic cells from chemical and mechanical damage through a protective carbohydrate external 
layer. If GSLs metabolism is altered, a series of diseases can develop24; these are rare in incidence 
(1 in 18000 live births worldwide) but severe and challenging to be treated. The glycolipid 
lysosomal storage disease are the most frequent cause of pediatric neurodegenerative disease. 
All glycosphingolipids share a common biosynthetic pathway, that starts from the condensation 
between palmitoyl-CoA and serine. Then, a long string of metabolic steps in the cytosol leads to 
the generation of ceramide, which can be converted to sphingomyelin, galactosylceramide or 
glucosylceramide. The two glycosyltransferases (galactosyl and glucosyl) that promote these last 
two transformations are localized in the endoplasmic reticulum25 and in the cytosol/Golgi 
membrane, respectively26. The glucosylceramide moves across the Golgi membrane where a 
galactose residue is added, under the agency of a glucosylceramide-specific 
galactosyltransferase27; the resulting lactosylceramide is the precursor of several different groups 
of glycosphingolipids (Figure 1.5). 
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Figure 1.5: Glycosphingolipid Synthesis. 
 
While the biosynthetic pathway proceeds in the cytosol, endoplasmic reticulum, and Golgi 
apparatus, the catabolism takes place in the lysosome (Figure 1.6). Specialized proteins, called 
sphingolipid activator proteins (SAPs), catalyze the hydrolysis of GSLs from the non-reducing 
terminus28; their inherited lack or malfunction results in the accumulation of the catabolism 
intermediates and, consequently, in the lysosomal storage disorders of glycolipids. The most 
common of these disorders is known as the Gaucher disease. 
 
 
Figure 1.6: Glycosphingolipid Catabolism. For every defect in a lysosomal glycosidase (in blue), there is an 
inherited pathology (in red). 
 
 
95 
 
1.2.2. GAUCHER DISEASE: CERAMIDE β-GLUCOSIDASE DEFICIENCY 
 
More than 75 gene mutations on the chromosome 1 lead to an impaired activity of ceramide β-
glucosidase, the enzyme which catalyzes the hydrolysis of glucosylceramide to glucose and 
ceramide, (EC 3.2.1.45). Depending on the combination of the alleles (null, severe or mild), the 
clinical phenotypes can be predicted (Type I, Type II/III)29. This disorder is called Gaucher 
disease, after Philippe Gaucher, the French doctor who first described its symptoms30 (anemia, 
fatigue, bruising, low blood platelet, skeletal disorders, enlargement of liver and spleen and, as 
described before, neurological pathologies), but its biochemical bases were elucidated just a 
century later. 
The lack or reduced activity of ceramide β-glucosidase cause an accumulation of 
glucocerebroside in macrophages of liver, lungs, spleen and bone marrow. There are three types 
of Gaucher disease31: 1) the non-neuropathic, the most common form, with enlargements of liver 
and spleen, anemia and skeletal weaknesses; 2) the acute infantile neuropathic, that is revealed 
after 6 months from the birth with a progressive brain damage, the enlargement of liver and spleen 
and spasticity; 3) the chronic neuropathic, characterized by progressive neurologic damages 
(arising also in adulthood), anemia, enlargement of liver and spleen and respiratory problems.  
There is not a cure for this disease, but some therapies have been developed to overcome the 
deficit of the enzyme capacity, in particular: 1) the direct administration of enzyme, 2) the bone 
marrow replacement, 3) the gene delivery and 4) the substrate deprivation (inhibiting the synthesis 
of glycosphingolipids). 
 The enzyme replacement therapy can be successful with some forms of the disorder. In 
particular, the size of the liver and the spleen can be decreased with an enzyme replacement 
treatment, but this is really expensive and life-long lasting. The research for new drugs is hampered 
by the rarity of the disease and high costs. 
 
1.2.3. EMPLOYMENT OF N-SUBSTITUTED IMINOSUGARS IN GAUCHER DISEASE 
THERAPY  
 
The commercially available drugs for the Gaucher disease therapy are recombinant 
glucocerebrosidase, and are Ceredase, Imiglucerase, Velaglucerase, Taliglucerase alfa and 
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Eliglustat, approved from 1991 to 2014 by FDA. NB-DNJ (XXIII), previously developed as anti-
HIV agent, was approved after multiple clinical studies for the substrate reduction therapy against 
type I Gaucher disease thanks to its low toxicity, proving less expensive than enzyme replacement 
treatment. XXIII prevents accumulation of glucosylceramide (GlcCer) inhibiting its 
glucosyltransferase-mediated biosynthesis. Tests on Tay-Sachs mice showed that the treatment 
with NB-DNJ could prevent the accumulation of GM2 ganglioside in the brain32, while the same 
treatment on healthy mice did not cause diseases, the only side effect being the disappearance of 
GSL in many organs33. 
Unfortunately, the lack of information about the enzyme structure and its binding sites makes 
the research of new GCS inhibitors more complicated. For this reason, a large number of DNJ 
derivatives, mimicking the ceramide substrate in the GCS active site, have been synthetized to be 
tested for their therapeutic potential on different diseases. The increase of the chain length led to 
stronger inhibitions toward lysosomal β-glucosidase (GCase), perhaps for of a better mimicking 
of ceramide. Substituents at C-1 and C-6 led to a loss of transferase inhibition, while the presence 
of the hydroxyl at C-4 is fundamental for the bioactivity. These results highlight the importance 
of three chiral centers for the mimicking and the potency34 (Figure 1.7). 
 
 
Figure 1.7: Mimicking of active moieties of ceramide. 
 
N-nonyl-DNJ (XXIV) is a good inhibitor for GCase with an IC50 = 1 µM; N-decyl and N-
dodecyl-DNJ (XXVI, Figure 1.7) are predominantly inhibitory. In 1993, a second generation of 
iminosugar inhibitors has been reported; these can inhibit glucosylceramide35, and include N-(5-
adamantane-1-yl-methoxypentyl)-DNJ (AMP-DNJ, XXVII), a very powerful inhibitor of non-
lysosomal and membrane glucosylceramidases (IC50 = 1.7 and 48 nM respectively). In the 
inhibition of glucosylceramide synthase, XXVI is 100 times more potent than XXIII and, 
considering the important role of GSLs in many other diseases, it may find several different 
therapeutic applications. In fact, the administration of XXVI to mice with hapten-induced 
ulcerative colitis resulted in beneficial anti-inflammatory responses36. A recent study on a large 
number of N-substituted DNJ and L-ido-DNJ37 indicated that the highest GCS, GBA1 and GBA2 
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inhibitory activity was showed by N-nonyloxypentyl-DNJ (XXVIII) and its L-epimer, suggesting 
their employment in lysosomal storage disorders, in particular Gaucher disease. 
 
 
Figure 1.7: Active N-substituted DNJ derivatives. 
 
 
1.3. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
Iminosugars are potent inhibitors of α- and β-glucosidases, and have been approved by FDA as 
antidiabetic and antiviral agents. More recently, a new use of iminosugars, in particular if N-
substituted, has been proposed: considering the fundamental role of glycosidases and 
glycosyltransferases in carbohydrate metabolism, in particular in glycosphingolipid catabolism, 
these inhibitors can be used as therapeutic agents in lysosomal storage disorders, in particular in 
type I Gaucher disease.  
The N-alkylated iminosugars potentially can be tested in further diseases involving 
carbohydrates: their substrate mimicking attitude can be refined with the employment of L-
iminosugars, that in several cases showed a higher activity than the corresponding D-enantiomers. 
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2. OBJECTIVES AND SYNTHETIC STRATEGY 
 
 
This section of the thesis was addressed to the synthesis of both the enantiomers of the N-(5-
adamantane-1-yl-methoxypentyl)-DNJ and the N-nonyloxypentyl-DNJ with the development of a 
convenient synthetic route. These DNJ derivatives will be tested for their potential biological 
activity in other lysosomal storage diseases. 
 
The stepwise strategy can be summarized in a few critical points: 
• The construction of a common precursor constituted by a protected pentanediol (Figure 
2.1). 
 
 
Figure 2.1: Construction of protected pentanediol. 
 
• The coupling of the common precursor with adamantane-methanol and nonanol, and 
subsequent oxidation to aldehyde of the terminal hydroxyl group in the alkyl chain 
(Figure 2.2). 
 
 
Figure 2.2: Coupling of protected pentanediol and oxidation. 
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• The final coupling between the two obtained aldehydes with the previously synthetized 
D- and L-DNJ (Figure 2.3). 
 
 
Figure 2.3: Final coupling to obtain D- and L- AMP-DNJ and N-nonyloxypentyl-DNJ. 
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3. RESULTS AND DISCUSSION 
 
 
The syntheses of N-(5-adamantane-1-yl-methoxypentyl)-DNJ38 and N-nonyloxypentyl-DNJ36 
have been already accomplished and described in literature. The synthetic route to AMP-DNJ is 
reported in Scheme 3.1: 
 
 
Scheme 3.1: (a) Adamantane-methanol, NaH; (b) Pd/C, H2; (c) DMSO, (COCl)2, TEA; (d) tetra-Bn-DNJ, Pd/C, H2, 
AcOH; (e) Pd/C, H2, HCl. 
 
The pathway to N-nonyloxypentyl-DNJ is described in Scheme 3.2: 
 
 
Scheme 3.2: (a) Adamantane-methanol, NaH; (b) Pd/C, H2; (c) PPh3, CBr4; (d) DNJ, K2CO3. 
 
To avoid the demanding reaction conditions required for the multiple hydrogenolytic de-O-
benzylations (Scheme 3.1) and the coupling between the alkyl bromide and the DNJ (80 °C for 16 
h, Scheme 3.2), the synthetic route developed in this thesis contemplates the use of p
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methoxybenzyl as a transient protecting group for pentanediol, in combination with a tosyl leaving 
group. 
 
 
3.1. CONSTRUCTION OF THE PROTECTED COMMON PRECURSOR 
 
The former explored strategy to obtain 2 involved a two-step sequence already described in 
literature39; in the first step, the adamantane-methanol reacted with 3,4-dihydro-2H-pyran in 
presence of p-toluenesulfonic acid to give a pyran adduct undergoing, in the second step, a 
reductive opening upon exposure to BH3 in THF. Unfortunately the second step met with failure, 
probably because in the literature is reported the reaction with the borane tetrahydrofuran complex 
stabilized with N-isopropyl-N-methyl-tert-butylamine, a reactive no more commercially available. 
Indeed, addition of DIPEA to the reaction mixture did not give results. 
 The latter explored route involved the strategy described in Scheme 3.1, with the combined 
use of the p-methoxybenzyl and the tosyl group in the derivatization of starting pentanediol. 
This latter was sequentially protected in excellent yield with a p-methoxybenzyl (to give 7) and 
a tosyl group (to give 8) (Scheme 3.3). Use of a large stoichiometric excess of pentanediol over 
PMBCl ensured the protection of only one hydroxyl group. 
 
 
Scheme 3.3: Synthesis of common hydrophobic intermediate 8. 
 
 
3.2. SYNTHESES OF ADAMANTANE- AND NONYL-ALDEHYDES 
 
Coupling of 8 and adamantane-methanol, activated by NaH, was carried out under highly 
anhydrous conditions to obtain ether 9. The radical deprotection with DDQ afforded alcohol 2, 
which was oxidized almost quantitatively to aldehyde 3 under Swern conditions (Scheme 3.4). 
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Scheme 3.4: Synthesis of adamantane aldehyde 3. 
 
Compound 8 was also coupled with nonanol to obtain the precursors of N-nonyloxypentyl-DNJ. 
As with 9, ether 10 was exposed to DDQ in order to remove the PMB protecting group, but the 
radical reaction led to the cleavage of the internal ether moiety, giving nonanol and other 
byproducts. TFA was also unsuccessful for the purpose, whereas ceric ammonium nitrate (CAN) 
eventually afforded the desired alcohol 11. This latter intermediate 11 was then oxidized to 
aldehyde 12, again under Swern conditions (Scheme 3.5). 
 
PMBO O
PMBO OTs
67%8
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1112
HO OO O
OH
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NaH
74%
(COCl)2,
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99%
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Scheme 3.5: Synthesis of nonyl aldehyde 12. 
 
 
3.3. COUPLING OF ALDEHYDES WITH D- AND L-DNJ 
 
Benzylated DNJ and L-DNJ (18, 19) were synthesized starting from commercially available 
2,3,4,5-tetra-O-benzyl-D-glucopyranose and 2,3,4,5-tetra-O-benzyl-L-glucopyranose, according 
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to Overkleeft et al.40 by the research group were this section of the thesis was carried out (Scheme 
3.6). 
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Scheme 3.6: (a) DMSO, Ac2O; (b) NH3/MeOH; (c) DMSO, Ac2O; (d) NH3/MeOH; (e) NaBH3CN, HCO2H; (f) 
LiAlH4. 
 
The coupling carried out with benzylated DNJ (18) and the adamantane-aldehyde 3 in presence 
of NaBH3CN gave the protected N-(5-adamantane-1-yl-methoxypentyl)-DNJ with an excellent 
yield (Scheme 3.7). 
 
 
Scheme 3.7: Construction of protected adamantane-DNJ (4). 
 
Unfortunately the deprotection of 4 carried out with BCl3 gave only byproducts. A change of 
strategy was then necessary, and it was decided to conduct the coupling with D- and L-DNJ after 
their deprotection. 
Indeed, benzylated DNJ and L-DNJ (18, 19) were successfully O-deprotected with an excess of 
BCl3 (Scheme 3.8). 
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Scheme 3.8: Syntheses of DNJ (21) and L-DNJ (24). 
 
The coupling between aldehyde 3 and either the DNJ enantiomers was carried out under mildly 
acidic conditions in presence of NaBH3CN, to provide products 5 and 22 (Scheme 3.9). 
 
 
Scheme 3.9: Synthesis of the final products 5 and 22. 
 
Final reductive amination between aldehyde 12 and either D- and L-DNJ (yielding 23 and 24) 
was carried out as with the adamantane derivative (Scheme 3.10). 
 
 
Scheme 3.10. Synthesis of final products 23 and 24. 
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3.4. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
An efficient synthetic route to N-(5-adamantane-1-yl-methoxypentyl)-DNJ and N-
nonyloxypentyl-DNJ and their enantiomers was accomplished, involving the construction of a 
common intermediate for the hydrophobic moiety. This pathway avoided the demanding reaction 
conditions required in previous described routes36,38, for example in the multiple hydrogenolytic 
de-O-benzylation of the iminosugar moiety or the long-lasting coupling between DNJ and a 
suitable alkyl bromide. The obtained products will be tested for their biological activity.  
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4. EXPERIMENTAL SECTION 
 
 
All air sensitive manipulations were carried out under dry nitrogen atmosphere. Solvents and 
all standard reagents were purchased from Sigma Aldrich, Alfa Aesar of VWR and were used 
without further purification. 
Analytical thin-layer chromatography was performed on SiO2 (Merck silica gel 60 F254), and 
the spots were located with ultraviolet radiation, iodine vapor and chromic mixture. 
Chromatography refers to flash chromatography and was carried out on SiO2 (Merck Kieselgel 60, 
230-400 mesh). Drying of organic extracts during workup of reactions was performed over 
anhydrous Na2SO4. Evaporation of solvent was accomplished with a rotary evaporator. NMR 
spectra were recorded at 400 MHz (1H) and 100.6 MHz (13C) (Bruker DRX, Bruker Avance) and 
chemical shifts are reported in δ values downfield from TMS or relative to residual chloroform 
(7.26 ppm, 77.0 ppm) as an internal standard. Data are reported in the following manner: chemical 
shift, integrated intensity, multiplicity, coupling constant (J) in Hertz (Hz), and assignment (when 
possible).  
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5-((4-Methoxybenzyl)oxy)pentan-1-ol (7). 
 
To a stirred suspension of NaH (376 mg, 9.40 mmol, 60% dispersion in mineral oil) in THF (13.5 
ml) under argon at 0 °C was added via cannula a solution of 1,5-pentanediol (3.0 ml, 28.6 mmol) 
in THF (4.5 ml). The reaction was heated to reflux for 3 h, then allowed to cool to rt. TBAI (79 
mg, 0.214 mmol) and PMBCl (591 µl, 4.27 mmol) were added, and the mixture was again heated 
to reflux for 12 h. Water was then added, and the crude was extracted with EtOAc. The combined 
organic extracts were dried over anhydrous Na2SO4, filtered and concentrated under reduced 
pressure. Flash chromatography (7:3 hexane-EtOAc) of the residue afforded 7 (949 mg, 99%). 
 
1H NMR (400 MHz, CDCl3): δ 1.41-1.47 (m, 2H, H-3), 1.54-1.67 (m, 4H, H-2, H-4), 3.45 (t, 2H, 
J = 6.5 Hz, H-5), 3.62 (t, J = 6.4 Hz, 2H, H-1), 3.80 (s, 3H, OCH3), 4.42 (s, 2H, CH2-Ar), 6.87 (d, 
J = 8.7 Hz, 2H, H-m Ar), 7.25 (d, J = 8.7 Hz, 2H, H-o Ar). 
 
13C NMR (100.6 MHz, CDCl3): δ 22.4 (C-3), 29.6 (C-4), 29.4 (C-2), 55.2 (OCH3), 62.7 (C-1), 
70.0 (C-5), 72.5 (CH2-Ar), 113.7 (C-m Ar), 129.2 (C-o Ar), 130.6 (C-i Ar), 159.1 (C-p Ar). 
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5-((4-Methoxybenzyl)oxy)pentan-1-yl 4-methylbenzenesulfonate (8). 
 
To a cooled (0 °C) solution of 7 (958 mg, 4.27 mmol) in pyridine (30 ml) was added p-
toluenesulfonyl chloride (1.61 g, 8.45 mmol), and the reaction mixture was stirred at the same 
temperature overnight. Ethyl acetate and water were added, and the crude was extracted. 
Combined organic extracts washed with brine, dried (Na2SO4), filtered, and concentrated under 
reduced pressure. Flash chromatography (8:2 hexane-EtOAc) of the residue afforded compound 8 
(1.535 g, 95%). 
 
1H NMR (400 MHz, CDCl3): δ 1.35-1.42 (m, 2H, H-3), 1.51-1.58 (m, 2H, H-4), 1.62-1.69 (m, 2H, 
H-2), 2.44 (s, 3H, CH3 Ts), 3.39 (t, J = 6.3 Hz, 2H, H-5), 3.80 (s, 3H, OCH3), 4.01 (t, J = 6.5 Hz, 
2H, H-1), 4.40 (s, 2H, CH2-Ar), 6.87 (d, J = 8.5 Hz, 2H, H-m PMB), 7.23 (d, J = 8.3 Hz, 2H, H-o 
PMB), 7.33 (d, J = 8.2 Hz, 2H, H-m Ts), 7.78 (d, J = 8.1 Hz, 2H, H-o Ts). 
 
13C NMR (100.6 MHz, CDCl3): δ 21.5 (CH3 Ts), 22.1 (C-3), 28.5 (C-2), 28.9 (C-4), 55.2 (OCH3), 
69.5 (C-1), 70.4 (C-5), 72.4 (CH2-Ar), 113.7 (C-m PMB), 127.8 (C-o Ts), 129.1 (C-o PMB), 129.8 
(C-m Ts), 130.4 (C-i PMB), 133.0 (C-p Ts), 144.6 (C-i Ts), 159.0 (C-p PMB). 
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5-(Adamantane-1-yl-methoxy)-1-((4-methoxybenzyl)oxy)pentane (9). 
 
To a dry solution of adamantanemethanol (438 mg, 2.63 mmol) in DMF (4.5 ml) was added at 0 
°C NaH (210 mg, 5.26 mmol, 60% dispersion in mineral oil), and the mixture was heated to 40 °C 
for one hour. Next, a dry solution of tosylate 8 (829 mg, 2.19 mmol) in DMF (1.5 ml) was added 
to the reaction and the mixture was stirred at the same temperature overnight. The reaction was 
then quenched at 0 °C with MeOH and extracted with EtOAc. The combined organic layers were 
dried (Na2SO4), filtered, concentrated under reduced pressure and the resulting residue was 
purified by flash chromatography (97:3 hexane-EtOAc) to furnish 9 (626 mg, 77%). 
 
1H NMR (400 MHz, CDCl3): δ 1.39-1.47 (m, 2H, H-3), 1.52 (br d, J = 2.4 Hz, 6H, H adamantane), 
1.55-1.60 (m, 2H, H adamantane), 1.62-1.72 (m, 8H, H-2, H-4, H adamantane), 1.95 (br s, 3H, H 
adamantane), 2.94 (s, 2H, CH2-adamantane), 3.37 (t, J = 6.6 Hz, 2H, H-5), 3.47 (t, J = 5.8 Hz, 2H, 
H-1), 3.80 (s, 3H, OCH3), 4.49 (s, 2H, CH2-Ar), 6.87 (d, J = 8.7 Hz, 2H, H-m Ar), 7.25 (d, J = 8.7 
Hz, 2H, H-o Ar). 
 
13C NMR (100.6 MHz, CDCl3): δ 22.8 (C-3), 28.3 (C adamantane), 29.4 (C-4), 29.6 (C-2), 34.0 
(C adamantane), 37.2 (C adamantane), 39.7 (C adamantane), 55.3 (OCH3), 70.1 (C-1), 71.9 (C-5), 
72.5 (CH2-adamantane), 81.9 (CH2-Ar), 113.7 (C-m Ar), 129.2 (C-o Ar), 130.7 (C-i Ar), 139.0 (C-
p Ar). 
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5-(Adamantane-1-yl-methoxy)pentan-1-ol (2). 
 
Compound 9 (616 mg, 1.66 mmol) was dissolved in CH2Cl2 (36 mL), and water (4 ml) and DDQ 
(752 mg, 3.31 mmol) were added. The resulting mixture was stirred at rt for 5 hours. The two 
phases were separated, and the organic layer was washed with water, dried and concentrated under 
reduced pressure. The crude 5 was purified by flash chromatography (hexane-EtOAc 8:2) to give 
pure 2 (363 mg, 87%). 
 
1H NMR (400 MHz, CDCl3): δ 1.41-1.70 (m, 18H, H-2, H-3, H-4, H adamantane), 1.95 (br s, 3H, 
H adamantane), 2.96 (s, 2H, CH2-adamantane), 3.39 (t, J = 6.6 Hz, 2H, H-5), 3.65 (t, J = 5.8 Hz, 
2H, H-1). 
 
13C NMR (100.6 MHz, CDCl3): δ 22.2 (C-3), 28.0 (C adamantane), 29.1 (C-4), 32.2 (C 
adamantane), 33.9 (C-2), 37.0 (C adamantane), 39.5 (C adamantane), 62.3 (C-1), 71.4 (C-5), 81.8 
(CH2-adamantane). 
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5-(Adamantane-1-yl-methoxy)pentan-1-al (3). 
 
A solution of oxalylchloride (32 µl, 0.375 mmol) in DCM (5 µl) was cooled to –78 °C. After 
dropwise addition of DMSO (53 µl, 0.750 mmol) in DCM (500 µl), the mixture was stirred for 30 
min. A dry solution of 2 (86 mg, 0.341 mmol) in DCM (500 µl) was added dropwise to the reaction 
at –78 °C. After two hours, TEA (237 µl, 1.70 mmol) was added, and the mixture was allowed to 
warm to rt over two hours. The reaction was quenched with few drops of aqueous HCl 0.01 M and 
extracted. The combined organic extracts were dried over anhydrous Na2SO4, filtered, and 
concentrated under reduced pressure, affording pure aldehyde 3 (86 mg, 99% yield). 
 
1H NMR (400 MHz, CDCl3): δ 1.50 (br s, 6H,  H adamantane), 1.55-1.69 (m, 10H, H-3, H-4, H 
adamantane), 1.93 (br s, 2H,  H adamantane), 2.44 (app t, J = 7.1 Hz, 2H, H-2), 2.92 (s, 2H, CH2-
adamantane), 3.36 (t, J = 5.9 Hz, 2H, H-5), 9.75 (s, 1H, H-1). 
 
13C NMR (100.6 MHz, CDCl3): δ 18.9 (C-3), 28.2 (C adamantane), 28.9 (C-4), 34.0 (C 
adamantane), 37.1 (C adamantane), 39.6 (C adamantane), 43.6 (C-2), 70.8 (C-5), 81.9 (CH2-
adamantane), 202.8 (C-1). 
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5-(Nonyloxy)-1-((4-methoxybenzyl)oxy)pentane (10). 
 
To a dry solution of nonanol (1.15 ml, 6.59 mmol) in DMF (30 ml) was added at 0 °C NaH (527 
mg, 13.9 mmol, 60% dispersion in mineral oil), and the mixture was heated to 50 °C for 3 hour 
(until the end of the gas evolution). Next, a dry solution of tosylate 8 (1.66 g, 4.39 mmol) in DMF 
(10 ml) was added to the reaction at 0 °C and the mixture was stirred at the same temperature 
overnight. The reaction was then quenched with MeOH and concentrated under reduced pressure. 
The resulting residue was purified by flash chromatography (97:3 hexane-EtOAc) to furnish 10 
(1.032 g, 67%). 
 
1H NMR (400 MHz, CDCl3): δ 0.88 (t, J = 6.2 Hz, 3H, H-9’), 1.26 (br s, 10H, H-4’, H-5’, H-6’, 
H-7’, H-8’), 1.39-1.45 (m, 2H, H-3’), 1.54-1.66 (m, 8H, H-2, H-3, H-4, H-2’), 3.36-3.41 (m, 4H, 
H-5, H-1’), 3.44 (t, J = 6.6 Hz, 2H, H-1), 3.80 (s, 3H, OCH3), 4.43 (s, 2H, CH2-Ar), 6.87 (d, J = 
8.4 Hz, 2H, H-m Ar), 7.25 (d, J = 8.3 Hz, 2H, H-o Ar). 
 
13C NMR (100,6 MHz, CDCl3): δ 14.0 (C-9’), 22.6 (C-3), 22.7 (C-8’), 28.1, 29.2, 29.5, 29.6, 29.7 
(C-2, C-4, C-2’, C-3’, C-4’, C-5’, C-6’), 31.8 (C-7’), 55.2 (OCH3), 70.0 (C-1), 70.8 (C-1’), 70.9 
(C-5), 72.4 (CH2-Ar), 113.6 (C-m Ar), 129.1 (C-o Ar), 130.7 (C-i Ar), 159.0 (C-p Ar). 
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5-(Nonyloxy)pentan-1-ol (11). 
 
Compound 10 (49 mg, 0.140 mmol) was suspended in a mixture of acetonitrile and water in ratio 
9:1 (1.5 ml), and CAN (383 mg, 0.699 mmol) was added. After 30 minutes the reaction mixture 
was extracted with EtOAc and aqueous NaHCO3. The combined organic extracts were dried, 
filtered and concentrated under pressure. Flash chromatography (9:1 to 8:2 hexane-EtOAc) of the 
residue gave the compound 11 (24 mg, 74%). 
 
1H NMR (400 MHz, CDCl3): δ 0.87 (t, J = 6.7 Hz, 3H, H-9’), 1.26 (br s, 10H, H-4’, H-5’, H-6’, 
H-7’, H-8’), 1.40-1.45 (m, 2H, H-3’), 1.53-1.62 (m, 8H, H-2, H-3, H-4, H-2’), 3.39 (app q, J = 
14.2, 6.6 Hz, 4H, H-5, H-1’), 3.64 (t, J = 6.5 Hz, 2H, H-1). 
 
13C NMR (100,6 MHz, CDCl3): δ 14.0 (C-9’), 22.3 (C-3), 22.5 (C-8’), 28.0, 29.2-29.6 (C-2, C-4, 
C-3’, C-4’, C-5’, C-6’), 31.8 (C-2’), 32.3 (C-7’), 62.3 (C-1), 70.6 (C-1’), 70.9 (C-5). 
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5-(Nonyloxy)pentan-1-al (12). 
 
A solution of oxalylchloride (34 µl, 0.406 mmol) in DCM (10 µl) was cooled to –78 °C. After 
dropwise addition of DMSO (58 µl, 0.812 mmol) in DCM (500 µl), the mixture was stirred for 30 
min. A dry solution of 11 (85 mg, 0.369 mmol) in DCM (500 µl) was added dropwise to the 
reaction at –78 °C. After two hours, TEA (257 µl, 1.84 mmol) was added, and the mixture was 
allowed to warm to rt over 90 minutes. The reaction was quenched with few drops of aqueous HCl 
0.01 M and extracted. The combined organic extracts were dried over anhydrous Na2SO4, filtered, 
and concentrated under reduced pressure, affording pure aldehyde 12 (70 mg, 99% yield). 
 
1H NMR (400 MHz, CDCl3): δ 0.80 (t, J = 6.2 Hz, 3H, H-9’), 1.19 (br s, 12H, H-3’, H-4’, H-5’, 
H-6’, H-7’, H-8’), 1.47 (dt, J = 13.5, 6.7 Hz, 2H, H-2’), 1.52 (dt, J = 14.3, 6.2 Hz, 2H, H-4), 1.64 
(dt, J = 14.4, 6.9 Hz, 2H, H-3), 2.39 (t, J = 7.1 Hz, 2H, H-2), 3.30 (t, J = 6.7 Hz, 2H, H-5), 3.33 (t, 
J = 6.3 Hz, 2H, H-1’), 9.69 (s, 1H, H-1). 
 
13C NMR (100,6 MHz, CDCl3): δ 14.0 (C-9’), 18.9 (C-3), 22.6 (C-8’), 26.1, 29.0-29.6 (C-4, C-3’, 
C-4’, C-5’, C-6’, C-7’), 31.8 (C-2’), 43.5 (C-2), 70.1 (C-5), 71.0 (C-1’), 202.5 (C-1). 
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(2R,3R,4R,5S)-1-(N-(5-(adamantan-1-ylmethoxy)pentyl))-2-((benzyloxy)methyl)piperidine-
3,4,5-tris(benzyloxy)) (4).  
 
A reaction flask was charged with aldehyde 3 (36 mg, 0.143 mmol), 2,3,4,5-tetra-O-benzyl-D-
nojirimycin (18) (30 mg, 0.0574 mmol), MeCN (966 µL) and glacial AcOH (34 µl), and finally 
was added NaBH3CN (7 mg, 0.115 mmol) under inert atmosphere. The reaction was stirred 
overnight, then was quenched with an aqueous solution of NaHCO3 and extracted. The combined 
organic extracts were dried over anhydrous Na2SO4, filtered, and concentrated under reduced 
pressure. Flash chromatography (95:5 to 8:2 hexane-EtOAc) of the resulting residue afforded 
compound 4 (56 mg, 99%). 
For NMR spectra and data see: J. Org. Chem. 2007, 72, 1088. 
 
 
 
 
 
(2R,3R,4R,5S)-2-(Hydroxymethyl)piperidine-3,4,5-triol), 1-deoxynojirimycin, DNJ (20).  
(2S,3S,4S,5R)-2-(Hydroxymethyl)piperidine-3,4,5-triol), L-1-deoxynojirimycin, L-DNJ (21). 
 
To a solution of 2,3,4,5-tetra-O-benzyl-D-nojirimycin (18) or 2,3,4,5-tetra-O-benzyl-L-nojirimycin 
(19) (246 mg, 0.470 mmol) in DCM (10 ml) was added at 0 °C BCl3 (4.70 ml, 4.70 mmol, solution 
1 M in DCM) and the mixture was allowed to warm to rt overnight. The reaction was quenched 
with MeOH at 0 °C and concentrated under reduced pressure. The residue was washed with Et2O, 
EtOAc and MeOH, and the resulting precipitate was dried, affording 20 or 21 (69 mg, 90%). 
For NMR spectra and data see: Org. Biomol. Chem. 2011, 9, 1372; Tetrahedron. 2007, 63, 6827. 
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N-(5-(adamantan-1-ylmethoxy)pentyl)-1-deoxynojirimycin, AMP-DNM (5). 
N-(5-(adamantan-1-ylmethoxy)pentyl)-1-L-deoxynojirimycin, L-AMP-DNM (22). 
 
A reaction flask was charged with aldehyde 3 (29 mg, 0.116 mmol), DNJ (20) or L-DNJ (21) (13 
mg, 0.0773 mmol), EtOH (1 mL) and glacial AcOH (10 µl), and finally was added NaBH3CN (7 
mg, 0.116 mmol) under inert atmosphere. The reaction was stirred for 2 days, then was 
concentrated under reduced pressure. The residue was suspended in HCl 5% (500 µl), neutralized 
to pH 7.5 with solid Na2CO3 and extracted with DCM. Combined organic extracts washed with 
brine, dried (Na2SO4), filtered, and concentrated under reduced pressure. Flash chromatography 
(7.6:2.2:0.2 DCM-MeOH-NH3 aq) of the resulting residue afforded compounds 5 and 22 (23 mg, 
85%). 
 
1H NMR (400 MHz, MeOD): δ 1.43-1.51 (m, 2H, H-3’), 1.56 (br s, 6H, H adamantane), 1.61-1.69 
(m, 4H, H-2’, H-4’), 1.74-1.87 (m, 6H, H adamantane), 1.94 (br s, 3H, H adamantane), 2.98 (br s, 
2H, CH2-adamantane), 2.99-3.07 (m, 2H, H-1’), 3.20 (dt, J = 12.1, 5.2 Hz, 1H, H-5), 3.30-3.48 
(m, 5H, H-1, H-2, H-3, H-4), 3.60 (t, J = 9.8 Hz, 1H, H-5’), 3.67-3.72 (m, 1H, H-5’), 3.90 (app d, 
J = 12.2 Hz, 1H, H-6), 4.11 (d, J = 12.2 Hz, 1H, H-6). 
 
13C NMR (100,6 MHz, MeOD): δ 22.6 (C-2’), 23.2 (C-3’), 28.2 (C adamantane), 28.7 (C 
adamantane), 36.8 (C adamantane), 39.3 (C adamantane), 52.6 (C-4’), 53.6 (C-1’), 54.2 (C-1), 
65.9 (C-6), 66.6 (C-5), 67.7 (C-2), 70.7 (C-4), 71.1 (C-5’), 76.9 (C-3), 81.6 (CH2-adamantane). 
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N-(Nonyloxypentyl)-1-deoxynojirimycin (23). 
N-(Nonyloxypentyl)-1-L-deoxynojirimycin (24). 
 
A reaction flask was charged with aldehyde 3 (45 mg, 0.197 mmol), DNJ (20) or L-DNJ (21) (21 
mg, 0.132 mmol), EtOH (1.6 mL) and glacial AcOH (10 µl), and finally was added NaBH3CN (12 
mg, 0.197 mmol) under inert atmosphere. The reaction was stirred for 2 days, then was 
concentrated under reduced pressure. The residue was suspended in HCl 5% (800 µl), neutralized 
to pH 7.5 with solid Na2CO3 and extracted with DCM. Combined organic extracts washed with 
brine, dried (Na2SO4), filtered, and concentrated under reduced pressure. Flash chromatography 
(DCM to 7:3 DCM-MeOH) of the resulting residue afforded compounds 23 and 24 (31 mg, 95%). 
 
1H NMR (400 MHz, MeOD): δ 0.89 (t, J = 7.1 Hz, 3H, H-9”), 1.29 (br s, 12H, H-3”, H-4”, H-5”, 
H-6”, H-7”, H-8”), 1.43-1.49 (m, 2H, H-3’), 1.52-1.58 (m, 2H, H-2”), 1.60-1.67 (m, 2H, H-4’), 
1.70-1.83 (m, 2H, H-2’), 2.97 (t, J = 11.9 Hz, 1H, H-1), 3.04 (br. d, J = 9.4 Hz, 1H, H-5), 3.19 (dt, 
J = 12.1, 5.3 Hz, 1H, H-1’), 3.30-3.31 (m, 2H, H-1’, H-3), 3.34-3.49 (m, 5H, H-1, H-5’, H-1”), 
3.61 (t, J = 9.8 Hz, 1H, H-4), 3.68-3.74 (m, 1H, H-2), 3.91 (br d, J = 12.6 Hz, 1H, H-6), 4.09 (br 
d, J = 12.4 Hz, 1H, H-6). 
 
13C NMR (100.6 MHz, MeOD): δ 14.6 (C-9”), 23.0 (C-8”), 23.9 (C-3’), 24.7 (C-2’), 25.0 (C-3”), 
27.4 (C-6”), 30.4, 30.5, 30.7, 30.9, 33.2 (C-4’, C-2”, C-4”, C-5”, C-7”), 54.1 (C-1’), 56.5 (C-1), 
57.6 (C-6), 67.5 (C-5), 69.5 (C-2), 70.7 (C-4), 71.8 (C-5’), 72.2 (C-1”), 79.6 (C-3). 
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1. INTRODUCTION 
 
 
Alkaloids are a group of natural products that contain mostly basic nitrogen atoms. They are 
found in a large variety of organisms from bacteria to animals, but also in fungi, plants, and 
sponges. Owing to their basic nature, alkaloids can be purified from crude extracts of source 
organisms by acid-base extraction. Despite several efforts, a true exhaustive classification of these 
compounds is lacking because of their great structural diversity. 
Some alkaloids are commonly known for their psychotropic and stimulant activities (cocaine, 
caffeine, nicotine), but they also have a wide range of pharmacological activities, including 
antimalarian (quinine), antiasthma (ephedrine)1, analgesic (morphine)2 or anticancer 
(homoharringtonines)1. Most of the pharmacological activities of alkaloids are still unknown, as 
well as their biological role for living organism that produce them. In last years the attention is 
focused on the possible exploitation of alkaloids in still incurable diseases, like cancer. 
Cancer collects different diseases involving abnormal cell growth with the potential to invade 
or spread from one tissue to another the body3. There are over 100 different known cancers that 
affect humans4. In 2012 about 14.1 million new cases of cancer occurred globally (not including 
skin cancer other than melanoma); it caused about 8.2 million deaths or 14.6% of all human 
deaths1. Because cancer is a class of diseases5, there will not ever be a single cure, and new 
different treatments are now being tested in clinical trials to compare the proposed treatment to the 
best existing one6.  There are intense efforts in scientific research to understand the disease 
processes and discover possible therapies. Madangamines7 constitute a relatively new family of 
marine alkaloids isolated from Haplosclerida sponges. Some members of this class of natural 
products show significant anticancer activity which can be of therapeutic interest in a future.  
 
 
1.1. MARINE SPONGES OF HAPLOSCLERIDA AS A SOURCE OF 
BIOACTIVE ALKALOIDS 
 
Sponges (phylum Porifera) are considered the most primitive multicellular form of life. They 
first appeared on Earth almost 600 million years ago and had just a little structural evolution since 
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that time8. Sponges, as well as other sessile marine invertebrates, are filter feeders that have 
developed efficient defense mechanisms against foreign aggressors including viruses, bacteria, or 
eukaryotic organisms8. Marine sponges are among the richest sources of pharmacologically-active 
chemicals from marine organisms and more than half of all known alkaloids of marine origin have 
been isolated from sponges. Often the bioactive secondary metabolites isolated from sponges are 
the outcome of functional enzyme clusters, which originated from the sponges and their associated 
microorganisms. More than five-thousand different products are known from sponges and their 
associated microorganisms, and their number increases of more than 200 new products each year. 
These large numbers are expected to come from the need of the sponges to acquire novel leads 
against bacterial, viral, fungal and parasitic diseases, as these infectious microorganisms evolve 
and develop resistance to existing compounds. 
Chemical studies carried out over the last decades proved that sponges are important sources of 
novel steroids, terpenoids, peptides, macrolides, and alkaloids9 featuring potential clinical interest. 
Indeed, several marine natural products have successfully advanced to the late stages of clinical 
trials and moreover a growing number of candidates is constantly considered as promising leads 
for extended preclinical assessment. 
In this context, marine sponges in the order Haplosclerida are the source of more than one 
hundred biogenetically related alkaloids, in particular of 3-alkylpyridine and 3-alkylpiperidine 
alkaloids. The first 3-alkylpiperidine sponge alkaloid, the halitoxin, was discovered in 1978 by 
Schmitz et al.10, and since then other chemical studies performed on Haplosclerida sponges 
allowed the isolation of a large variety of alkaloids.  
As a group, the 3-alkylpiperidines are characterized by the diversity and complexity of their 
chemical structures and by the range of biological activities that they exhibit11. There are eleven 
macrocyclic skeletons known within the 3-alkylpiperidine family: these include the 
haliclamine/cyclostellettamine, ingenamine, madangamine, ircinal, manzamine, halicyclamine, 
saraine 1-3, saraine A to C, petrosin, xestospongin/araguspongine and aragupetrosine skeletons 
(Figure 1.1). Three of these skeletal types, belonging to the ingenamine12, madangamine7 and 
halicyclamine13 alkaloids, were first isolated and all reported in 1994. For this reason, this is 
considered a relatively young line of research, and the potential of these alkaloids has not been 
still completely explored. 
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Figure 1.1: 3-alkylpiperidine alkaloids. 
 
The 3-alkylpiperidine alkaloids stand, from the beginning, as a challenge to the extant 
methodology for chemical structure elucidation. In the case of most of the macrocyclic 3-
alkylpiperdine alkaloids, the difficulties associated with analyzing the NMR data associated to the 
long chain alkyl bridges spanning the nitrogen containing polycyclic cores have complicated the 
structure elucidation leading occasionally to incorrect structural hypothesis. It is interesting to note 
that the saraines, a class of alkaloids isolated from Reniera sarai, a sponge extensively found in 
the Bay of Naples, have a chemical structure so complicated that was elucidated after 9 years of 
investigations by Cimino and co-workers14. The availability of 2D experiments conducted on high 
field NMR spectrometers and X-rays diffraction analysis finally proved to be a structural tool 
powerful enough to meet the challenge of unambiguously determining the connectivity in the long 
chain alkyl bridges14. 
Many types of biological activity were found in 3-alkylpiperidine alkaloids suggesting their 
potential use as source of drugs. In particular, the antileukaemic activities of the manzamines15, 
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the antibacterial and antitumoral properties of the saraines16 and madangamines17, have attracted 
much attention. 
 The combination of potent biological activity and structural complexity found in the 3-
alkylpiperidine alkaloids has spurred the interest synthetic chemists. To date synthetic efforts were 
undertaken towards the synthesis of each component of the family, in particular the most active 
manzamines18, saraines19 and madangamines20. 
 
 
1.2. BIOGENETIC THEORIES 
 
The first tentative biogenetic hypothesis for the 3-alkylpiperidine family was suggested by 
Cimino et al.14. The origin of these alkaloids can be envisaged in the reduced bis-3-alkylpyridine 
macrocycles suggesting a biogenetic relationship between the oligomeric halitoxins and the 3-
alkylpiperidine alkaloids. 
Indeed, it was from the isolation of manzamine A in 1988 that researchers began to realize that 
the biogenesis of all these types of polycyclic alkaloids could have a common path. An elegant 
hypothesis by Whitehead and Baldwin21 proposed that the manzamines arise from a bis-3-
alkyldihydropyridine precursor (Scheme 1.1). Curiously, this hypothesis anticipated the 
occurrence of two new classes of alkaloids corresponding to the pentacyclic and tetracyclic 
intermediates in their biogenetic scheme, the ircinal B (IV)22, the tetracyclic product, and 
ingenamines (II)12, the pentacyclic intermediate. 
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Scheme 1.1: Biogenetical proposal of Whitehead and Baldwin. 
 
According to the proposal, the bis-dihydropyridinium cycles arise from ammonia, a C10 di-
aldehyde and a C3 acrolein equivalent. These units are assembled into a 3-alkylpiperidine 
monomer that can either polymerize leading the oligomeric halitoxins or dimerize into a bis(3-
alkylpiperidine) macrocycle (I). The dimer (featuring tautomerism) evolved into intermediate II 
via an endo intramolecular [4+2] Diels-Alder cycloaddition. Final intermediate IV, corresponding 
to ircinal B, was originated via an hydrolytic ring-opening and a condensation with tryptophan. A 
further oxidation step led to the manzamine B (V) and similar paths lead to related polycyclic 
skeletons found in many of these complex alkaloids. 
In 1994, Kong et al.7,24 conjectured a different biosynthetic pathway to 3-alkylpiperidine and 
in particular to madangamines, outlined in Scheme 1.2. 
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Scheme 1.2: Kong’s biogenesis for madangamines. 
 
In the Kong model, in analogy with the Whitehead and Baldwin proposal, the biogenesis starts 
from ammonia, a C10 di-aldehyde, and a C3 acrolein equivalent and proceeds through a partially 
reduced bis-3-alkylpyridine (VI), which undergoes a [4+2] cycloaddition to generate the 
intermediate VII, related to the ingenamine class of alkaloids. This ingenamine-type intermediate 
can then undergo a fragmentation to give the tetracyclic intermediate IX, that gives the 
regioisomeric iminium ion X with a redox exchange between the two nitrogen atoms. Subsequent 
“aza-Prins-type” reaction generate the madangamine skeleton XI. It may be that enzyme(s) 
catalysing this rearrangement has a specific requirement for a particular chain length and 
functionality in the C-3 to N-11 bridge in the putative ingenamine precursor. Thus, most of the 
resulting madangamines have identical N-1 to C-3 bridges but show variations in the N-7 to C-9 
bridge. 
An alternatively theory, suggested by Marazano et al.25, is illustrated in Scheme 1.3. 
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Scheme 1.3: Marazano’s proposal for madangamines’ biosynthesis. 
 
In this proposal, Marazano suggests that manzamine alkaloids can alternatively be viewed as 
derived from two unsaturated long-chain aminoaldehydes and two malono-dialdehyde units. 
Natural 3-alkylpyridinium salt derivatives (XII) are obtained with a cyclization in an acidic 
medium; the resulting macrocycle with an intramolecular Diels-Alder reaction gives the tetracyclic 
intermediate XIII. An oxidation leads to the advanced intermediate of the syntheses of 
manzamines and ircinals (XIV): in fact, reduction of this tetracyclic compound followed by 
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oxidation can give access to ircinal derivatives such as ircinal B (n = 1, IV), precursor of 
manzamine. 
As an alternate pathway, intermediate XIV (n = 3) was reduced to give, after double-bond 
migration, amino aldehyde XV. Ring opening could then occur, leading to the imine derivative 
XVI whose reduction would afford secondary amine XVII. Cyclization to the corresponding 
double-iminium salt derivative XVIII, obtained by condensation, could then produce pentacyclic 
intermediate XIX, which with a final double-bond migration affords madangamine C. 
 
 
1.3. MADANGAMINE ALKALOIDS 
 
Madangamines, as seen above, are a group of complex optically active pentacyclic diamine 
alkaloids isolated from the marine sponge Xestospongia ingens of the order Haplosclerida, 
collected by hand using scuba on reefs off Madang, Papua New Guinea. They are apparently 
related to macrocycles like saraines, manzamines, ircinals, petrosins, through a common 
biogenetic bis-3-alkylpiridine precursor, as emerges from their structures and proposed biogenetic 
theories.  
Andersen et al.7 isolated in 1994 the first madangamine alkaloid, the A (XI, Figure 1.2), that 
showed in vitro cytotoxicity against murine leukemia P388 (ED50 0.93 µg/mL) and human lung 
A549 (ED50 14 µg/mL), brain U373 (ED50 5.1 µg/mL), and breast MCF-7 (ED50 5.7 µg/mL) cancer 
cell lines. The isolation was conducted with multiple extractions of specimens of X. ingens with 
MeOH, and the combined MeOH extracts were reduced in vacuo to an aqueous suspension. This 
suspension was diluted with distilled H2O and then partitioned sequentially against hexane and 
EtOAc. Repeated fractionation of the hexane-soluble materials using silica gel flash 
chromatography and normal-phase HPLC led to the isolation of madangamine A7. 
Madangamines from B to E (XX-XXIII) were isolated via the same way by Andersen et al. in 
199824. A detailed analysis of the NMR data and mass spectrometry identified the constitution and 
relative configurations of the whole structure of madangamines7,24. The basic madangamine 
skeleton consists of a tricyclic core (ABC rings) and two linear bridges (DE rings). The central 
tricyclic core, unprecedented among natural products, is constituted by two piperidine rings both 
in chair conformation cis-fused, attached to a carbocyclic ring with a slightly flattened chair 
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conformation. The E ring (N-1 to C-3 bridge) consists of two Z skipped double bonds, one 
connected to the carbocyclic ring, and is identical for A-E madangamines, while D ring (N-7 to C-
9 bridge) shows variations both in size (13 to 15-membered) and in the position and degree of 
unsaturation (Figure 1.2).  
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Figure 1.2: Madangamine alkaloids. 
 
All the madangamines are extremely non polar compounds, in fact they dissolve in the hexane 
layer, and this is probably related to their core structure. One of the two nitrogen atoms, the N-7, 
cannot readily invert because the cavity of the central core is too small to easily accommodate the 
C-21 alkyl group. Therefore, the lone pair on the N-7 nitrogen atom is locked in the center of the 
tricyclic core where it is relatively inaccessible for protonation and hydrogen bonding. The 
anticipated result would be a decreased basicity for the N-7 amine and consequently a reduced 
polarity for the madangamines. 
No data regarding the biological activity of B-E madangamines have been reported until now, 
but these alkaloids with their peculiar structure could be an interesting target for both the synthetic 
organic chemists and the pharmaceutical research. 
Another madangamine, the F (XXIV), was isolated in 2007 by Berlink et al.26 from 
Pachychalina alcaloidifera, a different Haplosclerid sponge, collected in Ilha do Pai, Niterói, Rio 
de Janeiro, Brazil27. The crude extract presented a very complex mixture of alkaloids difficult to 
separate. Madangamine F was isolated from the MeOH crude extract by column chromatography 
on silica gel using small amounts (10 g or less) of stationary phase, with a gradient of MeOH in 
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CH2Cl2 or a gradient of 1:1 MeOH/MeCN in CH2Cl2. XXIV shows a remarkable polarity respect 
to the other members of the madangamine group26. 
The comparison of NMR spectra of XXIV with those of other madangamines confirmed the 
structural identity of the madangamine central core. Nevertheless, madangamine F is the first 
member of the madangamine group of alkaloids featuring a C10 (instead of a C8) bridge bearing 
four insaturations between N-1 and C-3 and a hydroxyl group at C-4 (Figure 1.2). The occurrence 
of a hydroxyl group is noteworthy, because confirms that the madangamine skeleton 
biogenetically derives from ingenamines: its position corresponds to the C-4 position in the 
putative ingenamine precursor, which is commonly unsaturated at ∆3,4, and, therefore, is 
susceptible to an enzyme-mediated addition of H2O. 
According to Kumar, also madangamine F shows cytotoxic activity against human central 
nervous system SF295 (ED5019.8 µg/mL), breast MDA-MB435 (ED50 16.2 µg/mL), colon HCT8 
(ED50>25 µg/mL), and leukemia HL60 (ED5016.7 µg/mL) cancer cell lines26. 
 
 
1.4. PREVIOUS SYNTHETIC APPROACHES 
 
Nowadays, several total syntheses are reported for almost every member of the 3-alkylpiperide 
group, especially for the most representative alkaloids with potent pharmaceutical activity18,28. 
Nonetheless, in the case of the madangamine family, only one total synthesis has been reported 
just for madangamine D and was carried out by the research group were this thesis was partially 
developed20. However, several syntheses addressing various madangamine substructures have 
been previously reported by other groups25,29-37. 
The first approach to the tricyclic core of madangamine was reported in 1997 by Weinreb29, 
starting from enone key intermediate XXV (Scheme 1.4), obtained with Hiemsra’s metodology30.  
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 Scheme 1.4: (a) 1,3-butadiene; (b) TosMIC, t-BuOK; (c) DIBAL-H; (d) diallylamine, PPh3, Pd(OCOCF3)2; (e) 
HCl; (f) NH2OH·HCl; (g) LiAlH4; (h) p-BrC6H4SO2Cl, TEA, DMAP;(i) CsF/DMAP, TEA, TsCl; (j) 
NH2OCH2Ph·HCl (k) disiamylborane/H2O2, NaOH; (l) NaH, TBAI, PMBCl; (m) LiAlH4; (n) 
Hg(OCOCF3)2/(CF3)2CHOH, NaBH4. 
 
Though a [4+2] cycloaddition of enone XXV with butadiene at high pressure (12 kbar), the 
desired cis keto azadecalin derivative XXVI was obtained. The ketone functionality was then 
converted to nitrile and subsequently to aldehyde, at the same time an allyl chain was introduced 
selectively giving the appropriate stereochemistry to C-9 (XXVII). Further transformation led to 
primary amine XXVIII, and a two-step reaction with mercuric trifluoroacetate and sodium 
borohydride yielded the tricycle XXIX. The amino alcohol had appropriate functionalities for the 
subsequent construction of both macrocyclic rings, but the large number of steps required to get 
XXIX makes this strategy not suitable. 
 
Kibayashi31 in 2004 proposed a synthesis for the diazatricyclic core involving an intramolecular 
N,O-acetalization of a keto-aminophenol (Scheme 1.5). 
 
 
 
Scheme 1.5: (a) CH2(CN)CO2Et, t-BuOK; (b) (CH2OH)2, p-TsOH; (c) 35% HCHO, KHCO3; (d) MOMCl, i-Pr2EtN; 
(e) (i) LiBH4; (ii) MOMCl, i-Pr2EtN; (f) DIBAL-H i; (g) salicylaldehyde/NaBH4; (h) PPTS; (i) AlH3; (j) H2, Pd/C; 
(k) (i) Boc2O, NaH; (ii) BnBr, NaH;(iii) TBAF;(l) PCC;(m) Tebbe reagent; (n) (i) 9-BBN;(ii) NaOH, H2O2;(o) 
PhthNH, DEAD, Ph3P; (p) (i) HCl;(ii) H2NNH2·xH2O; (q) CbzCl;(r) MsCl, TEA; (s) t-BuOK. 
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Cyclohexanone XXX was subjected to Michael addition and appropriate protections to give 
nitrile ester XXXI that, via several reductions and a final reductive amination with salicylaldehyde, 
was converted to aminophenol XXXII. Upon treatment of XXXII with pyridinium p-
toluenesulfonate in acetone–H2O under reflux, the transiently formed keto-aminophenol 
undergoes intramolecular condensation to give the tetracyclic N,O-acetal XXXIII consisting of 
the 2-azabicyclo[3.3.1]nonane nucleus. Subsequent processes led to ketone XXXIV and then to 
primary alcohol XXXV as a single diastereoisomer, through a hydroboration with 9-BBN from 
the less congested convex β-face. The Mitsunobu reaction, followed by deprotection and 
protection steps, converted the intermediate XXXV to the primary alcohol XXXVI, which via a 
mesylation and treatment to t-BuOK led to the tricyclic compound XXXVII.  
This strategy, despite the efficiency, led to a tricyclic compound that lacked a functionalization 
on C-3, making the construction of E ring impossible. 
Two years later Kibayashi published another paper32 with a different approach to the synthesis 
of madangamine, synthetizing the ACE ring system (Scheme 1.6). 
 
 
Scheme 1.6: (a) CH2(CN)CO2Et; (b) o-C6H4(CH2OH)2, p-TsOH; (c) (i) HCHO; (ii) TBDMSCl, imidazole; (d) (i) 
LiBH4; (ii) TBAF; (e) (i) BnBr, NaH; (ii) PPTS; (f) (i) TBDMSCl; (ii) OsO4, NMO; (g) (i) (CH2OH)2, TMSCl; (ii) 
TBDMSOTf, 2,6-lutidine; (h) DIBAL-H/o-(OH)C6H4CHO, NaBH4; (i) HCl; (j) LiAlH4, AlCl3; (k) H2, Pd(OH)2: (l) 
(i) (Boc)2O; (ii) DMP; (m) (CF3CH2O)2P(=O)CH2CO2Me, KHMDS, 18-crown-6; (n) DIBAL-H; (o) MeCO2Cl; (p) 
(Z)-Bu3SnCH=CH(CH2)4OTBDPS, Pd(dba)2; (q) TBAF; (r) (i) DMP; (ii) TFA; (iii) NaBH(OAc)3. 
 
The cyclohexanone XXXVIII was subjected to Michael addition, protections and 
hydroxymethylation to give nitrile ester XXXIX, that was converted to XL via cleavage of the 
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cyclic acetal. With a strategy similar to the previous one, Kibayashi obtained the reductive 
amination product XLI and then the tetracyclic N,O-acetal XLII as a single diastereoisomer. After 
reductive cleavage of the acetal, hydrogenation, protection and oxidation of XLII, a Still’s Z-
selective Wittig-Horner olefination was accomplished, giving the (Z)-exo-olefin XLIII as major 
product with undesired (E)-isomer in ratio 11:1. The mixture was reduced and 
methoxycarbonylated, leading to XLIV, and to the skipped diene XLV as a single stereoisomer 
after a palladium-catalyzed coupling with the (Z)-vinylstannane, (1,1-
dimethylethyl)(dimethyl){[(5Z)-6-(tributylstannanyl)hex-5-enyl]oxy}silane. Finally, the 11-
membered ring was fabricated by a sequential reaction involving oxidation of XLV with Dess–
Martin periodinane followed by deprotection and intramolecular reductive amination giving rise 
to the expected tricyclic product XLVI. 
This strategy also led to a tricyclic compound lacking a functionalization on C-5, and thus 
unusable to give the pentacyclic madangamine. 
 
A different proposal came from Marazano25 in 2005, who basing upon his biogenetic theory, 
linked madangamines to ircinals. The condensation of the sodium salt of 
diethylacetonedicarboxylate with a dihydropyridinium salt derivative is the key reaction of the 
scheme (Scheme 1.7).  
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Scheme 1.7: (a) BnBr/NaBH4; (b) LDA/n-BuBr; (c) DIBAH; (d) BnNH2; (e) t-BuOK; (f) oxalic acid; (g) py, 
(CF3CO)2O; (h) m-CPBA/(CF3CO)2O; (i) acetone dicarboxylate diethyl ester sodium salt/K2CO3. 
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Nicotinic acid methyl ester (XLVII) after seven step gave the tetrahydropyridine XLVIII, that 
afforded derivative XLIX after a treatment with m-CPBA and trifluoroacetic anhydride. 
Dihydropyridinium salt XLIX was treated with the sodium salt of acetone dicarboxylate diethyl 
ester at ambient temperature, and provided adducts La and Lb in an inseparable mixture. 
Treatment of the crude mixture with an alkaline solution provided two tricyclic products LIa and 
Lib via rearrangement.  
This biogenetically inspired strategy demonstrated the possibility of obtaining the tricyclic 
system with a stereoselective approach with a little number of steps, but unfortunately also in this 
case the C-9 lacks of functionalization required to complete the synthesis of madangamines. 
 
In 2008 Bonjoch33 proposed a synthesis of the tricyclic core of madangamines in a 10-step 
sequence starting from a 4-(aminomethyl)anisole derivative (Scheme 1.8). 
 
 
 
Scheme 1.8: (a) Li, NH3; (b) (i) NCCH2CO2H, PyBOP, TEA; (ii) HCl; (c) NaOEt; (d) AllBr, LDA; (e) (CH2OH)2, 
p-TsOH; (f) AlH3; (g) (i) NsCl, TEA; (ii) HCl; (h) L-selectride; (i) DEAD; PPh3; TEA. 
 
The synthesis began with a Birch reduction of the 4-methoxybenzylamine34 (LII), followed by 
a reductive amination of the resulting dihydroanisole then coupled with cyanoacetic acid. After an 
acid treatment intermediate LIII was obtained. Reaction of LIII with NaOEt induced the 
isomerization of the double bond and then an intramolecular Michael process to 
diastereoselectively give the cis-perhydroisoquinoline LIV. An allylation, followed by a 
protection and a reduction led to diamino derivative LV. After nosylation and cleavage of the 
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acetal group, the resulting ketone was reduced with L-selectride giving the axial alcohol LVI, that 
finally gave the target tricycle LVII with a SN2 substitution. 
In 2015 Bonjoch35 accomplished the synthesis of the tetracyclic ABCD ring system of 
madangamines D-F, starting from a tricyclic derivative synthetized with a different strategy 
respect to the previous one (Scheme 1.9).  
 
 
 
Scheme 1.9: n = 5,6 or 7. (a) PhSH, K2CO3; (b) carboxylic acid chloride, TEA; (c) Grubbs II; (d) H2, Pd/C; (e) 
LiAlH4. 
 
Removal of nosyl group followed by amidation between secondary amine and a carboxylic acid 
with a terminal double bond (constituted by 9, 10 or 11 members, to obtain D ring of madangamine 
E, D or F respectively) afforded intermediate LIX. The RCM was undertaken using Grubbs 
second-generation catalyst, giving LX. Finally, reductions and N-debenzylation led to tetracyclic 
system LXI. 
Akin to other reported strategies, the favorable number of steps cannot compensate the lacking 
of functionalization at C-3 that makes the final annulation of E ring impossible.  
 
Finally, in 2014, the research group of Mercedes Amat and Joan Bosch accomplished the first 
total synthesis of a member of madangamine family20, with a strategy tuned during a work of many 
years (Scheme 1.10). The construction of madangamine D allowed to obtain the absolute 
configuration of madangamines which, until that moment, was only been inferred by correlation 
with that of their presumed biosynthetic precursors, the ingenamines. Furthermore, the obtaining 
of pure madangamine D allowed to run a cytotoxicity test, because it was always isolated in a 
mixture with other madangamines. Madangamine D showed significant in vitro cytotoxic activity 
against human colon HT29 (GI50 4.4 µg mL-1) and pancreas PSN1 (GI50 7.4 µg mL-1) cancer cell 
lines.  
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Scheme 1.10: (a) LiHMDS, (Boc)2O/C6H5SeCl; (b) H2O2; (c) AllMgBr, TMSCl; (d) Grubbs II; (e) NaH, 
(CH2O)2CH(CH2)3Br; (f) Na, NH3/LiAlH4/(Boc)2O; (g) TEA, MsCl; (h) NaN3; (i) m-CPBA; (j) Me3P; (k) TsCl, 
TEA; (l) NaH, BnBr; (m) TFA/ClCO(CH2)5CH=CH2, TEA; (n) HCl/t-BuOK, Br- Ph3P+CH3; (o) Grubbs I; (p) H2, 
Pd/C/DMP; (q) NaHMDS, Br- (Z)-Ph3P+CH2CH2CH=CH(CH2)3CO2Me;(r) Na, naphthalene; (s) LiOH/EDCI, HOBt; 
(t) LiAlH4. 
 
In the Amat-Bosch scheme, the enantiopure lactam36 LXII was converted to LXIII with a 
conjugate addition of an allyl chain and then the intermediate LXIV was obtained by a RCM and 
a stereoselective alkylation. At this point, the removal of the chiral auxiliary followed by protection 
of the resulting nitrogen with Boc and the conversion of hydroxyl to azide afforded product LXV. 
Oxidation of bicyclic LXV led to the formation of an epoxide, and the azide moiety was reduced 
with a Staudinger reaction to a primary amine. The spontaneous cyclization and protection of the 
resulting secondary amine moiety afforded the diazatricyclic core of madangamines (LXVI). The 
next step was the construction of D ring, achieved with a RCM between the terminal double bonds 
of two alkyl chains (LXVII). One of the chains was obtained with an acylation of nitrogen with 
7-octenoyl chloride, and the other via a Wittig methylenation of unprotected acetal moiety. 
Reduction of the resulting double bond led to saturated ring. The last E ring was assembled with a 
Wittig reaction of the ketone moiety anchored to the tetracyclic system, followed by the amidation 
between the carboxyl and the cyclic secondary amine. 
The construction of E ring in this strategy shows some weaknesses: the Wittig reaction between 
the alkyl chain and the ketone moiety of the tetracyclic system has just a selectivity Z/E 2:1.  
 
The most recent approach to the tricyclic core of madangamines was reported by Chida37 in 
2015, who started from the synthesis of the cis fused diazadecalin structure (Scheme 1.11). 
148 
 
 
Scheme 1.11: (a) AllOTIPS, 9-BBN/PdCl2, Cs2CO3; (b) (i) DIBAL-H, BF3·Et2O; (ii) Ac2O, py, DMAP; (c) (i) 
AllBr, NaH; (ii) MeC(OMe)3, t-BuCO2H; (d) (i) HCONH2, NaOMe; (ii) 2-TMS-ethanol, PhI(OAc)2; (e) (i) Grubbs 
I; (ii)HC≡CCH2Br, NaH; (f) PdCl2, CO, NaOAc; (g) Pd2dba3·CHCl3, HCO2H; (h) NaBH4; (i) MeNHOMe·HCl, i-
PrMgCl; (j) DIBAL-H; (k) (i) Ph3PCH3Br, n-BuLi; (ii) AllTMS, Grubbs II; (l) BF3·Et2O. 
 
Enol tosylate LXX gave, via a Suzuki-Miyaura coupling, a reduction of the ester and an 
acetylation, the allylic acetate LXXI. The N-allylation of LXXI, followed by acetate methanolysis, 
and a subsequent Johnson-type Claisen rearrangement with MeC(OMe)3 provided intermediate 
LXXII. The resulting methyl ester LXXII was subjected to a sequence of amidation and Hofmann 
rearrangement. A subsequent RCM, followed by N-propargylation, afforded enyne LXXIII. This 
alkyne was then carbonylated to give LXXIV that led to the AB-ring system in presence of 
Pd2dba3·CHCl3. Methyl ester LXXV was converted to LXXVI via a Wittig reaction and a cross-
metathesis reaction. A stepwise cyclization finally provided the diazatricyclic core. 
This synthetic sequence led to a product with functionalization both on C-3 and C-9, but the 
transformation of the single bond on C-3 to a Z double bond remains a really hard task, especially 
without changing the procedure for the closure of C ring. 
 
 
1.5. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
Beyond the intrinsic interest connected with their nature and chemistry, madangamines may 
also result a possible tool in cancer therapy. Cancer is a complex mixture of diseases without a 
definitive cure and cause millions deaths per years. A solution could be found in scientific research 
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and in testing new isolated natural substances with interesting pharmaceutical properties. In this 
context, madangamines, a class of alkaloids recently isolated from a marine sponge, are showing 
interesting cytotoxic activities in vitro, and new tests in vivo could confirm the possible potential 
application of these compounds as drugs. Unfortunately, the current methods of isolation of these 
alkaloids cannot permit to have enough material for an extensively use of these substances. For 
this reason, organic chemists are searching new strategies to obtain madangamines. The synthetic 
routes reported in literature address mainly the diazatricyclic core of madangamines, contemplate 
a large number of steps and not always allow the construction of last two external macrocycles. 
Moreover, although some approaches are reported to get the two external macrocycles, a 
comprehensive convenient madangamines synthesis integrating the different cyclic and 
macrocyclic units is still lacking. 
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2. OBJECTIVES AND SYNTHETIC STRATEGY 
 
 
The approach of the Mercedes Amat group to madangamine alkaloids can be divided in two 
synthetic parts which include: 1) the construction of the fully-functionalized bridged diazatricyclic 
central core, common to all madangamines from A to E, using a general methodology for synthesis 
of enantiopure aza-heterocycles from phenylglycinol-derived oxazolopiperidone lactams38 as 
chiral scaffolds, and 2) the subsequent annulations of the macrocyclic rings D and E. In this 
context, during my stage carried out in her research group, my studies focused on the development 
of a new and efficient methodology for the assembly of the macrocyclic E ring and the construction 
of the fully functionalized tricyclic core of these alkaloids as key steps for the enantioselective 
synthesis of the ABCE system of madangamines A-E. 
The stepwise strategy can be outlined in few critical points: 
• The assembly of the common chiral diazatricyclic nucleus of madangamines, taking 
advantage of the chiral induction given by (R)-phenylglycinol which can be considered 
a source of chiral ammonia (Figure 2.1). 
 
 
Figure 2.1: Assembly of ABC system. 
 
• The synthesis of a model system of these alkaloids constituted by A and C rings (Figure 
2.2). 
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Figure 2.2: Construction of the model system. 
 
• The construction of the unsaturated eastern E ring of madangamines with a stereo-
controlled formation of the (Z)-double bond between C-3 and C-20 and its eventual 
incorporation to the ABC tricyclic system (Figure 2.3). 
 
 
Figure 2.3: Construction E ring. 
 
Starting from the total synthesis of madangamine A, the most biologically active member of 
this group of alkaloids, these efforts will pave the way to a comprehensive access route to the other 
members of the madagamine family.  
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3. RESULTS AND DISCUSSION 
 
 
3.1. CONSTRUCTION OF THE DIAZATRICYCLIC CORE 
 
Piperidine rings are commonly present in many bioactive natural products, in particular in 
alkaloids, and their obtaining by a simple synthesis could be a powerful tool in the construction of 
a large plethora of potential drugs owning this kind of structure. In recent years, the Amat-Bosch 
research group focused its attention on the synthesis of oxazolopiperidone lactams starting from 
phenylglycinol38, as source of enantiopure substituted piperidines.  
These lactams were synthetized for the first time by Meyers in 1984 via a cyclocondensation 
between a 1,5 dicarbonylic ester and phenylglycinol paving the way to the preparation of 
iminosugars and piperidine and tetrahydroisoquinoline alkaloids39. These “first-generation 
oxazolopiperidone lactams” can undergo a stereoselective introduction of various substituents at 
different positions (except position 5) of the piperidine ring, controlled by their conformational 
rigidity. The Amat-Bosch research group prepared many enantiopure piperidine derivatives 
following this synthetic strategy (Figure 3.1). 
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Figure 3.1: Few examples of first generation oxazolopiperidone lactams prepared by the research group starting 
from enantiomer R of phenylglycinol. 
 
Later on, a more straightforward procedure for the synthesis of enantiopure polysubstituted 
piperidines was developed by the research group, leading to the construction of “second-
generation oxazolopiperidone lactams”. Phenylglycinol reacts with a dicarbonylic ester already 
bearing appropriate substituents that will give a α,β and/or γ enantiopure polysubstituted 
piperidines. Amat-Bosch research group synthetized a huge library of enantiopure alkaloids 
featuring higher complexity with respect to the previous synthetized ones (Figure 3.2). 
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Figure 3.2: Few examples of second generation oxazolopiperidone lactams prepared by the group starting from 
enantiomer R of phenylglycinol. 
 
In light of these results, it was decided to take advantage form the experience of the group using 
this strategy to construct the BC ring system of madangamines, via a synthetic pathway allowing 
a multi-gram scale production of the bicyclic system20. The (R)-phenylglycinol and a dicarbonylic 
racemic ester bearing an allylic chain after a cyclocondensation gave access to functionalized 
piperidinic rings. The subsequent stereoselective conjugate addition stereoselectively introduces 
an allyl substituent required for the construction of the ciclohexene ring, built by a ring-closing 
metathesis. The final removal of the phenylethanol moiety of the chiral inductor produce a cis 
bicyclic system (Scheme 3.1).  
 
 
Scheme 3.1: Synthesis of BC ring system. 
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The first challenge of this thesis has been the construction of the chiral oxazolopiperidone 
lactam from a racemic oxoester, exploiting a dynamic kinetic resolution.  
In the first approach 4-pentenal reacted with piperidine and then with methyl acrylate, 
producing the racemic 4-formyl-6-heptenoate (1) in an overall 64% yield (Scheme 3.2). 
 
 
Scheme 3.2: Synthesis of the dicarbonylic racemic ester. 
 
The cyclocondensation of this product with (R)-phenylglycinol in presence of Na2SO4 afforded 
the couple of isomeric lactams 2 and 3 in ratio 8.8:1.2 with an yield of 81%, leading to the B ring 
of madangamines and the first stereocenter R in position 5 (Scheme 3.3). 
 
 
Scheme 3.3: Assembly of B ring. 
 
These results indicated that a dynamic kinetic resolution had occurred during the 
cyclodehydration reaction (Scheme 3.4): the interaction of (R)-phenylglycinol and 1 generate two 
imines (A and B) in equilibrium via enamine C. These two imines can generate four 
diastereoisomeric oxazolidines (d-g), but only the two isomers in with the allylic chain is in 
equatorial position in the chair-like transition step (e and f) lead to an irreversible lactamization. 
The formation of oxazolidine 2 is faster than its diastereoisomer 3 because the methyl ester 
approaches to the nitrogen atom from the less hindered face of the oxazolidine ring (Scheme 3.4). 
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Scheme 3.4: Dynamic kinetic resolution for B ring fabrication. 
 
The next addressed step was the construction of carbocyclic C ring.  
To build the skeleton of the ring it has been employed a highly stereoselective conjugated 
addition of organocuprates to this unsaturated lactam 5 with another procedure developed by 
Amat-Bosch research group38.  
Since α,β-unsaturated lactams are poor Michael acceptors, the introduction of an electron 
withdrawing group40 as methoxy carbonyl at the C-6 position was required in order to improve the 
reactivity of these compounds towards the addition of organocuprates41, and of a phenylselenium 
group that could lead, via an oxidation step, to unsaturated lactam 5. The conjugate addition of the 
allylcuprate (formed in situ) afforded the mixture of isomerizable epimers at C-6 (6) with an exo-
facial diastereoselectivity (Scheme 3.5). This process allowed to synthesize an important 
intermediate, direct precursor of the BC ring system, and to install the second contiguous 
stereocenter at the C-7 position of madangamine. 
 
 
Scheme 3.5: Construction of intermediate 6. 
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The stereoselectivity of the process is due to the rigid structure of the molecule caused by the 
amide bond. The conformation of the six-membered ring is determined by the configuration of C-
8a (Scheme 3.6).  
 
 
Scheme 3.6: Stereoselective control in conjugate addition. 
 
The attack of the nucleophile is axial to the electrophilic carbon leading a chair-like transition 
state (the lower energy intermediate at low temperatures), in a process that involves a 
stereoelectronic control. The attack on the endo face would lead to a boat-like transition state and 
is kinetically disfavored.  
The synthesis of the tricyclic lactams 7, including the generation of C ring of madangamines, 
occurred with a ring closing metathesis catalyzed by a 2nd generation Grubbs catalyst. The 
alcoxycarbonyl group present in starting lactam 6 not only increased the acidity of the C=O α 
position, to permit the conjugate addition and the subsequent alkylation, but also acted as a 
precursor of the aminomethyl chain required for the synthesis of the A ring of the tricyclic core. 
The alkylation of 7 occurred from the more accessible face, the less hindered exo-face, giving 
compound 8 as single product, producing the chiral center in position 6, that coincide with 
sterocenter in position 9 of madangamine (Scheme 3.7).  
 
 
Scheme 3.7: RCM and alkylation. 
 
The next step is the removal of the chiral inductor. Previous studies on similar molecules 
demonstrated that the treatment of the lactam with sodium metal in liquid ammonia followed by a 
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strong reduction with LiAlH4 gave the best results. In fact, reaction with Pb(OAc)4, CAN, HCl, 
Lewis acids, alkali metals encapsulated in silica gel (Na-K-SG)42, trans-acylating reagents (1-
chloroethyl chloroformate)43, did not give the desired product. Reaction with LiAlH4 followed by 
mesylation and elimination gave only byproducts. 
Thus, the reaction with sodium in liquid ammonia gave a mixture of unstable alkoxy(hydroxy) 
lactams 9, that were immediately treated with an excess of LiAlH4 to give, as only product, the 
aminoalcohol 10, which was finally converted in to the N-Boc derivative 11 with an overall yield 
of 45% (Scheme 3.8). 
 
 
Scheme 3.8: Removal of the chiral inductor. 
 
To build the A ring it has been necessary the conversion of the hydroxylmethyl group in position 
4 to an azidomethyl chain, that could constitute afterwards the secondary amine moiety of the A 
piperidine ring. This interconversion has been accomplished via mesyl derivative, leading to 13 
via a long reaction due to the steric hindrance of the bicyclic system (Scheme 3.9). 
 
 
Scheme 3.9: Conversion of alcoholic moiety to azide. 
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The annulation of A ring was previously accomplished by Amat-Bosch research group with 
Weinreb methodology29, which involves an aminomercuriation reaction followed by oxidation, 
but the complicate experimental protocol led the group to a change of strategy with a more wieldy 
one. 
Azide 13 was oxidized stereoselectively to the single isomer epoxide 14 with m-CPBA. The 
azide moiety of 14 was converted to amine with a Staudinger reduction in presence of PMe3, and 
spontaneously attacked the epoxide ring, leading to the ABC tricyclic system. The secondary 
amine of this derivative was immediately protected with a tosyl, affording 15, and the alcoholic 
moiety at C-3 was converted to benzoyl ester, giving finally the desired protected ABC 
diazatricyclic core of madangamines 16 (Scheme 3.10). 
 
Scheme 3.10: Construction of the ABC system. 
 
 
3.2. ASSEMBLY OF E RING 
 
Having achieved the first purpose, new procedures to synthetize stereoselectively the E 
macrocycle have been explored. The construction of this ring is the most complicated step in the 
synthesis of madangamine, because it includes the challenging skipped (Z,Z)-diene. To avoid the 
waste of the ABC diazatricyclic core, a model compound was employed to evaluate the synthetic 
strategies only involving the AC ring moiety (Figure 3.3). 
 
 
Figure 3.3: Model system. 
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3.2.1. PREPARATION OF THE MODEL SYSTEM 
 
In order to explore as much as possible different strategies, the synthesis of a model system, 
less expensive and more rapid than the diazatricyclic core of madangamine, was required to get a 
morphan derivative including the AC ring system of the nucleus of the alkaloids.  
To this aim, the exocyclic double bond of commercially available 4-vinylcyclohexene was 
selectively hydroborated, and after an oxidative work-up the alcohol 17 was obtained, that was 
converted to azide 18 with a similar but easier procedure used for the previously described 13. The 
annulation of the piperidine ring was achieved after the oxidation of the endocyclic double bond 
to the corresponding diastereoisomeric epoxides 19 and the Staudinger reduction of azide moiety 
intermediates followed by a spontaneous cyclization. The nitrogen of the obtained unstable 
intermediate 20 was selectively protected with a tosyl group with a satisfying overall yield, 
considering the impossibility of the epoxide syn-oriented to the alkyl chain to cyclize. Mild 
oxidation of this alcohol 21 using Dess-Martin periodinane provided the target AC bicyclic 
compound 22 in 87% yield (Scheme 3.16).  
 
 
Scheme 3.16: Construction of the model system. 
 
 
3.2.2. PREVIOUS SYNTHETIC APPROACHES 
 
In early studies, the Amat and Bosch research group had investigated different approaches to 
the construction of the E ring. The first strategy contemplated the closure of the ring via a stepwise 
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strategy, because the hardest challenge was the build-up of the exocyclic Z double bond. It was 
initially considered the use of the Still-Gennari modification (HWE-SGM)44 of the Horner-
Wadsworth-Emmons reaction (HWE), a method that contemplate the use of methyl 
[bis(trifluoroethyl)phosphono]acetate in presence of KHMDS/18-crown-6 in THF. The 
mechanism of this reaction is not completely understood, but there is a general consensus that the 
stereoselectivity is thermodynamically controlled. This reaction had been successfully reported by 
Kibayashi on a similar morphan skeleton32 (Scheme 3.11). 
 
 
Scheme 3.11: Kibayashi proposal. 
 
Disappointingly, although excellent stereoselectivity was reported by Kibayashi, any attempt 
to induce the same Z stereoselectivity in the model compounds failed, as a mixture of isomeric 
compounds was obtained in very low yields and the desired Z-olefin was the minor product of the 
reaction with protected morphan systems. Probably steric factors play an important role in this 
step. The employment of a modified protocol (b), reported by Masaume and Roush45, gave just an 
insufficient slight improvement (Scheme 3.12). 
 
 
Scheme 3.12: Still-Gennari reaction on AC ring system. 
 
In a further approach, the conversion of the ketone into a dibromoalkene moiety was tried, in 
the hypothesis that the most accessible Br atom might be prone to a chemoselective debromination 
into E- and Z-isomers of terminal vinyl bromides for the steric hindrance of the molecule (Scheme 
3.13).  
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Scheme 3.13: Strategy for chemoselective debromination. 
 
Both the approaches, the Wittig-type reaction with CBr446 and the catalytic methodology 
involving the conversion of a tosylhydrazone derivative47, gave very low yields (Scheme 3.14). 
 
 
Scheme 3.14: Formation of the dibromoalkene derivative. 
 
Following these attempts, a more direct route was explored, that involves the installation of a 
carbon chain with a Z-selective Wittig reaction and the annulation of the E ring through an 
intramolecular macrolactamization. This strategy was tested on the same AC model system, and a 
more complicated system bearing the ABC ring core, and in both cases the desired Z-exo-olefin 
was obtained as major product. Unfortunately, when the Wittig reaction was tested on the 
tetracyclic system, a strong erosion of stereoselectivity was observed20 (Scheme 3.15).  
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Scheme 3.15: Wittig reaction. 
 
In light of these results, a completely different strategy was clearly needed. 
 
 
3.2.3. NEW SYNTHETIC APPROACHES 
 
Three different strategies are in study to face this hard challenge, based on a former amidation 
between a long linear alkyl chain and the nitrogen of the morphan and a subsequent reaction of 
annulation. The new synthetic proposal are outlined below:  
• The RCM metathesis via Grubbs catalysts strategy: a construction of a linear alkyl chain of 
nine carbons bearing in positions 5 and 8 two double bonds (the former Z), followed by 
amidation with the nitrogen of the morphan and a final ring-closing metathesis promoted by 
Grubbs catalysts between the two double bonds. 
• The McMurry strategy: The synthesis of a similar alkyl chain of eight carbons bearing in 
position 5 a Z double bond and in position 8 a protected (or masked) aldehyde moiety, which 
could give, after the amidation, a McMurry reaction with the carbonyl of the morphan. 
• The olefin metathesis with Schrock catalyst: The amidation of the former alkyl chain with the 
two double bonds and the model system, followed by an olefin metathesis promoted by 
Schrock catalyst (Figure 3.4). 
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Figure 3.4: General synthetic plan. 
 
 
 
3.2.4. THE RING-CLOSING METATHESIS VIA GRUBBS CATALYSTS STRATEGY 
 
Olefin metathesis involves a rearrangement of unsaturated carbon-carbon bonds in presence of 
metal carbene catalysts48. In most of cases this reaction is used to form C-C bonds with the 
production, as the sole byproduct, of the volatile and easy to remove ethylene thus increasing the 
interest of both academic and industrial scientists. Generally we find the olefin metathesis in three 
related groups of reaction, the ring-opening metathesis polymerization, the ring-closing metathesis 
and acyclic cross metathesis.  
The ring-closing metathesis (RCM) is employed for the synthesis of medium and large sized 
rings starting from acyclic diene precursors, and is preferred to other reaction for its adaptability 
to different substrates matched to the tolerance towards many functional groups. Furthermore, a 
large number of catalysts can be employed in this reaction, though the molybdenum and ruthenium 
complexes are the most utilized (Figure 3.5).  
 
 
Figure 3.5: Examples of olefin metathesis catalysts. 
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These catalysts (in particular the Ru-carbene systems), are active also in presence of air, 
moisture or low impurities, and can be stored in air atmosphere, and for this reason are the most 
used catalysts. 
A series of [2+2] cycloadditions and cycloreversion compose the general mechanism of olefin 
metathesis49. An equilibrium is established between all the intermediates, and for this reason is 
necessary to move this equilibrium in favour of the products, to avoid to get a mixture of olefins. 
One of the products of the general mechanism is the volatile ethene, so the process is entropically 
shifted on the desired cycloalkane (Figure 3.6). 
 
 
Figure 3.6: Olefin metathesis catalytic cycle. 
 
As depicted in the above figure, a [2+2] cycloaddition between the catalyst and the diene leads 
to a metallocyclobutane intermediate, which evolves to a metal-carbene compound via a [2+2] 
cycloreversion with a loss of ethylene. This intermediate gives another intramolecular 
cycloaddition affording an instable bicyclic derivate, which opens giving the desired cyclic 
product and the starting catalyst. 
If the reaction is not sufficient diluted, the acyclic diene metathesis polymerization can compete 
with the ring-closing metathesis, in particular in case of macrocyclization. The competing reaction 
is more important with substrates featuring an increased ring size and conformational renstriction, 
but the slow addition of the substrate and high temperatures can favour the ring closure50.  
 
The first explored strategy for the cyclization of E ring was the one concerning the RCM. 
According to this approach, the final annulation of the E ring would involve a terminal olefinic 
chain (previously enchained to the system with an amidation) and a double bond anchored to the 
morphan (Figure 3.7).  
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Figure 3.7: RCM strategy. 
 
The first step was the construction of the alkyl chain that will constitute the skeleton of E ring. 
To build a long linear alkyl chain with a Z double bond, it was necessary a Wittig reaction between 
smaller carbon fragments. Moreover, the chain needs an ester at an extremity so to allow an 
amidation reaction with the secondary amine of the model system. The linear C-5 fragment with a 
terminal ester (methyl 5-oxopentanoate (24)) was easily prepared by methanolysis of commercial 
δ-valerolactone and subsequent oxidation of the instable intermediate 23 with PCC (Scheme 3.17). 
 
 
Scheme 3.17: Synthesis of ester aldehyde 24. 
 
To carry out a Wittig reaction it was necessary the generation of a phosphonium salt. Salt 25 
was easily obtained by reacting 4-bromo-1-butene with triphenylphosphine in refluxing toluene 
(Scheme 3.18). 
 
 
Scheme 3.18: Preparation of the phosphonium salt 25. 
 
Different bases were investigated to promote the Wittig reaction between 24 and 25. Use of 
NaHMDS produced compound 26 only in traces, whereas n-BuLi allowed a slight increase in yield 
(40%). Finally, the use of LDA, in presence of HMPA, afforded ester 26 in a good 79% yield. 
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Basic hydrolysis of alkyl chain 26 with an aqueous solution of LiOH produced acid 27 in a fairly 
good yield (82%) (Scheme 3.19). 
 
Scheme 3.19: Construction of acid 27. 
 
The ring-closing metathesis involves double bonds, so it was necessary to transform the ketone 
moiety of the bicyclic model system 22 (Scheme 3.16) into an alkene.  
One of the most explored reactions in organic synthesis is the alkylidenation of aldehydes and 
ketones. The most applied technique is the Wittig reaction, that presents various limitations 
associated to the steric environment and to moisture sensibility of the intermediates. In 1978 
Tebbe51 synthetized a library of titanium-based reagents that could transfer a methylene via a 
tetracyclic intermediate with a compound bearing a carbonyl with a mechanism similar to one of 
the olefin metathesis (Figure 3.8). 
 
 
Figure 3.8: Tebbe reagent mechanism. 
 
In presence of a Lewis base, a carbene is generated, that give a cycloaddition with a carbonyl, 
affording the unstable tetracyclic intermediate. The cycloreversion [2+2], particularly favoured by 
the oxophilicity of the Ti(IV), leads to the alkene and a titanium oxide species. The advantages of 
Tebbe reagent over the Wittig reaction are the requirement of less basic condition of reactions and 
the lower occurrence of β-elimination. Furthermore, the Tebbe reagent can add a methylene also 
to esters, lactones and amides and does not racemize chiral α carbons. 
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Petasis in 199052 proposed an alternative to the classical Tebbe reagent. The Petasis catalyst, a 
dimethyltitanocene, is less expensive, needs shorter preparation time, is less air or moisture 
sensitive and does not produce residual aluminium reagents. The mechanism of reaction is really 
similar to the Tebbe’s one (Figure 3.9). 
 
 
Figure 3.9: Petasis reagent mechanism. 
 
The dimethyltitanocene is easily converted to the active carbenolic complex via a thermal α-
elimination, that gives the same tetracyclic intermediate previously described with a carbonylic 
compound, and the same cycloreversion.  
 
To convert the ketone moiety of the model system 22 (Scheme 3.16) to an olefin, a first route 
was explored, using a Wittig reaction, but only by-products were recovered. The second strategy 
involved the Tebbe reagent, but the unreacted starting product was always recovered. Petasis 
reagent was then examined under the conditions reported by Bennasar in 2006 for methylenation 
of N-acylamides53. This method provided the desired product 28 (Scheme 3.20), but an 
equilibrium between the starting material and the final product was established, limiting the 
production of the alkene; nevertheless, unreacted starting product can be recovered. Increase of 
either the catalyst loading or the reaction time only led to the formation of by-products (Table 
3.1). 
 
 
Scheme 3.20: Olefination of ketone 22. 
169 
 
 
Equiv. Petasis Reaction time Yield (%) Conversion By-products 
1.5 3h 39 65 Yes 
2 5h 46 56 No 
2 6h 47 69 No 
2.5 5h + night Traces Traces Yes 
2.5 + 2.5a 5h + 5hb 38 60 No 
5 4h + 4hb 29 34 Yes 
a: Added after one day of reaction; b: reaction in two days, with night at room temperature 
Table 3.1: Explored conditions for the olefination. 
 
The synthetic route involves at this point the removal of the tosyl protecting group from alkene 
28 upon exposure to sodium naphtalenide. The subsequent amidation with alkyl chain 27, 
promoted by DCC and DMAP, led to olefinic compound 29 in a good yield (Scheme 3.21). 
 
 
Scheme 3.21: Synthesis of amide 29. 
 
A wide set of ring-closing metathesis conditions were screened on amide 29, with both first and 
second generation Grubbs catalysts (Scheme 3.22); unfortunately, all these attempts met with 
failure (Table 3.2), giving byproducts or dimers, probably because of the low accessibility of the 
exocyclic double bond attached to the ring. 
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Scheme 3.22: Failed ring-closing metathesis. 
 
Catalyst (%) Solvent Temperature /  Reaction time Dilution 
Dimers and  
by-products 
2nd gen. (10 + 10)a Toluene 
25 °C/ 4 hours 
50 °C / 1 night 
70 °C / 1 day 
90 °C/ 1 day 
0.1 mmol per 5 mL 
(0.02 M) Yes 
2nd gen. (10) Toluene 120 °C / 2 days 0.1 mmol per 10 mL 
 (0.01 M) Yes 
1st gen. (10) CH2Cl2 40 °C / 24 hours 0.1 mmol per 200 mL 
 (0.5 mM) Yes 
1st gen. (10 + 10 + 5)a Toluene 
50 °C / 1 day 
70 °C/ 1 night 
90 °C/ 1 day 
120 °C / 5 days 
0.1 mmol per 1 L 
(0.1 mM) Yes 
a: portionwise addition in different days 
Table 3.2: Explored conditions for the ring-closing metathesis. 
 
In the light of all these results, the strategy was slightly changed, planning to perform the closure 
of the E ring with a McMurry reaction. 
 
 
3.2.5. THE MCMURRY STRATEGY 
 
The second explored proposal was the one concerning the final annulation of the E ring via a 
McMurry reaction involving two carbonyls, one at the end of an alkyl chain (previously attached 
onto the bicyclic system with an amidation) and the second anchored to the morphan (Figure 
3.10).  
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Figure 3.10: McMurry strategy. 
 
The McMurry reaction was firstly described in 197454 and since then has a relevant role in 
organic chemistry. Both ketone and aldehydes in presence of low-valent titanium reagents can give 
a reductive dimerization by single electron transfer to afford alkenes. The original reagent system 
was composed of TiCl3 and LiAlH4, but the low reproducibility of the reaction lead McMurry to 
look for a new system, composed of TiCl3 and Li, Zn-Cu, Mg or alkali (or the most used TiCl4/Zn). 
The mechanism involves two step, the formation of the carbon-carbon bond via reductive 
dimerization and the deoxygenation of the pinacol intermediate (Figure 3.11). 
 
O
R1 R2
O
R3 R4
2e- O
R1 R2
O
R3 R4
O O
R2
R1 R3
R4
Step 1: carbon-carbon bond formation
Step 2: deoxygenation
O O
R2
R1 R3
R4
R1
R2
R3
R4
Ti0 Ti2+
 
Figure 3.11: McMurry reaction mechanism. 
 
The stereochemical outcome of the reaction is not controlled, because a mixture of threo and 
erythro diols is obtained in the first step, and in the second step the cleavage of the two C-O bonds 
is not concerted, leading then to a mixture of Z and E alkenes. The intramolecular reactions have 
more predictable stereoselectively and always high yields. This reaction is compatible with a large 
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number of functional groups and is proving increasingly valuable in the synthesis of natural 
products requiring the formation of six to fifteen-membered rings55. 
In the case of the eleven-membered E ring of madangamines, the formation of the double bond 
between C-3 and C-20 with stereochemistry Z could be favoured by the presence of the other Z 
double bond between C-17 and C-18. The reagent systems applicable that will be applied are 
TiCl4/Zn, the most utilized; the TiCl3(DME)2/Zn-Cu, more soft and specific for intramolecular 
couplings, and the TiCl3/Li, preferable in presence of amides. The difference between these 
systems is not due to the reactive species, that is presumed to be the Ti(0), but their preparation, 
that probably leads to distinct particle sizes, surface area, physical nature of the surface (edges, 
corners, holes), and in particular solvent. Indeed, the solvent can stabilize the Ti(0) during its 
formation; the most used solvent is THF, that can also help the electron transfer by solubilizing 
the intermediates and is not reduced in the reaction conditions. 
 
The following scheme shows the synthetic route leading to the requisite alkyl chain (Scheme 
3.23). To get the new target compound, a different phosphonium salt of three carbons with a 
protected alcohol (31) was synthesized starting from 3-bromopropan-1-ol. Different bases were 
investigated to promote the Wittig coupling between the phosphonium salt and the previously 
employed aldehyde 24. The use of NaHMDS gave the desired product but only in low amounts 
(13%), whereas n-BuLi allowed a slight increase in yield (43%). Finally, the use of LDA, in 
presence of HMPA, afforded the ester 33 in a satisfying of 70%. 
 
 
Scheme 3.23: Synthesis of alkyl chain 33. 
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Basic hydrolysis of ester 33 with an aqueous solution of LiOH in a two-phase system with THF 
produced acid 34 with a slow reaction and a modest yield (Scheme 3.24); for this reason a 
systematic study of the reaction was performed (Table 3.3). 
 
 
Scheme 3.24: Basic hydrolysis of ester 33. 
 
Entry Base Eq. Solvents M of base Time Product Desilylated acid 
1 LiOH 20 THF/H2O 0.3 3 days Yes (49%) No 
2 LiOH 20+20 THF/H2O 0.3 24 h Yes (37%) Yes (Traces) 
3 LiOH 40 THF/H2O 0.3 24 h Yes (7%) Yes (Traces) 
4 LiOH 40+40 THF/H2O 0.6→1.2 36 h No Yes 
5 LiOH 60 THF/H2O 0.6 6 h No Yes 
6 LiOH 20 THF/MeOH/H2O 0.2 1h Yes (Traces) Yes (Major) 
7 LiOH 5 THF/MeOH/H2O 0.2 1 h Yes (Traces) Yes (Major) 
8 LiOH 1 THF/MeOH/H2O 0.1 1 h Yes (Traces) Yes (Major) 
9 KOH 20 THF/MeOH 0.3 3h No Yes 
10 KOH, NH2OH 20, 10 THF/MeOH 0.6 2h Yes (Traces) Yes (Major) 
11 LiOH, H2O2 2, 4 THF/H2O 1 2h No Yes 
Table 3.3: Studies of basic hydrolysis. 
 
Starting from the observation that the standard hydrolysis with LiOH (entry 1) in a biphasic 
water/THF mixture required a long reaction time and didn’t provide high yields, the first attempt 
was addressed to an increase of the amount of base (entries 3-5). Unfortunately, the yield of the 
desired product decreased in favor of a desilylated acid. The addition of methanol56, allowed to 
get a monophasic system, with a dramatic decrease of the reaction time and an increase of the 
desilylated byproduct, even with 1 equivalent of LiOH (entries 6-8). Other bases were 
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investigated57 (entries 9-11), but the best results were obtained with LiOH. Consequently, it was 
decided to utilize the classic biphasic reaction, with the idea of revisiting this step in case of a 
successful McMurry strategy. 
Coming back to the overall synthesis of the model system (Scheme 3.16), the impossibility of 
employing compound 22 in this strategy to avoid its breaking with sodium naphtalenide solution 
(required for the removal of the tosyl group) forced the use of a protected alcoholic function instead 
of the ketone moiety. For this reason, the protected model compound 21 previously synthesized 
was exploited, and ketone moiety of 22 was reduced to alcohol (Scheme 3.25) in different reaction 
conditions. 
 
 
Scheme 3.25: Reduction of ketone 22. 
 
Borohydride reduction proceeded smoothly (10 minutes) with a variety of solvents 
(MeOH/DCM, MeOH/THF, EtOH) and only in the presence of DCM the reaction were slower. 
Other reducing agents were used (NaBH3CN, LiAlH4), always obtaining good results and 
quantitative yields, and the combination of PMHS (polymethylhydrosiloxane) and TBAF58 that 
produced a mixture of the two alcohols in ratio 1:1. 
Curiously, the reduction led to the other isomer of the alcohol 21 obtained from previously 
described epoxide opening (Scheme 3.16). In fact, in that synthetic approach the cyclization occurs 
with the attack of the primary amine to the epoxide on the opposite side of the ring, producing a 
cycle with the hydroxyl group and the hydrogen in a cis relationship; consequently, in the resulting 
bicyclic product the hydroxyl group is axially oriented. In the reduction the hydride attacks the 
most accessible face, with an axial orientation, giving an equatorial hydroxyl (Figure 3.12).  
 
 
Figure 3.12: Isomers of alcohol 21. 
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To pursue the McMurry strategy, both morphan alcohols 21 and 35 were protected with the 
TBDMS group, namely the same protecting group planned to be introduced in the alkyl chain 
precursor 34. Surprisingly, while the protection of the morphan 21 (derived from the epoxide 
opening) was slow and afforded the product in traces, the protection of the morphan 35 (obtained 
via hydride reduction) was faster and gave much better yield. Considering that the alcoholic moiety 
should be oxidized to ketone, the synthesis proceed from protected compound 35. N-detosylation 
of 35 was successfully accomplished by sodium naphtalenide reduction producing 38 with an 
excellent yield without any loss of the protecting group. Carbodiimide-mediated amidation of 38 
with 34 gave the desired product 39 in traces with a large number of byproducts (Scheme 3.26). 
 
 
Scheme 3.26: Failed synthesis of protected dialcohol 39. 
 
At this stage, a more direct route to the desired keto-aldehyde was undertaken. Thus, acylation 
of the aza-bicycle 20, resulting from the intramolecular epoxide opening, was attempted trying to 
take advantage of the higher reactivity of the amino function compared with that of the secondary 
hydroxyl group. The route contemplates the conversion of the acid alkyl chain 34 to acyl chloride, 
and in a second step the amidation with the unprotected morphan 20, using a mild base as K2CO3 
to suppress the esterification reaction of the alcoholic function, and thus avoid the redundant steps 
of N-protection and deprotection (Scheme 3.27). Unfortunately, during the generation of the acyl 
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chloride, the strong acidic medium desilylated the alkyl chain, leading to a mixture of products 
(the desired one was present in traces). 
 
 
Scheme 3.27: Amidation on unprotected morphan 20. 
 
Considering the unsatisfactory results, a new alkyl chain is going to be synthetized with a 
different protecting group. After unsuccessful attempts of protecting the alcoholic moiety of 3-
bromopropan-1-ol with a p-methoxybenzyl group, a new strategy will be explored, starting from 
2-(2-bromoethyl)-1,3-dioxolane (Scheme 3.28). 
 
 
Scheme 3.28: Synthesis of new alkyl chains. 
 
 
3.2.6. THE OLEFIN METATHESIS WITH SCHROCK CATALYST 
 
A final approach was investigated, involving a different olefin metathesis between a carbonyl 
(the ketone moiety of the morphan system) and a double bond (on an alkyl chain previously 
attached to the model system with an amidation), promoted by Schrock catalyst59 (Figure 3.13). 
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Figure 3.13: Cyclization promoted by Schrock catalyst. 
 
The first annulations between an alkene and a carbonyl moiety were carried out by Clive, 
oxidizing with the ozone the double bond to carbonyl and then inducing coupling between the 
carbonyls in presence of low-valent titanium reagents60. This titanium catalyst is prepared under 
milder conditions than the ones described by McMurry55 (Figure 3.14).  
 
 
Figure 3.14: Clive’s annulation mechanism. 
 
The introduction of the olefin metathesis in this process afforded the innovative direct one-step 
reaction that does not need the oxidation of the double bond to carbonyl. The mechanism of this 
new olefin metathesis is really close to the classical one (Figure 3.15). 
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Figure 3.15: Carbonyl olefination mechanism. 
 
A substantial difference is the absence of a catalytic cycle: the catalyst during the process is 
oxidized and is not more usable. Another weakness of the carbonyl olefination is the need for a 
higher temperature and longer reaction time respect to the classical olefin metathesis. 
The promoters employed in carbonyl olefination are alkylidene complexes of molybdenum, 
already successfully used in the synthesis of tetracyclic ABCE system of manzamine A61, like 
Schrock catalyst (Figure 3.16),.  
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Figure 3.16: Schrock catalyst. 
 
 
To get the desired ketone moiety on the morphan system without a protecting group on the 
nitrogen, the mixture of epoxides 19 was reduced to amine in presence of Me3P and, after the 
spontaneous cyclization, unstable intermediate 20 was obtained. Compound 20 was then protected 
with a tert-butyloxycarbonyl group, easier to remove than tosyl group. The alcoholic moiety of 41 
was then converted to ketone with DMP, affording product 42 (Scheme 3.29).  
 
 
Scheme 3.29: Synthesis of the Boc-protected model system. 
 
Removal of tert-butyloxycarbonyl protecting group was easily achieved in presence of TFA 
and amidation with the previously synthetized alkyl chain 27 (in ring-closing metathesis strategy, 
Scheme 3.19) gave intermediate 43. Schrock catalyst proved capable to promote the 
intramolecular olefin metathesis in a low yield and on a small scale reaction, leading to the desired 
ACE tricyclic system (Scheme 3.30). The reaction conditions will be further optimized. 
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Scheme 3.30: Synthesis of the ACE system. 
 
 
3.3. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
For their structural complexity, madangamine construction is still a challenge for synthetic 
chemists. After the total synthesis of madangamine D, the assembly of other members of this 
family are now under investigation by Amat-Bosch research group. An improved synthetic 
pathway for its diazatricyclic core has been developed respect to described one20, that could be 
easily adapted to other members of madangamine family. The fully functionalized core common 
to all madangamines has been assembled, having now in hand considerable amounts of this three 
bridged diazatricyclic ABC ring systems in enantioselective fashion. A model system of the AC 
ring moiety has been designed and synthetized, that has been employed for the assessment of as 
many synthetic approaches as possible for the construction of E ring, avoiding the excessive 
consumption of the precious ABC tricyclic system. Several ring-closing strategies were 
investigated for the E ring build-up and different protecting groups were tested. The use of Grubbs 
catalysts in the metathesis approach and the use of TBDMS protecting group for the alkyl chain to 
react with the morphan system proved unfruitful. The search thus moved toward the synthesis of 
another carboxylic acid derivative with a dioxolane as protecting group for the carbonyl moiety at 
the terminal position of the alkyl chain, that in future could react with the morphan system and 
essay the final cyclization with a McMurry reaction. Moreover, the Schrock catalyst has been 
explored to promote ring-closing metathesis between the ketone moiety of the morphan and the 
alkene moiety of the alkyl chain, that finally gave the desired ACE system. 
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Optimization of the reaction with Schrock catalyst is in progress in the Amat-Bosch research to 
achieve a scalable procedure. In case of success, the reaction will be applied on the fully 
functionalized diazatricyclic system. In parallel, the McMurry strategy, that involves less 
expensive reactives, is under scrutiny and will be selected in case of promising results. Also, the 
final annulation of D ring has already be planned, evaluated on a model system (made by B ring) 
and reported in literature by Amat-Bosch research group60. The approach is based on a chain 
bearing two skipped triple bonds to get a cross-coupling with the alkyne moiety anchored to the 
model system. The reduction of the alkyne led to the selective formation of three Z double bonds. 
The final macrolactamization produced the precursor of D ring (Scheme 3.31). 
 
 
Scheme 3.31: Construction of D ring on a model system. 
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4. EXPERIMENTAL SECTION 
 
 
All air sensitive manipulations were carried out under dry argon or nitrogen atmosphere. 
Solvents and all standard reagents were purchased from Sigma Aldrich, Alfa Aesar of Acros and 
were used without further purification. 
Analytical thin-layer chromatography was performed on SiO2 (Merck silica gel 60 F254), and 
the spots were located with 1% aqueous KMnO4 or hexachloroplatinate. Chromatography refers 
to flash chromatography and was carried out on SiO2 (SDS silica gel 60 ACC, 35-75 mm, 230-240 
mesh ASTM). Drying of organic extracts during workup of reactions was performed over 
anhydrous MgSO4 or Na2SO4. Evaporation of solvent was accomplished with a rotary evaporator. 
NMR spectra were recorded at 300 or 400 MHz (1H) and 75.4 or 100.6 MHz (13C), and chemical 
shifts are reported in δ values downfield from TMS or relative to residual chloroform (7.26 ppm, 
77.0 ppm) as an internal standard. Data are reported in the following manner: chemical shift, 
integrated intensity, multiplicity, coupling constant (J) in Hertz (Hz), and assignment (when 
possible). Assignment and stereochemical determinations are given only when they are derived 
from definitive two-dimensional NMR experiments (HSQC-COSY). Optical rotations were 
measured on Perkin-Elmer 241 polarimeter. [α]D values are given in 10-1 deg cm2 g-1.IR spectra 
were performed in a spectrophotometer Nicolet Avantar 320 FT-IR and only noteworthy IR 
absorptions (cm-1) are listed. High-resolution mass spectra (HMRS; LC/MSD TOF Agilent 
Technologies) were performed by Centres Científics i Tecnològics de la Universitat de Barcelona. 
Mass spectra (MS) data are reported as m/z (%). 
The IUPAC nomenclature was used in the NMR assignation of all compounds whereas for the 
sake of clarity, madangamine biogenetic numbering has been employed throughout the 
dissertation. 
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Methyl-4-formyl-6-heptenoate (1). 
 
4-Pentenal (4.64 mL, 0.0470 mol) was added dropwise during 30 minutes to a stirred, ice-cold 
suspension of anhydrous potassium carbonate (2.21 g, 0.0160 mol) in piperidine (12 mL). Stirring 
was continued at room temperature for 2 days and the mixture filtered through sintered glass. The 
residue was washed thoroughly with ether which was subsequently removed under reduced 
pressure affording the piperidine enamine of 4-pentenal, as a pale yellow oil. To a solution of 
methyl acrylate (7.62 mL, 0.0846 mol) in 75 mL of dry acetonitrile, cooled below 5 °C, was added 
the above enamine in 19 mL of dry acetonitrile during 30 min. The mixture was stirred at room 
temperature for 5 hours and then refluxed for 72 hours. Glacial acetic acid (10.5 mL) in water (75 
mL) was added and the mixture refluxed for further 8 hours. Ether (250 mL) was added to the 
residue and the organic layer was washed with 3 N HCl (100 mL), saturated NaHCO3 (100 mL), 
brine (100 mL) and finally dried with MgSO4 and filtered. Removal of the organic solvents left 
methyl-4-formyl-6-heptenoate (1, 5.10 g, 64%) as a brown oil that was used in the next reaction 
without further purification. 
 
1H NMR (300 MHz, CDCl3): δ 1.80 (m, 1H, H-3), 1.98 (m, 1H, H-3), 2.21-2.51 (m, 5H, 2H-2, H-
4, 2H-5), 3.67 (s, 3H, CH3), 5.09 (m, 2H, H-7), 5.76 (m, 1H, H-6), 9.63 (d, J = 2.1 Hz, 1H, CHO). 
 
13C NMR (75.4 MHz, CDCl3): δ 23.2 (C-3), 31.2 (C-5), 32.9 (C-2), 50.3 (CH3), 51.7 (C-4), 117.6 
(C-7), 134.3 (C-6), 173.4 (C-1), 203.7 (CHO). 
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(3R,8R,8aR)-8-Allyl-5-oxo-3-phenyl-2,3,6,7,8,8a-hexahydro-5H-oxazolo[3,2-a]pyridine (2). 
 
A mixture of racemic methyl 4-formyl-6-heptenoate1 (4.60 g, 29.0 mmol), (R)-phenylglycinol 
(3.98 g, 29.0 mmol), and anhydrous Na2SO4 (17.0 g, 120 mmol) in Et2O (115 mL) was stirred at 
0 °C for 2 hours. The resulting suspension was filtered through celite and concentrated under 
reduced pressure. The residue was heated at 80 °C for 18 hours under vacuum (10-15 mmHg). 
Flash chromatography (8:2 hexane-EtOAc to EtOAc) of the residue afforded oxazolopiperidone 2 
(5.30 g, 71%) and its (8S,8aS)-diastereoisomer 3 (753 mg, 10%). 
 
Compound 2 (major isomer, lower Rf):  
 
[α]D22 = – 32.8 (c 1.0, EtOH).  
 
IR (film): 1655 (NCO) cm-1. 
 
1H NMR (400 MHz, CDCl3, COSY, gHSQC): δ 1.45 (dddd, J = 13.8, 13.8, 12.0, 7.2 Hz, 1H, H-
7), 2.02 (m, 3H, H-7, H-8, CH2 allyl), 2.30 (ddd, J = 18.0, 12.0, 6.6 Hz, 1H, H-6), 2.42 (ddd, J = 
18.0, 7.2, 1.8 Hz, 1H, H-6), 2.62 (m, 1H, CH2 allyl), 4.01 (dd, J = 9.0, 1.2 Hz, 1H, H-2), 4.11 (dd, 
J = 9.0, 6.9 Hz, 1H, H-2), 4.53 (d, J = 8.7 Hz, 1H, H-8a), 4.92 (d, J = 6.6 Hz, 1H, H-3), 5.12 (m, 
2H, CH2=), 5.86 (dddd, J = 16.5, 10.2, 7.8, 6.0 Hz, 1H, CH=), 7.20-7.30 (m, 5H, C6H5). 
 
13C NMR (100.6 MHz, CDCl3): δ 23.6 (C-7), 31.2 (C-6), 35.4 (CH2 allyl), 39.1 (C-8), 58.9 (C-3), 
73.7 (C-2), 91.9 (C-8a), 117.4 (CH2=), 126.2, 128.4 (C-o, m C6H5), 127.4 (C-p C6H5), 134.6 
(CH=), 141.4 (C-i C6H5), 167.1 (NCO). 
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Elemental analysis calcd (%) for [C16H19NO2·¼ H2O]: C 73.40, H 7.51, N 5.35.Found: C 73.71, 
H 7.25, N 5.41.  
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Compound 3 (minor isomer, higher Rf):  
 
[α]D22 = – 59.9 (c 1.0, EtOH).  
 
IR (film): 1658 (NCO) cm-1. 
 
1H NMR (400 MHz, CDCl3, COSY, gHSQC): δ 1.53 (m, 1H, H-7), 1.66 (m, 1H, H-8), 1.96 (m, 
1H, H-7), 2.07 (dt, J = 16.5, 8.4, 8.4 Hz, 1H, CH2 allyl), 2.35 (ddd, J = 18.6, 12.0, 6.6 Hz, 1H, H-
6), 2.56 (m, 2H, H-6, CH2 allyl), 3.75 (dd, J = 9.0, 7.8 Hz, 1H, H-2), 4.47 (dd, J = 9.0, 8.1 Hz, 1H, 
H-2), 4.69 (d, J = 8.4 Hz, 1H, H-8a), 5.13 (m, 2H, CH2=), 5.25 (t, J = 7.8 Hz, 1H, H-3), 5.83 (dddd, 
J = 16.5, 10.2, 8.1, 6.0 Hz, 1H, CH=), 7.25-7.34 (m, 5H, C6H5).  
 
13C NMR (100.6 MHz, CDCl3): δ 22.7 (C-7), 31.3 (C-6), 35.8 (CH2 allyl), 39.5 (C-8), 58.3 (C-3), 
72.3 (C-2), 92.0 (C-8a), 117.4 (CH2=), 126.0, 128.7 (C-o, m C6H5), 127.5 (C-p C6H5), 134.6 
(CH=), 139.4 (C-i C6H5), 168.7 (NCO). 
 
Elemental analysis calcd (%) for [C16H19NO2·¼ H2O]: C, 73.40; H, 7.51; N, 5.35. Found: C, 73.27; 
H, 7.25; N, 5.51. 
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(3R,8S,8aR)-8-Allyl-6-(methoxycarbonyl)-5-oxo-3-phenyl-6-(phenylselenyl)-2,3,6,7,8,8a-
hexahydro-5H-oxazolo-[3,2-a]pyridine (4). 
 
Lithium bis(trimethylsilyl)amide (1M in THF, 17.1 mL, 17.09 mmol) was slowly added at –78 °C 
to a solution of lactam 2 (2.0 g, 7.77 mmol) in anhydrous THF (120 mL), and the resulting mixture 
was stirred for 90 minutes. Then, methyl chloroformate (0.600 mL, 7.77 mmol) and, after 90 
minutes of continuous stirring at –78 °C, phenylselenyl chloride (2.09 g, 10.9 mmol) were added 
to the solution. The resulting mixture was stirred for a further 1 hour and poured into saturated 
aqueous NH4Cl. The aqueous layer was extracted with EtOAc, and the combined organic extracts 
were dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. Flash 
chromatography (9:1 hexane-EtOAc to 1:1 hexane-EtOAc) of the resulting oil afforded 4 as a 
mixture of C-6 epimers (3.14 g, 86% overall yield). 
 
Epimer 4a (higher Rf):  
 
[α]D22= -99.3 (c 0.7, CHCl3). 
 
IR (film): 1667 (NCO), 1725 (COO) cm-1. 
 
1H NMR (400 MHz, CDCl3, COSY, gHSQC): δ 1.82 (dd, J=14.0, 12.4 Hz, 1H, CH2 allyl), 1.98(m, 
2H, H-7, H-8), 2.33 (dd, J = 14.0, 2.8 Hz, 1H, CH2 allyl), 2.41 (m, 1H, H-7), 3.58 (s, 3H, CH3), 
4.00 (dd, J= 9.2, 2.0 Hz, 1H, H-2), 4.05 (dd, J= 9.2, 6.8 Hz, 1H, H-2), 4.15 (d, J= 8.8 Hz, 1H, H-
8a), 4.87 (dd, J= 6.8, 2.0 Hz, 1H, H-3), 5.03 (m, 2H, CH2=), 5.17 (dddd, J= 16.8, 10.4 7.6, 6.4 Hz, 
1H, CH=), 7.26-7.66 (m, 10H, ArH). 
 
13C NMR (100.6 MHz, CDCl3): δ 34.8 (C-7), 36.6 (CH2), 37.7 (C-8), 53.0 (CH3), 54.0 (C-6), 59.4 
(C-3), 74.0 (C-2), 91.8 (C-8a), 117.7 (CH2=), 126.4-138.2 (C-o, m, p), 133.7 (CH=), 140.5 (C-i), 
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HRMS (ESI) calcd for [C24H25NO4Se + H]+: 471.0948, found: 471.0955.  
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Epimer4b (lower Rf): 
 
[α]D22 = +18.5 (c 0.5, CHCl3). 
 
1H NMR (400 MHz, CDCl3, COSY, gHSQC): δ 1.98 (m, 1H, CH2 allyl), 2.00 (dd, J = 15.2, 11.6 
Hz, 1H, H-7), 2.08 (dd, J= 15.2, 4.0 Hz, 1H, H-7), 2.32 (m, 1H, H-8), 2.52 (m, 1H, CH2 allyl), 
3.73 (s, 3H, CH3), 4.10 (dd, J = 9.2, 1.2 Hz, 1H, H-2), 4.17 (dd, J = 9.2, 6.8 Hz, 1H, H-2), 4.63 (d, 
J = 9.2 Hz, 1H, H-8a), 4.97 (m, 3H, H-3, CH2=), 5.59 (dddd, J = 16.0, 10.0, 8.0, 6.0 Hz, 1H, CH=), 
7.23-7.47 (m, 10H, ArH). 
 
13C NMR (100.6 MHz, CDCl3): δ 33.6 (C-7), 35.0 (CH2), 36.5 (C-8), 53.3 (CH3), 55.6 (C-6), 59.6 
(C-3), 73.8 (C-2), 91.6 (C-8), 117.8 (CH2=), 126.8-138.3 (C-o, m, p), 134.0 (CH=), 140.5 (C-i), 
162.8 (NCO), 171.0 (COO). 
 
HRMS (ESI) calcd for [C24H25NO4Se + H]+: 471.0948, found: 471.0946.  
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(3R,8S,8aR)-8-Allyl-6-(methoxycarbonyl)-5-oxo-3-phenyl-2,3,8,8a-tetrahydro-5H-
oxazolo[3,2-a]pyridine (5). 
 
30% aqueous H2O2 (0.729 mL) and pyridine (0.358 mL, 4.42 mmol) were added to a solution of 
selenides 4 (1.60 g, 3.40 mmol) in CH2Cl2 (231 mL), and the resulting mixture was stirred at rt for 
2 hours. The two phases were separated, andthe organic layer was washed with water, dried and 
concentrated to give crude 5 (1.65 g) as an oil, wich was used in the next reaction without further 
purification. 
 
IR (film): 1673 (NCO), 1741 (COO) cm-1. 
 
1H NMR (300 MHz, CDCl3): δ 2.31 (dt, J = 14.4, 8.7 Hz, 1H, CH2 allyl), 2.70 (dm, J = 14.4, 1H, 
CH2 allyl), 2.91 (m, 1H, H-8), 3.78 (s, 3H, CH3), 4.20 (dd, J= 9.0, 2.4 Hz, 1H, H-2), 4.24 (dd, J= 
9.0, 6.0 Hz, 1H, H-2), 4.87 (d, J= 10.5 Hz, 1H, H-8a), 5.03 (dd, J= 6.0, 2.4 Hz, 1H, H-3), 5.27 (m, 
2H, CH2=), 5.86 (dddd, J= 15.3, 10.88.7, 5.7 Hz, 1H, CH=), 7.20-7.36 (m, 5H, C6H5). 
 
13C NMR (75.4 MHz, CDCl3): δ 33.5 (CH2), 41.2 (C-8), 52.3 (CH3), 58.3 (C-3), 74.4 (C-2), 89.8 
(C-8a), 119.0 (CH2=), 126.8-128.5 (C-o, m, C6H5), 127.7 (C-p, C6H5), 129.7 (C-6), 133.3 (CH=), 
140.2 (C-iC6H5), 147.6 (C-7), 157.3 (COO), 164.3 (NCO). 
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(3R,7R,8S,8aR)-7,8-Diallyl-6-(methoxycarbonyl)-5-oxo-3-phenyl-2,3,6,7,8,8a-hexahydro-
5H-oxazolo[3,2-a]pyridine (6). 
 
LiCl (1.20 g, 28.4 mmol) was dried at 80 °C for 1 hour under vacuum (10–15 mmHg) in a three-
necked, 250 mL round-bottomed flask. Then, CuI (5.40 g, 28.4 mmol) and THF (150 mL) were 
added under an inert atmosphere, and the mixture was stirred at room temperature for 5 minutes. 
The suspension was cooled to –78 °C, and allylmagnesium bromide (28.4 mL of a 1 M solution in 
Et2O, 28.4 mmol), TMSCl (3.60 mL, 28.4 mmol), and unsaturated lactam 5 (7.11 mmol) in THF 
(5 mL) were successively added. The resulting mixture was stirred at –78 °C for 18 hours. The 
reaction was quenched with saturated aqueous NH4Cl, and the resulting mixture was filtered 
through celite. The aqueous layer was extracted with EtOAc, and the combined organic extracts 
were dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure. Flash 
chromatography (9:1 to 7:3 hexane-EtOAc) of the resulting oil gave 6 (2.05 g, 81% yield) as a 
mixture of C-6 epimers (ratio 2:1). 
 
IR (film): 1665 (NCO), 1736 (COO) cm-1. 
 
1H NMR (300 MHz, CDCl3, COSY, gHSQC): δ 1.80 (ddd, J = 14.1, 12.0, 9.0 Hz, 1H,  CH2 allyl), 
2.16 (dt, J = 14.1, 9.3, 9.3 Hz, 1H, CH2 allyl), 2.34 (dm, J = 12.0 Hz, 1H,  H-7), 2.44-2.70 (m, 3H, 
H-8, CH2 allyl), 3.43 (d, J = 1.5 Hz, 1H, H-6), 3.60 (s, 3H,  CH3O), 4.02 (dd, J = 9.3, 1.8 Hz, 1H, 
H-2), 4.15 (dd, J = 9.3, 7.2 Hz, 1H, H-2), 4.62 (d, J = 9.6 Hz, 1H, H-8a), 4.91 (dd, J = 7.2, 1.8 Hz, 
1H, H-3), 5.14 (m, 4H, CH2=), 5.68 (dddd, J = 15.0, 10.2, 9.0, 4.8 Hz, 1H, CH=), 5.84 (dddd, J = 
15.3, 9.9, 8.7, 5.1 Hz, 1H, CH=), 7.26-7.33 (m, 5H, C6H5). 
 
13C NMR (75.4 MHz, CDCl3): δ 31.6, 31.8 (CH2), 36.9 (C-7), 38.5 (C-8), 51.5 (C-6), 52.3 (CH3O), 
59.6 (C-3), 73.9 (C-2), 89.4 (C-8a), 117.4, 118.5 (CH2=), 126.4, 128.2 (C-o, m), 127.4 (C-p), 
134.4, 134.8 (CH=), 140.5 (C-i), 162.3 (NCO), 170.6 (COO). 
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HRMS (ESI) calcd for [C21H25NO4 + H]+: 356.1783, found: 356.1779. 
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(3R,6aR,10aS,10bR)-6-(Methoxycarbonyl)-5-oxo-3-phenyl-2,3,6,6a,7,10,10a,10b-octahydro -
5H-oxazolo[2,3-a]isoquinoline (7). 
 
Second generation Grubbs catalyst (642 mg, 0.756 mmol) was added to a solution of lactam 6 
(3.58 g, 10.1 mmol) in CH2Cl2 (1.44 L). The mixture was stirred for 18 hours at room temperature, 
and the resulting suspension was concentrated. Flash chromatography (4:1 to 3:2 hexane-EtOAc) 
of the residue gave tricyclic lactam 7 as a mixture of C-6 epimers (2.80 g, 85% yield).  
 
IR (film): 1667 (NCO), 1738 (COO) cm-1. 
 
1H NMR (400 MHz, CDCl3, COSY, gHSQC): δ 2.00 (m, 1H, H-7), 2.20 (m, 1H, H-7), 2.43 (m, 
2H, H-10), 2.50 (m, 1H, H-6a), 2.70 (m, 1H, H-10a), 3.18 (s, 1H, H-6), 3.60 (s, 3H, CH3O), 3.96 
(dd, J = 9.0, 1.2 Hz, 1H, H-2), 4.12 (dd, J = 9.0, 6.9 Hz, 1H, H-2), 4.85 (d, J = 9.9 Hz, 1H, H-10b), 
4.92 (dd, J = 6.9, 1.2 Hz, 1H, H-3), 5.69 (m, 2H, H-8, H-9), 7.22-7.35 (m, 5H, C6H5). 
 
13C NMR (100.6 MHz, CDCl3): δ 25.1 (C-10a), 28.0 (C-7), 32.6 (C-10), 33.5 (C-6a), 52.2 (CH3O), 
53.9 (C-6b), 59.4 (C-3), 73.6 (C-2), 87.1 (C-10b), 124.4, 124.8 (C-8, C-9), 126.8, 128.0 (C-o, m), 
127.2 (C-p), 140.6 (C-i), 162.0 (NCO), 170.2 (COO).  
 
Elemental analysis calcd (%) for [C19H21O4N·1⁄4 H2O]: C, 68.76; H, 6.53; N, 4.22. Found: C, 68.82; 
H, 6.90; N, 4.20. 
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(3R,6R,6aR,10aS,10bR)-6-[3-(1,3-Dioxolan-2-yl)ethyl]-6-(methoxycarbonyl)-5-oxo-3-
phenyl-2,3,6,6a,7,10,10a,10b-octahydro-5H-oxazolo[3,2-a]isoquinoline (8). 
 
A solution of isoquinoline 7 (880 mg, 2.70 mmol) in dry DMF (2 mL) was added to a cooled (0º 
C) suspension of NaH (161 mg of a 60% dispersion in mineral oil, 4.02 mmol) in dry DMF under 
an inert atmosphere, and the resulting mixture was stirred at 0º C for 1 hour. Then TBAI (198 mg, 
0.536 mmol) and 2-(2-bromoethyl)-1,3-dioxolane (1.59 ml, 13.5 mmol) were added to the solution 
and the mixture was stirred overnight at room temperature. The reaction was quenched with 
aqueous NH4Cl, extracted firstly with diethyl ether and then with CH2Cl2. Combined organic 
extracts washed with brine, dried (Na2SO4), filtered, and concentrated under reduced pressure. 
Flash chromatography (7:3 to 1:1 hexane-EtOAc) of the resulting residue afforded compound 8 
(905 mg, 78%). 
 
[α]22D  = –35.2 (c 0.7, CHCl3). 
 
IR (film): 1655 (NCO), 1738 (COO) cm-1. 
 
1H NMR (400 MHz,CDCl3, COSY, gHSQC): δ 1.44 (m, 2H, H-2’), 1.85 (dm, J = 17.2 Hz, 1H, 
H-7), 1.99 (m, 2H, H-1’), 2.16 (tm, J = 17.2 Hz, 1H, H-7), 2.27 (ddd, J = 11.6, 5.6 , 3.6 Hz, 1H, 
H-6), 2.46 (m, 2H, H-10), 2.58 (dd, J = 9.6, 4.8 Hz, 1H, H-10a), 3.71 (s, 3H, CH3O), 3.75, 3.80 
(2m, 4H, CH2O), 4.05 (dd, J = 9.2, 1.6 Hz, 1H, H-2), 4.13 (dd, J = 9.2, 6.8 Hz, 1H, H-2), 4.61 (t, 
J = 4.8 Hz, 1H, H-3’), 4.90 (d, J = 9.6 Hz, 1H, H-10b), 4.92 (dd, J = 6.8, 1.6 Hz, 1H, H-3’), 5.67 
(m, 2H, H-8, H-9), 7.10-7.20 (m, 5H, C6H5). 
 
13C NMR (100.6 MHz, CDCl3): δ 25.6-25.7 (C-7, C-10), 29.4 (C-2’), 31.4 (C-1’), 33.4 (C-10a), 
40.0 (C-6a), 51.9 (CH3O), 58.4 (C-6b), 59.7 (C-3), 64.6 (CH2O), 73.5 (C-2), 87.0 (C-10b), 104.1 
(C-3’), 124.3-124.6 (C-8 C-9), 126.6 -128.3 (C-o, m C6H5), 127.4 (C-p), 141.5 (C-i), 165.1 (NCO), 
171.8 (COO). 
 
HRMS (ESI) calcd for [C24H30NO6 + H]+: 428.2068, found: 428.2062. 
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(4R,4aR,8aS)-2-(tert-Butoxycarbonyl)-4-[3-(1,3-dioxolan-2-yl)ethyl]-4-(hydroxymethyl)-
1,2,3,4,4a,5,8,8a-octahydroisoquinoline (11). 
 
First step: Liquid ammonia (15 mL) was condensed at -78 ºC in a three-necked, 100 mL round-
bottomed flask equipped with a coldfinger condenser charged with dry ice-acetone, and then a 
solution of lactam 8 (200 mg, 0.454 mmol) in THF (10 mL) was added. The temperature was 
raised to -30 ºC and sodium metal was added in small portions until the blue color persisted for 2 
minutes. The reaction was quenched by the addition of solid NH4Cl until the blue color 
disappeared, and the mixture was stirred at room temperature for 4 hours. The residue was digested 
at room temperature with CH2Cl2, and the resulting suspension was filtered through celite. The 
solution was concentrated under reduced pressure. 
 
Second step: A solution of the above residue (mixture of compounds 9) in anhydrous dioxane (14 
mL) was added dropwise to lithium aluminium hydride (235 mg, 6.19 mmol) in a 3 necked flask 
at 0 ºC, under argon atmosphere and the resulting mixture was stirred overnight at reflux. The 
reaction was quenched with distilled water and NaOH 10%, dried with MgSO4, filtered and 
concentrated to give the amino alcohol 10, which was used in the next step without further 
purification. 
 
Third step: Di-tert-butyl-dicarbonate (0.103 mL, 0.449 mmol) was added dropwise to a solution 
of the above amino alcohol 10 in anhydrous CH2Cl2 (7 mL) at room temperature under inert 
atmosphere and the resulting mixture was stirred for 20 hours. The solution was poured into 
saturated aqueous NH4Cl and extracted with CH2Cl2. The combined organic extracts were washed 
with brine, dried, filtered, and concentrated. Flash chromatography (9:1 to 1:1 hexane-EtOAc) of 
the residue gave the compound 11 (71 mg, 45% overall yield from 8).  
 
[α]22D = -8.34 (c 0.44, CH2Cl2). 
 
IR (film): 1683 (C=O), 3480 (OH) cm-1. 
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1H NMR (400 MHz, CDCl3,COSY, gHSQC):δ 1.45 (s, 9H, [(CH3)3C]), 1.58-1.76 (m, 4H, H-1’, 
H-2’), 1.78-1.96(m, 2H, H-8, H-4a), 1.98-2.30 (m, 4H, H-5, H-8, H-8a), 2.67-2.77 (m, 2H, H-1, 
H-3), 3.42(s, 2H, CH2OH), 3.59-3.62 (m, 2H, H-1,H-3), 3.85-3.98 (2m, 4H, CH2O), 4.87(t, J = 
4.8 Hz, 1H, H-3’), 5.60 (m, 2H, H-6, H-7). 
 
13C NMR (100.6 MHz, CDCl3): δ 21.6(C-5), 24.0 (C-1’), 27.2 (C-2’), 27.9 (C-8a), 28.4 (C-
8,[(CH3)3C]), 34.2(C-4), 45.4(C-1,C-3),64.9 (CH2O), 68.2 (CH2OH), 79.5 ([(CH3)3C]), 104.7 (C-
3’), 124.8 (C-6, C-7), 155.0 (NCOO). 
 
HRMS (ESI) calcd for [C20H33NO5 + Na]+: 390.2251, found: 390.2263. 
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(4R,4aR,8aS)-4-(Azidomethyl)-2-(tert-butoxycarbonyl)-4-[3-(1,3-dioxolan-2-yl)ethyl]-
1,2,3,4,4a,5,8,8a-octahydroisoquinoline (13). 
 
First Step: Anhydrous TEA (2.18 ml, 15.6 mmol) and methanesulfonyl chloride (1.21 ml, 15.6 
mmol) were added at 0 ºC under an inert atmosphere to a stirred solution of alcohol 11 (1.98 g, 
5.19 mmol) in anhydrous CH2Cl2 (86 ml), and the resulting mixture was stirred at room 
temperature for 4 hours. The reaction was quenched with a saturated aqueous NH4Cl solution and 
extracted with CH2Cl2. The combined organic extracts were dried, filtered and concentrated to 
give a yellow oil which was used in the next step without purification.  
 
Second Step: NaN3 (2.03 g, 31.2 mmol) was added to a solution of the above mesylate 12 in 
anhydrous DMF (15 ml) and the mixture was heated to 90 ºC. After 48 hours, more NaN3 (2.03 g, 
31.2 mmol) was added and the resulting mixture was stirred at 90 ºC for an additional 24 hours. 
Then the reaction was quenched with distilled water, extracted with CH2Cl2, The organic extracts 
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were dried, filtered and concentrated under pressure to give an oil. Flash chromatography (hexane 
to 9:1 hexane-EtOAc) of the residue gave the azido compound 13 (1.69 g, 83%). 
 
[α]22D = -35.2 (c 0.595, CH2Cl2).  
 
IR (film): 1691 (C=O), 2100 (N3) cm-1. 
 
1H NMR (400 MHz, CDCl3,COSY, gHSQC):δ 1.35 (s, 9H, [(CH3)3C]), 1.44-2.08 (m, H, 10H, H-
1’, H-2’, H-4, H-4a, H-5, H-8a), 1.88-2.08 (m, 4H, H-5, H-8, H-8b), 2.49-2.63 (m, 2H, H-1, H-3), 
3.10 (s, 2H, CH2N3), 3.59-3.62 (m, 2H, H-1,H-3), 3.72- 3.85 (2m, 4H, CH2O), 4.72 (t, J = 4.8 Hz, 
1H, H-3’), 5.48 (m, 2H, H-6, H-7). 
 
13C NMR (100.6 MHz, CDCl3): δ 21.6 (C-2’), 25.8 (C-5), 27.8 (C-8a), 27.9 ([(CH3)C], C-8), 28.4 
(C-1’), 34.8 (C-4a), 39.7 (C-4), 43.4-45.0 (C-1, C-3), 54.0 (CH2N3), 64.9 (CH2OH), 79.7 
[(CH3)3C], 104.6 (C-3’), 123.9, 124.6 (C-6, C-7), 155.0 (NCOO). 
 
HRMS (ESI) calcd for [C20H32N4O4 + Na]+: 415.2316, found: 415.2334. 
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(4R,4aR,6S,7S,8aS)-2-(tert-Butoxycarbonyl)-4-[3-(1,3-dioxolan-2-yl)ethyl]-7-hydroxy-6,4-
(iminomethano)-9-(p-toluenesulfonyl)perhydroisoquinoline (15). 
 
First step: m-Chloroperoxybenzoic acid (1.48 g, 77% of purity, 6.61 mmol) was added to a solution 
of azide 13 (1.22 g, 3.00 mmol) at 0 °C in CH2Cl2, (43 mL) and the mixture was allowed to warm 
slowly to room temperature. After 5 hours, the reaction was quenched with saturated aqueous 
NaHCO3, and the mixture was extracted with CH2Cl2. The organic extracts were dried, filtered 
and concentrated under reduced pressure to give azido epoxide 14, which was used in the next step 
without purification. 
 
Second step: Me3P (4.8 mL of a 1 M solution in THF, 4.80 mmol) was added to a solution of the 
above azido epoxide 14 in THF (60 mL), and the mixture was stirred at room temperature for 2 
hours. Water (6 mL) was added, and the resulting mixture was stirred overnight at room 
temperature and concentrated under reduced pressure to afford a diazatricyclic alcohol. 
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Third step: TEA (0.410 mL, 3.00 mmol) was added dropwise to a stirring solution of the above 
aminoalcohol in anhydrous CH2Cl2 (50 mL) at 0 ºC. A solution of p-toluenesulfonyl chloride (572 
mg, 3.00 mmol) in anhydrous CH2Cl2 (5 mL) was transferred via cannula, and the stirring was 
continued at 0 ºC for 2.5 hours. The reaction was then quenched with saturated aqueous NH4Cl, 
and the aqueous layer was extracted with CH2Cl2. The combined organic extracts were dried, 
filtered and concentrated under reduced pressure to afford the protected tricyclic compound 15 
(998 mg, 62% in three steps) after flash chromatography (9:1 to 1:1 hexane-EtOAc). 
 
[α]D22 = +24.01 (c 1.5, CHCl3). 
 
IR (film): 1689 (C=O), 3490 (OH) cm-1. 
 
1H NMR (400 MHz, CDCl3, COSY, gHSQC): δ 1.35, 1.41 (m, 13H, [(CH3)3C], H-1’,H-2’), 1.45 
(m, 1H, H-4a), 1.59-1.64 (m, 3H, 2H-8, H-5a), 1.92 (d, J = 16.0 Hz, 1H, H-5b), 1.97 (m, 1H, H-
8a), 2.33 (s, 3H, CH3Ts), 2.60-2.78 (m, 2H, H-1a, H-3b), 3.03 (d, J = 12.5 Hz, 1H, H-10a), 3.24 
(d, J = 12.9 Hz, 1H, H-10b), 3.76 (m, 2H, CH2O), 3.83 (masked, 1H, H-7), 3.86 (m, 2H, CH2O), 
3.90 (masked, 2H, H-1a, H-3b), 3.96 (s, 1H, H-6), 4.60 (s, 1H, H-3’), 7.22 (d, J = 8.1 Hz, 2H, H-
m Ts), 7.64 (d, J = 8.2 Hz, 2H, H-o Ts). 
 
13C NMR (100.6 MHz, CDCl3) : δ 21.1 (CH3Ts), 21.9 (C-5), 27.3 (C-1’), 28.2 [(CH3)C],29.4 (C-
2’), 30.7 (8a), 32.3 (C-8), 32.4 (C-4), 35.2 (C-4a), 46.8 (C-10), 50.8 (C-6), 48.4-49.6 (C-1, C-3), 
64.8 (2CH2O),67.3 (C-7), 80,0 [(CH3)C], (104.4 (C-3’), 127.2 (C-o Ts), 129.9 (C-m Ts), 137.6 (C-
p Ts), 143.3 (C-i Ts), 155.3 (NCOO). 
 
HRMS (ESI) calcd for [C27H40N2O7S + H]+: 537.2629, found: 537.2613. 
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(4R,4aR ,6S,7S,8aS)-7-(p-Benzoyloxy)-2-(tert-butoxycarbonyl)-4-[3-(1,3-dioxolan-2-
yl)ethyl]-6,4-(iminomethano)-9-(p-toluensulfonyl)perhydroisoquinoline (16). 
 
Triethylamine (40 µL, 0.296 mmol) and DMAP (2.4 mg, 0.0198 mmol) were added to a stirred 
solution of tricyclic compound 15 (56 mg, 0.0990 mmol) in CH2Cl2 (2.5 mL). After 30 minutes 
benzoic anhydride (34 mg, 0.150 mmol) was added and the resulting mixture was stirred at room 
temperature overnight. The reaction was quenched by the addition of a solution of NH4Cl and the 
aqueous layer was extracted with CH2Cl2. The combine organic extracts were dried over MgSO4, 
filtered, and concentrated under reduced pressure. Flash chromatography (9:1 to 1:1 hexane-
EtOAc) of the residue afforded compound benzoic compound 16 (40 mg, 65%) as a white foam. 
 
IR (film): 1715 (C=O) cm-1. 
 
1H NMR (400 MHz, CDCl3, COSY, gHSQC): δ 1.22 (m, 2H, H-2’), 1.29-1.45 (m, 11H, H-1’, 
[(CH3)3C]), 1.49-1.62 (m, 2H, H-4a, H-8), 1.66-1.74 (m, 1H, H-8), 1.86 (s, 2H, H-5), 1.97 (s, 1H, 
H-8a), 2.34 (s, 3H, CH3Ts), 2.50-2.81 (m, 2H, H-1, H-3), 3.03 (d, J = 12.5 Hz, 1H, H-10), 3.47 (d, 
J = 12.9 Hz, 1H, H-10), 3.73-3.89 (masked, 2H, H-1, H-3), 3.77, 3.87 (2m, 4H, 2CH2O), 4.24 (s, 
1H, H-6), 4.72 (s, 1H, H-3’), 5.03 (s, 1H, H-7), 7.23 (d, J = 8.1 Hz, 2H, H-m Ts), 7.38 (t, J = 7.8 
Hz, 2H, H-o C6H5), 7.50 (t, J = 7.4 Hz, 1H, H-p C6H5), 7.74 (d, J = 8.2 Hz, 2H, H-o Ts), 7.93 (dd, 
J = 8.2, 1.5 Hz, 2H, H-m C6H5). 
 
13C NMR (100.6 MHz, CDCl3): δ 21.8 (CH3Ts), 23.7 (C-5),27.3 (C-1’), 28.1 [(CH3)C], 28.2 (C-
2’), 29.6 (C-8), 30.9 (C-8a), 31.1 (C-4), 34.7 (C-4a), 47.2 (C-10), 48.3 (C-6), 49.3-49.8 (C-1, C-
3), 64.7 (2CH2O),69.2 (C-7), 80.0 [(CH3)C], 104.2 (C-4’), 127.2 (C-o Ts), 128.4 (C-m C6H5), 
129.5 (C-o C6H5), 129.7 (C-m Ts), 133.1 (C-p C6H5), 137.1 (C-p Ts), 143.4 (C-i Ts), 155.5 
(NCOO). 
 
HRMS (ESI) calcd for [C34H44N2O8S + H]+: 641.2891, found: 641.2877. 
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2-(3-Cyclohexenyl)ethanol (17). 
 
BF3·Et2O (3.8 mL, 30.5 mmol) was added dropwise over 30 minutes under inert atmosphere to a 
cooled (0 °C) solution of 2-methyl-2-butene (30.5 mL, 61.0 mmol of a 2 M solution in THF) and 
NaBH4 (855mg, 22.2 mmol) in anhydrous THF (14 mL), and the resulting mixture was stirred at 
0 °C for 1 h. 4-Vinylcyclohexene (3.6mL, 27.7 mmol) was then added dropwise over a 5 minutes 
and the solution was stirred at room temperature for 2 h. The borane intermediate was oxidized by 
slowly addition at 0 °C of NaOH 3 N (25 mL) and H2O2 30% (25 mL), and the resulting solution 
was stirred overnight at 70 °C. The mixture was extracted with Et2O and the combined organic 
extracts were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure 
affording alcohol 17 (3.4 g, 99%). 
 
IR (film):3400 (OH) cm-1. 
 
1H NMR (400 MHz, CDCl3, COSY, HSQC): δ 1.26 (m, 1H, H-5), 1.54 (m, 2H, H-1’), 1.69 (dm, 
J = 14.8 Hz, 1H, H-3), 1.72 (m, 2H, H-4, H-5), 2.05 (m, 2H, H-6), 2.11 (dm, J = 14.8 Hz, 1H, H-
3), 3.71 (t, J = 6.8 Hz, 2H, H-2’), 5.65 (m, 2H, H-1, H-2). 
 
13C NMR (100.6 MHz, CDCl3): δ 25.0 (C-6), 28.8 (C-5), 30.1 (C-4), 31.7 (C-3), 39.4 (C-1’), 60.8 
(C-2’), 126.0, 127.0 (C-1,C-2). 
 
HRMS (ESI) calcd for [C8H14O + H]+: 127.1117, found: 127.1114. 
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4-(2-Azidoethyl)-1-cyclohexene (18). 
 
First step: Triethylamine (6.52 mL, 46.8 mmol) and mesyl chloride (4.83 mL, 62.4 mmol) were 
added dropwise to a stirring solution of alcohol 17 (3.4 g, 27.4 mmol) in anhydrous CH2Cl2 (400 
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mL) cooled to 0 °C under inert atmosphere. After the end of addition, the mixture was allowed to 
heat slowly to room temperature and was stirred for additional 2 h. Saturated aqueous NH4Cl was 
added and the mixture was extracted with CH2Cl2. The combined organic extracts were dried over 
anhydrous Na2SO4, filtered and the solvent was concentrated under reduced pressure. Flash 
chromatography (hexane to 8:2 hexane – ethyl acetate) affords the corresponding mesyl derivative 
(6.42 g, 99%). 
 
Second step: NaN3 (10.9 g, 167.7 mmol) was added to a solution of the above compound (9.809 g, 
41.9 mmol) in anhydrous DMF (250 mL) and the mixture was heated at 60 °C for 3 h. The resulting 
mixture was quenched with distilled water. The aqueous layer was extracted with CH2Cl2, and the 
combined organic extracts were washed 6 times with water, dried with Na2SO4 and concentrated 
under reduced pressure to give an oil. Flash chromatography (hexane) afforded azide derivative 
18 (5.068 g, 80%) as a colourless oil. 
 
1H NMR (300 MHz, CDCl3): δ 1.29 (m, 1H, H-5), 1.53-1.80 (m, 5H, H-5, H-4, H-3, 2H-1’), 2.05 
(m, 3H, 2H-6, H-3), 3.33 (t, J = 6.9 Hz, 2H, H-2’), 5.66 (m, 2H, H-1, H-2). 
 
13C NMR (75.4 MHz, CDCl3): δ 24.8 (C-6), 28.4 (C-5), 30.8 (C-4), 31.3 (C-3), 35.1 (C-1’), 49.1 
(C-2’), 125.8, 126.9 (C-1, C-2). 
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3-(2-Azidoethyl)-7-oxabicyclo[4.1.0]heptane (19). 
 
m-Chloroperoxybenzoic acid (2.2 g, technical grade 77%, 9.934 mmol) was added to a cold (0 °C) 
solution of azide 18 (1.0 g, 6.622 mmol) in CH2Cl2 (50 mL), and the mixture was allowed to warm 
slowly to room temperature. After 4 h under stirring at room temperature, the mixture was washed 
with saturated aqueous NaHCO3, then saturated aqueous Na2S2O3, dried over anhydrous Na2SO4, 
filtered and concentrated under reduced pressure to give a mixture of epoxydes (1.1 g, 99%) which 
was used in the next step without further purification. 
 
IR (film): 1262 (C-O-C), 2097 (N=N=N) cm-1. 
 
1H NMR (400 MHz, CDCl3, COSY, HSQC): δ 0.88-1.00 (m, 2H, 2H-5), 1.11-1.21 (m, 1H, H-5), 
1.31-1.53 (m, 8H, 2H-3, 1H-4, 1H-5, 4H-1’), 1.56-1.65 (m, 1H, H-4), 1.70-1.78 (m, 1H, H-6), 
1.82-1.90 (m, 1H, H-6), 1.97-2.10 (m, 2H, 1H-3, 1H-6), 2.13-2.21 (m, 2H, 1H-3, 2H-6), 3.12-3.18 
(m, 4H, 2H-1, 2H-2), 3.26-3.30 (m, 4H, H-2’). 
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13C NMR (100.6 MHz, CDCl3): δ 23.3 (C-6), 24.1 (C-5), 25.0 (C-6), 26.9 (C-5), 27.2 (C-4), 29.9 
(C-4), 30.3 (C-3), 31.6 (C-3), 34.9 (C-1’), 35.4 (C-1’), 48.8 (C-2’), 49.1 (C-2’), 51.4 (C-1), 51.6 
(C-1), 52.4 (C-2), 52.8 (C-2). 
 
HRMS (ESI) calcd for [C8H13N3O + H]+: 168.1131, found: 168.1136. 
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8-Hydroxy-2-(toluenesulfonyl)-2-azabicyclo[3.3.1]nonane (21). 
 
First step: Me3P (2.40 mL of a 1 M solution in THF, 2.40 mmol) was added to a solution of the 
above epoxydes 19 (150 mg, 0.904 mmol) in THF/H2O (22 mL, 9:1), and the mixture was stirred 
at room temperature for one night. The resulting solution was concentrated under reduced pressure 
to afford crude 2-ABN framework (20) as pale yellow oil.  
 
Second step: A solution of toluenesulfonyl chloride (297mg, 1.56 mmol) in anhydrous CH2Cl2 (8 
mL) and triethylamine (185µL, 1.32 mmol) were added dropwise to a solution of the above amino 
alcohol (20) in anhydrous CH2Cl2 (4.5 mL) at 0 °C under inert atmosphere. The mixture was stirred 
for 4 h at 0 °C, poured into saturated NH4Cl, and the resulting solution was extracted with CH2Cl2. 
The combined organic extracts were washed with brine, dried over anhydrous MgSO4, and 
concentrated under reduced pressure. Flash chromatography (hexane to 1:1 hexane-EtOAc) gave 
alcohol 21(80mg, 30% overall yield from epoxides 19). 
 
IR (film): 3600 (OH) cm-1. 
 
1H NMR (300 MHz, CDCl3): δ 1.26-2.05 (m, 9H, 2H-4, 2H-9, H-5, 2H-6, 2H-7), 2.43 (s, 3H, 
CH3), 3.18 (qp, J= 6.3 Hz, 1H, H-3), 3.50 (qp, J= 6.3 Hz, 1H, H-3), 3.75 (m, 1H, H-1), 4.10 (br. 
s, 1H, H-8), 7.30 (d,J= 8.1 Hz, 2H, H-o Ts), 7.70 (d,J= 8.1 Hz, 2H, H-m Ts). 
 
13C NMR (75.4 MHz, CDCl3): δ 21.4 (CH3 Ts), 23.3 (C-5), 24.1 (C-7), 25.8 (C-6, C-4), 27.6 (C-
9), 40.9 (C-3), 53.3 (C-1), 68.7 (C-8), 127.1 (C-o Ts), 129.6 (C-m Ts), 136.8 (C-i Ts), 143.2 (C-p 
Ts). 
 
HRMS (ESI) calcd for [C15H22NO3S + H]+: 296.1215, found: 296.1208. 
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8-Oxo-2-(toluenesulfonyl)-2-azabicyclo[3.3.1]nonane (22). 
 
Dess-Martin Periodinane (2.957 g, 6.971 mmol) was added at room temperature to a stirring 
solution of bicyclic alcohol 21 (1.371 g, 4.647 mmol) in CH2Cl2 (100 mL) under inert atmosphere. 
After one night of stirring at room temperature, a saturated (1:1) solution of NaHCO3-Na2S2O3was 
slowly added. The resulting mixture was stirred vigorously for 45 min and extracted with CH2Cl2. 
The combined organic extracts were dried over anhydrous Na2SO4, filtered, and concentrated 
under reduced pressure. The residue was purified by flash chromatography (hexane–
hexane/EtOAc 7:3), affording ketone 22 (1.183 g, 87%). 
 
IR (film): 1716 (C=O) cm-1. 
 
1H NMR (400 MHz, CDCl3): δ 1.84-1.89 (m, 3H, H-4, H-9, H-6), 1.95 (m, 1H, H-6), 2.12 (m, 3H, 
H-5, H-4, H-9), 2.28 (m, 2H, 2H-7), 2.41 (s, 3H, CH3 Ts), 3.27 (m, 1H, H-3), 3.65 (dt, J = 12.4, 
6.0 Hz, 1H, H-3), 4.21 (t, J = 2.8 Hz, 1H, H-1), 7.28 (dd, J = 8.0, 0.8 Hz, 2H, H-o Ts), 7.65 (d,J= 
8.0 Hz, 2H, H-m Ts). 
 
13C NMR (100.6 MHz, CDCl3): δ 21.5 (CH3 Ts), 23.6 (C-5), 29.8 (C-4), 30.6 (C-6), 33.1 (C-9), 
38.1 (C-7), 40.6 (C-3), 59.2 (C-1), 127.6 (C-o Ts), 129.5 (C-m Ts), 134.8 (C-i Ts), 143.5 (C-p Ts), 
207.7 (C-8). 
 
HRMS (ESI) calcd for [C15H19NO3S + H]+: 294.1158, found: 294.1150. 
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Methyl 5-oxopentanoate (24). 
 
Sulfuric acid (200 µL) was slowly added to a solution of δ-valerolactone (9.27 mL, 99.9 mmol) in 
MeOH (50 mL). After one night, the reaction was quenched with CaCO3 and filtered on celite 
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(washings with diethyl ether). The filtered was dried at 0 °C under reduced pressure and dissolved 
in 500 mL of CH2Cl2. PCC (32.3 g, 149.8 mmol) and celite (32 g) were added to this solution at 0 
°C and the reaction was stirred overnight. The reaction mixture was filtered on silica (washings 
with hexane and hexane-EtOAc 9:1) and dried, giving methyl 5-oxopentanoate 24 (12.076 g,93% 
in two steps).  
 
1H NMR (300 MHz, CDCl3): δ 1.96 (t, J=7.5 Hz, 2H, 2H-3), 2.39 (t, J=7.5 Hz, 2H, 2H-2), 2.56 
(td, J= 7.5, 1.5 Hz, 2H, 2H-4), 3.69 (s, 2H, OCH3), 9.78 (t, J=1,5 Hz, 1H, CHO). 
 
13C NMR (74.6 MHz, CDCl3): δ 16.8 (C-3), 32.4 (C-2), 42.3 (C-4), 51.0 (OCH3), 172.8 (CO2Me), 
201.1 (CHO). 
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3-Butenyltriphenylphosphonium bromide (25). 
 
A mixture of 4-bromo-1-butene (3.2 mL, 31.5 mmol) and triphenylphosphine (8.27 g, 31.5 mmol) 
in toluene (21 mL) was heated at reflux for 24 h. The reaction mixture was then cooled to rt and 
filtered over a Buchner funnel. A white solid was collected, which was washed with toluene and 
dried under high vacuum to afford desired product (8.5 g, 68%).  
Experimental procedure from: Org. Biomol. Chem. 2014,12, 330. 
For NMR and mass data see: Org. Lett. 2007, 9, 445. 
 
 
 
(Z)-Methyl 5,8-nonadienoate (26). 
 
LDA (138 µL, 0.277 mmol) was slowly added at −40 °C to a mixture of the phosphonium salt 25 
(120 mg, 0.302 mmol), previous dried at 40 °C under vacuum with a trap of P2O5 over a weekend, 
in HMPA (190 µL, 0.110 mmol) and THF (1 mL). After stirring at −40 °C for one hour, a solution 
of aldehyde 24 in THF (250µL) was added to the mixture cooled at −78 °C and the reaction was 
stirred overnight, allowing the temperature raise to rt. The reaction was then quenched with NH4Cl 
and extracted with diethyl ether. The combined organic extracts were dried over anhydrous 
Na2SO4, filtered, and concentrated under reduced pressure. Flash chromatography (hexane to 
hexane – Et2O 95:5) gave the desired product 26 (33 mg, 79%). 
 
IR (film): 1741 (O-C=O) cm-1. 
 
1H NMR (400 MHz, CDCl3, COSY, HSQC): δ 1.70 (dt, J = 14.4,8.0 Hz, 2H, H-3), 2.09 (appdd, J 
= 13.2,6.4 Hz, 2H, H-4), 2.32 (t, J = 7.2 Hz, 2H, H-2), 2.78 (appt, J = 6.0 Hz,2H, H-7), 3.67 (s, 
3H, OCH3), 4.97 (dq, J = 10.4, 3.2,1.6 Hz, 1H, H-9), 5.03 (dq, J = 15.2, 4.0,2.0 Hz, 1H, H-9), 
5.39-5.48 (m, 2H, H-5, H-6), 5.80 (ddt, J = 16.4, 10.0,6.4 Hz, 1H, H-8). 
 
13C NMR (400 MHz, CDCl3): δ 4.7 (C-3), 26.4 (C-4), 31.4 (C-7), 33.4 (C-2), 51.4 (OCH3), 114.7 
(C-9), 127.8 (C-5), 129.6 (C-6), 136.8 (C-8), 174.1 (C-1). 
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(Z)-5,8-Nonadienoic acid (27). 
 
An aqueous solution of LiOH (1 M, 31 mL, 30.95 mmol) was added to a solution of the ester 26 
(130 mg, 0.774 mmol) in THF (25 mL), and the resulting mixture was stirred at room temperature 
for 4 h. The reaction was quenched by addition of saturated aqueous NaCl, and the solution was 
washed with Et2O. The aqueous layer was then acidified until pH 5 and extracted with Et2O. The 
combined organic extracts were dried over anhydrous Na2SO4, filtered, and concentrated under 
reduced pressure to afford the corresponding acid 27, which was used in the next step without 
further purification (98 mg, 82%). 
 
IR (film): 1709 (O-C=O) cm-1. 
 
1H NMR (400 MHz, CDCl3, COSY, HSQC): δ 1.71 (dt, J = 14.8, 7.2 Hz, 2H, H-3), 2.12 (appdd, 
J = 14.0, 7.2 Hz, 2H, H-4), 2.36 (t, J = 7.2 Hz, 2H, H-2), 2.79 (appt, J = 6.0 Hz, 2H, H-7), 4.98 
(dq, J = 10.0, 2.8, 1.2 Hz, 1H, H-9), 5.03 (dq, J = 17.2, 3.2, 1.6 Hz, 1H, H-9), 5.39-5.49 (m, 2H, 
H-5, H-6), 5.80 (ddt, J = 17.2, 10.8, 6.0 Hz, 1H, H-8). 
 
13C NMR (100.6 MHz, CDCl3): δ 24.4 (C-3), 26.3 (C-4), 31.5 (C-7), 33.2 (C-2), 114.7 (C-9), 
128.0 (C-5), 129.5 (C-6), 136.8 (C-8), 179.3 (C-1). 
 
HRMS (ESI) calcd for [C9H12O2 + H]+: 153.0921, found: 153.0916. 
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8-Methylene-2-(toluenesulfonyl)-2-azabicyclo[3.3.1]nonane (28). 
 
MeLi (457 µL of a solution 1.6 M in Et2O, 0.376 mmol) was slowly added at 0 ºC in the dark 
under inert atmosphere to a suspension of Cp2TiCl2 (87 mg, 0.348 mmol) in anhydrous Et2O (1.5 
mL) cooled at 0 °C. After stirring at this temperature for 1h, the reaction mixture was quenched 
with H2O and extracted in the dark with Et2O. The combined organic extracts were dried and 
concentrated under reduced pressure in absence of light to give Cp2TiMe2 as an orange solid. A 
solution of above solid (0.348 mmol) in anhydrous toluene/pyridine (100:1, 2 mL) was added 
under argon atmosphere to a solution of bicyclic ketone 22 (51 mg, 0.174 mmol) in anhydrous 
toluene (500 µL) at room temperature, and the resulting mixture was stirred at reflux temperature 
in the dark for 6h. The solvent was then removed, and the resulting residue was treated with 8:2 
Et2O/CH2Cl2. The precipitate was filtered and the liquid filtrate concentrated. Purification by flash 
chromatography (hexane to 9:1 hexane–EtOAc) afforded alkene 28 (24 mg), recovering 16 mg of 
the starting ketone 22 (47%, 69% considering the unreacted ketone). 
 
IR (film): 1160 (N-SO2-C) cm-1. 
 
1H NMR (400 MHz, CDCl3, COSY, HSQC): δ 1.63-1.75 (m, 4H, H-4, 2H-6, H-9), 1.90-1.95 (m, 
1H, H-9), 1.98-2.03 (m, 2H, H-4, H-5), 2.09-2.14 (m, 2H, 2H-7), 2.40 (s, 3H, CH3 Ts), 3.19-3.27 
(m, 1H, H-3), 3.58-3.64 (m, 1H, H-3), 4.53 (t, J = 3.3 Hz, 1H, H-1), 4.70 (dt, J = 1.9,1.3 Hz, 1H, 
=CH2), 4.86 (t, J = 1.8 Hz, 1H, =CH2), 7.24 (dd, J = 8.0,0.6 Hz, 2H, H-m Ts), 7.67 (dt, J = 8.6,2.0 
Hz, 2H, H-o Ts). 
 
13C NMR (100.6 MHz, CDCl3): δ 21.5 (CH3 Ts), 24.5 (C-5), 29.6 (C-4), 30.3 (C-7), 30.9 (C-6), 
34.9 (C-9), 41.9 (C-3), 55.1 (C-1), 111.7 (=CH2), 127.7 (C-m Ts), 129.1 (C-o Ts), 136.1 (C-p Ts), 
142.8 (C-i Ts), 146.1 (C-8). 
 
HRMS (ESI) calcd for [C16H21NO2S + H]+: 292.1366, found: 292.1367. 
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(Z)-8-Methylene-2-nona-5,8-dien-1-oxo-2-azabicyclo[3.3.1]nonane (29). 
 
First step: Sodium metal (384 mg, 16.70 mmol) was added at room temperature to a solution of 
naphthalene (1068 mg, 8.33 mmol) in THF (24 mL). After stirring for 2 h, part of the mixture 
(10.04 mL) was added at -78 °C to a solution of the tosyl derivative 28 (225 mg, 0.773 mmol) in 
THF (20 mL). After 10 min at -78 °C, a few drops of saturated aqueous NH4Cl were carefully 
added, and the resulting solution was dried over anhydrous Na2SO4, filtered and concentrated 
under reduced pressure. This crude was used without further purification in the next step. 
 
Second step: To a stirred solution of acid 27 (62 mg, 0.4 mmol) and above amine (0.4 mmol) in 
CH2Cl2 (2 mL) was added dropwise a solution of DCC (99 mg, 0.480 mmol) and DMAP (5 mg, 
0.04 mmol) in CH2Cl2 (1.5 mL) at -20 °C under argon. After the end of addition, the mixture was 
allowed to heat slowly to room temperature and was stirred for one night. The dicyclohexylurea 
was then filtered off and the filtrate was extracted with HCl 0.5 M and then with Na2CO3. The 
combined organic extracts were dried over anhydrous Na2SO4, filtered, and concentrated under 
reduced pressure. The product was purified by flash chromatography (hexane-EtOAc 98:2), 
affording amide 29 (85 mg, 78% in two steps). 
 
IR (film): 1410 (CH2-C=C), 1644 (N-C=O) cm-1. 
 
1H NMR (400 MHz, CDCl3, COSY, HSQC, rotamers): δ 1.68-1.79 (m, 12H, 2H-4, 2H-6, 2H-7, 
2H-9, 4H-3'),1.91-1.99 (m, 4H, 2H-4, 2H-9), 2.08-2.13 (m, 6H, 2H-5, 4H-4'), 2.23-2.52 (m, 6H, 
2H-7, 4H-2'), 2.76-2.81 (m, 4H, 4H-7'), 3.46-3.54 (m, 2H, 2H-3), 3.60 (ddd, J = 12.8, 7.6, 3.6 Hz, 
1H, 1H-3), 3.92 (ddd, J = 14.4, 7.6, 4.4 Hz, 1H, 1H-3), 4.33 (t, J = 2.8, 1H, 1H-1), 4.75-4.80 (m, 
3H, =CH2), 4.95-5.11 (m, 4H, 1H-1, 2H-9', =CH2), 5.39-5.48 (m, 4H, 2H-5', 2H-6'), 5.75-5.85 (m, 
2H, 2H-8'). 
 
13C NMR (100.6 MHz, CDCl3, rotamers): δ 24.6, 24.7 (C-5), 24.9 (C-3'), 26.7, 26.8 (C-4'), 28.7 
(C-9), 29.7 (C-7), 29.9 (C-9), 31.0 (C-3'), 31.4, 31.5 (C-7'), 31.8 (C-6), 32.9 (C-7), 33.2, 33.4 (C-
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2'), 34.4 (C-7), 38.4, 41.4 (C-3), 50.8, 55.3 (C-1), 109.8, 111.4 (=CH2), 114.5, 114.6 (C-9'), 127.3, 
127.4 (C-5'), 130.2, 130.3 (C-6'), 136.9, 137.0 (C-8'), 146.8, 148.4 (C-8), 172.2, 173.5 (C-1’). 
 
HRMS (ESI) calcd for [C18H27NO + H]+: 274.2165, found: 274.2166. 
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3-Bromo-1-(tert-butyldimethylsilyloxy)propane (31). 
 
Triethylamine (3.6 mL, 26.0 mmol), dimethylaminopiridine (122 mg, 1.0 mmol) and tert-
butyldimethylsilane chloride (3.6 g, 24.0 mmol) were added to a solution of 3-bromopropanol (1.8 
mL, 20 mmol) in anhydrous THF (30 mL) under inert atmosphere at room temperature. After 18 
h stirring at room temperature, saturated NH4Cl was added and the resulting mixture was extracted 
with Et2O. The combined organic extracts were dried over anhydrous Na2SO4, and concentrated 
under reduced pressure. Flash chromatography (hexane) gave protected alcohol 31 (4.8 g, 96%) 
as colourless oil. 
 
1H NMR (400 MHz, CDCl3): δ 0.07 (s, 6H, CH3Si), 0.90 [s, 9H, (CH3)3C], 2.03 (m, 2H, H-2), 
3.51 (t, J = 6.6 Hz, 2H, H-1), 3.73 (t, J = 5.4 Hz, 2H, H-3). 
 
13C NMR (100.6 MHz, CDCl3): δ -5.4 (2CH3Si), 18.3 [(CH3)3CSi], 25.9 [(CH3)3CSi], 30.7 
(CH2Br), 35.5 (CH2), 60.4 (CH2O). 
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3-(tert-Butyldimethylsilyloxy)propyltriphenyl-phosphonium bromide (32). 
 
Triphenylphosphine (5.0 g, 19.1 mmol) was added to a solution of protected alcohol 31 (4.0 g, 
15.9 mmol) in anhydrous benzene (3 mL) under argon atmosphere. The mixture was heated at 85 
°C for 18 h and then was cooled to room temperature. Ether was added to the resulting solution 
and a white solid was formed. The residue was filtered and washed several times with ether. Flash 
chromatography of the resulting solid (CH2Cl2 to 9:1 CH2Cl2-MeOH) afforded phosphonium salt 
32 (7.9 g, 96%). 
 
1H NMR (300 MHz, CDCl3): δ 0.04 (s, 6H, CH3Si), 0.85 [s, 9H, (CH3)3C], 1.95 (m, 2H, H-2), 
3.98 (m, 4H, H-1, H-3), 7.69-7.90 (m, 15H, C6H5). 
 
13C NMR (75.4 MHz, CDCl3): δ -5.3 (2CH3Si), 18.2 [(CH3)3CSi], 18.7, 19.2 (CH2P), 25.9 
[(CH3)3CSi], 26.0, 26.1 (CH2), 61.6, 61.8 (CH2O), 118.0, 118.8 (C-iC6H5), 130.3-133.7 (C-o, m 
C6H5), 134.9 (C-p C6H5). 
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m.p. 216 °C. 
 
HRMS (ESI) calcd for [C21H22OP – TBDMSi + H]+: 321.1403, found: 321.1398. 
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(Z)-Methyl 8-(tert-butyldimethylsilyloxy)-5-octenoate (33). 
 
LDA (890 µL, 1.424 mmol) was slowly added at -40 °C to a mixture of the phosphonium salt 32 
(1 g, 1.940 mmol), previous dried at 40 °C under vacuum with a trap of P2O5 over a weekend, in 
HMPA (1.225 mL, 7.055 mmol) and THF (6 mL). After stirring at -40 °C for one hour, a solution 
of aldehyde 24 in THF (2.50 mL) was added to the mixture cooled at -78 °C and the reaction was 
stirred overnight, allowing the temperature raise to room temperature. The reaction was then 
quenched with NH4Cl and extracted with diethyl ether. The combined organic extracts were dried 
over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. Flash chromatography 
(hexane to hexane–Et2O 98:2) gave the desired product 33 (390 mg, 70%). 
 
IR (film): 1742 (COO) cm-1. 
 
1H NMR (400 MHz, CDCl3, COSY, HSQC): δ 0.05 (s, 6H, CH3Si), 0.89 [s, 9H, (CH3)3CSi], 1.69 
(m, 2H, 2H-3), 2.08 (m, 2H, 2H-4), 2.25 (m, 2H, 2H-7), 2.31 (t, J = 8.0 Hz, 2H, 2H-2), 3.60 (t, J 
= 6.4 Hz, 2H, CH2OSi), 3.67 (s, 3H, CH3O), 5.40 (m, 2H, H-5, H-6). 
 
13C NMR (100.6 MHz, CDCl3): δ -5.3 (CH3Si), 18.3 [(CH3)3CSi], 24.8 (C-3), 25.9 [(CH3)3CSi], 
26.7 (C-4), 31.1 (C-7), 33.5 (C-2), 51.5 (CH3O), 62.9 (C-8), 126.9, 130.3 (C-5, C-6), 174.1 (NCO). 
 
HRMS (ESI) calcd for [C15H30O3Si + H]+: 287.2000, found: 287.2042. 
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(Z)-8-(tert-Butyldimethylsilyloxy)-5-octenoic acid (34). 
 
An aqueous solution of LiOH (1 M, 28.5 mL, 28.5 mmol) was added to a solution of the ester 33 
(407 mg, 1.423 mmol) in THF (41 mL), and the resulting mixture was stirred at room temperature 
overnight. The reaction was quenched by addition of saturated aqueous NaCl, and the solution was 
extracted first with Et2O, then the combined aqueous extracts were acidified until pH 5 and 
extracted again with Et2O. The combined organic extracts were dried over anhydrous Na2SO4, 
filtered, and concentrated under reduced pressure. Flash chromatography (EtOAc) afforded the 
corresponding acid 34, without further purification (190 mg, 49%). 
 
IR (film): 1708 (COO) cm-1. 
 
1H NMR (400 MHz, CDCl3, COSY, HSQC): δ 0.05 (s, 6H, CH3Si), 0.89 [s, 9H, (CH3)3CSi], 1.69-
1.76 (m, 2H, 2H-3), 2.12-2.17 (m, 2H, 2H-4), 2.30-2.39 (m, 4H, 2H-7, 2H-2), 3.66 (t, J = 6.4 Hz, 
2H, 2H-8), 5.40-5.46 (m, 1H, H-6), 5.49-5.56 (m, 1H, H-5). 
 
13C NMR (100.6 MHz, CDCl3): δ -5.3 (CH3Si), 18.4 [(CH3)3CSi], 24.5 (C-3), 25.9 [(CH3)3CSi], 
26.5 (C-4), 30.7 (C-7), 33.2 (C-2), 62.2 (C-8), 126.6 (C-6), 131.6 (C-5), 178.9 (C-1). 
 
HRMS (ESI) calcd for [C14H27O3Si - H]+: 271.1735, found: 271.1738. 
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8-Hydroxy-2-(toluenesulfonyl)-2-azabicyclo[3.3.1]nonane (35). 
 
NaBH4 (183 mg, 4.833 mmol) was added to a solution of ketone 22 (944 mg, 3.222 mmol) in THF 
(9 mL) and MeOH (9 mL) at 0 °C, and the resulting mixture was for 10 minutes. The reaction was 
quenched by addition of saturated aqueous NaHCO3, and the solution was extracted with Et2O, 
dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. Alcohol 35 was 
obtained without further purification (866 mg, 91%). 
 
IR (film): 3600 (OH) cm-1. 
 
1H NMR (400 MHz, CDCl3, COSY, HSQC): δ 1.30-1.35 (m, 1H, H-9), 1.41-1.46 (m, 1H, H-9), 
149-1.58 (m, 3H, H-4, 2H-6), 1.63-1.77 (m, 2H, H-4, H-7), 1.79-1.86 (m, 2H, H-5, H-7), 2.36 (s, 
3H, CH3), 3.18-3.25 (m, 1H, H-3), 3.44-3.51 (m, 1H, H-3), 3.54-3.58 (m, 1H, H-8), 3.95 (br. s, 
1H, H-1), 7.25 (d, J = 8.0 Hz, 2H, H-o Ts), 7.70 (d, J = 8.8 Hz, 2H, H-m Ts). 
 
13C NMR (100.6 MHz, CDCl3): δ 21.3 (CH3 Ts), 22.7 (C-5), 27.6 (C-4), 28.3 (C-7), 29.3 (C-6), 
29.4 (C-9), 41.6 (C-3), 53.7 (C-1), 71.0 (C-8), 127.1 (C-o Ts), 129.6 (C-m Ts), 135.7 (C-i Ts), 
143.4 (C-p Ts). 
 
HRMS (ESI) calcd for [C15H22NO3Si + H]+: 296.1315, found: 296.131. 
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8-(tert-Butyldimethylsilyloxy)-2-(toluenesulfonyl)-2-azabicyclo[3.3.1]nonane (37). 
 
TEA (123 µL, 0.881 mmol) and DMAP (4 mg, 0.0339 mmol) were added under inert atmosphere 
to a solution of alcohol 35 (200 mg, 0.678 mmol) and TBDMSCl (123 mg, 0.814 mmol) in THF 
(6 mL), and the reaction was stirred at reflux overnight. The reaction mixture was quenched by 
addition of saturated aqueous NH4Cl, and the solution was extracted with Et2O, dried over 
anhydrous Na2SO4, filtered, and concentrated under reduced pressure. Purification by flash 
chromatography (hexane to 7:3 hexane-EtOAc) afforded compound 37 (92 mg), recovering 108 
mg of the starting alcohol 35 (33%, 72% considering the unreacted alcohol). 
 
1H NMR (400 MHz, CDCl3, COSY, HSQC): δ 0.06 (s, 6H, CH3Si), 0.82 [s, 9H, (CH3)3CSi], 1.36-
1.43 (m, 4H, H-6, H-9), 1.51-1.63 (m, 3H, H-4, H-7), 1.69-1.74 (m, 2H, H-5, H-7), 2.29 (s, 3H, 
CH3), 3.32-3.37 (m, 2H, H-3), 3.67 (ddd, J = 11.2, 7.2,4.4 Hz, 1H, H-8), 4.14 (br. s, 1H, H-1), 7.13 
(d, J = 7.6 Hz, 2H, H-o Ts), 7.70 (d, J = 8.4 Hz, 2H, H-m Ts). 
 
13C NMR (100.6 MHz, CDCl3): δ 0.2 (CH3Si), 23.4 (CH3 Ts), 26.3 (C-5), 29.4 [(CH3)3CSi], 30.9 
(C-4), 33.9 (C-7), 36.4 (C-6), 36.9 (C-9), 47.2 (C-3), 57.6 (C-1), 76.8 (C-8), 132.3 (C-o Ts), 134.2 
(C-m Ts), 143.7 (C-i Ts), 147.3 (C-p Ts). 
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8-(tert-Butyldimethylsilyloxy)-2-azabicyclo[3.3.1]nonane (38). 
 
Sodium metal (96 mg, 4.176 mmol) was added at room temperature to a solution of naphthalene 
(267 mg, 2.083 mmol) in THF (6 mL). After stirring for 2 h, part of the mixture (800 µL) was 
added at -78 °C to a solution of the tosyl derivative 37 (25 mg, 0.0611 mmol) in THF (1.6 mL). 
After 10 min at -78 °C, a few drops of saturated aqueous NH4Cl were carefully added, and the 
resulting solution was dried over anhydrous Na2SO4, filtered and concentrated under reduced 
pressure. Flash chromatography on basic alumina (EtOAc to 8:2 EtOAc-methanol) afforded 
compound 38 (11 mg, 71%). 
 
1H NMR (400 MHz, CDCl3, COSY, HSQC): δ 0.04 (s, 3H, CH3Si), 0.05 (s, 3H, CH3Si), 0.89 [s, 
9H, (CH3)3CSi], 1.39-1.44 (m, 2H, 2H-9), 1.58-1.63 (m, 2H, 2H-6), 1.68-1.71 (m, 1H, H-4a), 1.83-
1.87 (m, 2H, H-5, H-7a), 1.91-1.97 (m, 2H, H-4b, H-7b), 2.83-2.88 (m, 2H, H-1, H-3a), 3.28 (dt, 
J = 12.4, 5.6 Hz, 1H, H-3b), 3.74 (ddd, J = 10.8, 7.6, 4.0 Hz, 1H, H-8). 
 
13C NMR (100.6 MHz, CDCl3): δ -4.7 (CH3Si), -4.5 (CH3Si), 18.1 [(CH3)3CSi], 25.0 (C-5), 25.9 
[(CH3)3CSi], 29.6 (C-6), 30.5 (C-4), 32.0 (C-7), 32.1 (C-9), 41.3 (C-3), 52.1 (C-1), 73.6 (C-8). 
 
HRMS (ESI) calcd for [C14H30NOSi + H]+: 256.2091, found: 256.2084. 
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2-(tert-Butoxycarbonyl)-8-hydroxy-2-azabicyclo[3.3.1]nonane (41). 
 
First step: Me3P (12.5 mL of a 1 M solution in THF, 12.5 mmol) was added to a solution of the 
epoxydes 19 (1.67 g, 10.0 mmol) in THF/H2O (170 mL, 6:1) and the mixture was stirred overnight 
at 70 °C. The resulting solution was concentrated under reduced pressure to afford crude (2-ABN) 
framework as pale yellow oil.  
 
Second step: A solution of di-tert-butyl dicarbonate (2.1 g, 10.0 mmol) in anhydrous CH2Cl2 (3 
mL) was added dropwise to a solution of the above amino alcohol (10.0 mmol) in anhydrous 
CH2Cl2 (222 mL) at room temperature under inert atmosphere. The mixture was stirred for 2 h, 
poured into water, and the resulting solution was extracted with CH2Cl2. The combined organic 
extracts were washed with brine, dried over anhydrous MgSO4, filtered and concentrated under 
reduced pressure. Flash chromatography (9:1 to 6:4 hexane-EtOAc) gave alcohol 41 (1.28 g, 55% 
overall yield from 19) as colourless oil. 
 
IR (film): 3453 (OH), 1689, 1666 (C=O) cm-1. 
 
1H NMR (300 MHz, CDCl3, rotamers): δ 1.45 [s, 9H, C(CH3)3], 1.45 (masked, 2H, H-6), 1.57 (m, 
1H, H-7), 1.65 (m, 2H, H-4, H-9), 1.91 (m, 3H, H-4, H-9, H-5), 2.06, 2.14 (d, J = 13.2 Hz, 1H, H-
7), 2.50 (br. s, 1H, OH), 3.42 (m, 1H, H-3), 3.53 (m, 1H, H-3), 3.93 (s, 1H, H-1), 3.99 (s, 1H, H-
8). 
 
13C NMR (75.4 MHz, CDCl3, rotamers): δ 24.0, 24.2 (C-5), 25.0, 25.1 (C-7), 25.6, 25.8 (C-6), 
26.6, 26.8 (C-4), 27.9, 28.2 (C-9), 28.4 [C(CH3)3], 39.1, 40.0 (C-3), 50.9, 51.3 (C-1), 66.6, 67.6 
(C-8), 79.3, 79.4 [C(CH3)3], 156.0, 156.1 (CO). 
 
HRMS (ESI) calcd for [C13H23NO3 + H]+: 264.1570, found: 264.1577. 
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2-(tert-Butoxycarbonyl)-8-oxo-2-azabicyclo[3.3.1]nonane (42). 
 
Dess-Martin Periodinane (5.7 g, 13 mmol) was added at room temperature to a solution of bicyclic 
alcohol 41 (1.28 g, 5.3 mmol) in CH2Cl2 (196 mL). After 18 h of stirring at room temperature, a 
saturated (1:1) solution of NaHCO3-Na2S2O3 was slowly added. The resulting mixture was stirred 
vigorously for 1 h and extracted with CH2Cl2. The combined organic extracts were dried over 
anhydrous Na2SO4, filtered, and concentrated under reduced pressure. Flash chromatography 
(hexane to 1:1 EtOAc-hexane) afforded ketone 42 (1.07 g, 85%) as a colorless oil.  
 
IR (film): 1696, 1705 (C=O) cm-1. 
 
1H NMR (400 MHz, CDCl3, COSY, HSQC): δ 1.40 [s, 9H, (CH3)3C], 1.79, 1.81 (2m, 2H, H-6, 
H-4), 1.91 (m, 2H, H-9), 2.08 (m, 1H, H-6), 2.10-2.20 (m, 3H, H-5, H-4, H-7), 2.76 (m , 1H, H-
7), 3.43 (m, 1H, H-3), 3.73 (m, 1H, H-3), 4.20 (m, 1H, H-1). 
 
13C NMR (100.6 MHz, CDCl3): δ 22.6 (C-5), 28.2 [(CH3)3C], 28.3 (C-4), 31.9 (C-6), 35.3 (C-9), 
35.3 (C-7), 37.2 (C-3), 60.0 (C-1), 80.6 [(CH3)3C], 155.1 (COO), 210.3 (CO). 
 
HRMS (ESI) calcd for [C13H21NO3 + Na]+: 262.1419, found: 262.1416. 
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(Z)-8-Oxo-2-nona-5,8-dien-1-oxo-2-azabicyclo[3.3.1]nonane (43). 
 
First step: TFA (1.1 ml) was added at room temperature to a solution of ketone 42 (69 mg, 0.289 
mmol) in CH2Cl2 (3.2 mL). After stirring for 30 min, the mixture was concentrated under reduced 
pressure. This crude was used without further purification in the next step. 
 
Second step: To a stirred solution of acid 27 (45 mg, 0.292 mmol) and above amine (0.289 mmol) 
in CH2Cl2 (1.6 mL) was added dropwise a solution of DCC (71 mg, 0.345 mmol) and DMAP (4 
mg, 0.03 mmol) in CH2Cl2 (1.1 mL) at -20 °C under argon. After the end of addition, the mixture 
was allowed to heat slowly to room temperature and was stirred for one night. The 
dicyclohexylurea was then filtered off and the filtrate was extracted with HCl 0.5 M and then with 
Na2CO3. The combined organic extracts were dried over anhydrous Na2SO4, filtered, and 
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concentrated under reduced pressure. The product was purified by flash chromatography (hexane-
EtOAc 8:2), affording amide 43 (40 mg, 50% in two steps). 
 
1H NMR (400 MHz, CDCl3, COSY, HSQC, rotamers): δ 1.66-1.73 (m, 2H, H-3’),1.83 (dm, 2H, 
H-4), 1.90-1.98 (m, 4H, H-4, H-6, H-9), 2.00-2.12 (m, 3H, 2H-4’, H-6), 2.13-2.19 (dm, 1H, H-9), 
2.22-2.24 (m, 1H, H-5), 2.28-2.36 (m, 2H, H-2’), 2.42-2.48 (m, 1H, H-7), 2.59-2.68 (m, 1H, H-7), 
2.79 (t, J = 5.6 Hz, 2H, H-7’), 3.41-3.55 (m, 3H, H-3), 3.99 (ddd, J = 12.0, 7.2, 4.8 Hz, 1H, H-3), 
4.21 (br s, 1H, H-1), 4.62 (br s, 1H, H-1), 4.96 (dm, J = 10.0 Hz, 1H, =CH2), 5.03 (dm, J = 16.8 
Hz, 1H, =CH2), 5.42-5.45 (m, 2H, H-5', H-6'), 5.81 (ddt, J = 16.8, 10.0, 6.8, 6.8 Hz, 1H, H-8’). 
 
13C NMR (100.6 MHz, CDCl3, rotamers): δ 23.7, 23.8 (C-5), 24.9 (C-3'), 26.6 (C-4'), 29.0 (C-4), 
30.2 (C-6), 31.4, 31.5 (C-7’), 32.5 (C-9), 32.9, 33.0 (C-2'), 33.8 (C-4), 35.6, 37.2 (C-7), 37.3, 39.8 
(C-3), 57.8, 59.5 (C-1), 114.5 (=CH2), 127.5, 127.6 (C-6’), 130.0, 130.1 (C-5'), 136.9-137.0 (C-
8'), 172.5-173.8 (C-1'), 208.7-210.3 (C-8). 
 
HRMS (ESI) calcd for [C17H25NO2 + H]+: 276.1958, found: 276.1955. 
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BCE system (30). 
 
Schrock catalyst (36 mg, 0.0470 mmol) was added under inert atmosphere to a solution of 43 (15 
mg, 0.0470 mmol) in benzene (5.2 ml), and the mixture was heated to 30 °C for one night, and to 
reflux for additional 24 hours. The reaction was then concentrated under reduced pressure. Flash 
chromatography (hexane to 2:8 EtOAc-hexane) afforded product 30 in traces. 
 
HRMS (ESI) calcd for [C16H24NO + H]+: 246.1852, found: 246.1845. 
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LIST OF ABBREVIATIONS 
 
(CF3)2CHOH 1,1,1,3,3,3-hexafluoro-2-propanol 
(C6H11)2BH dicyclohexylborane 
(CF3CH2O)2P(=O)CH2CO2Me methyl bis(2,2,2-trifluoroethyl)phosphonoacetates 
(CF3CO)2O trifluoroacetic anhydride 
(CH2O)2CH(CH2)3Br 2-(3-bromopropyl)-1,3-dioxolane 
(CH2OH)2 1,2-etanediol 
(COCl)2 oxalyl chloride 
(Z)-Bu3SnCH=CH(CH2)4OTBDPS (1,1-dimethylethyl)(dimethyl){[(5Z)-6-(tributylstannanyl)hex-5-
enyl]oxy}silane 
3TC lamivudine 
9-BBN 9-borabicyclo(3.3.1)nonane  
ABC abacavir 
Ac acetyl 
Ac2O acetic anhydride 
AcOH acetic acid 
AIDS human acquired immunodeficiency syndrome  
AlCl3 aluminium chloride 
AlH3 aluminium hydride  
AllBr allyl bromide 
AllMgBr allyl magnesium bromide 
AllOTIPS (allyloxy)triisopropylsilane 
AllTMS allyltrimethylsilane 
AMP-DNJ N-(5-adamantane-1-yl-methoxypentyl)-1-deoxy-nojirimycin 
Ar aryl 
ART anti-retroviral therapy  
AZT zidovudine 
AZTTP zidovudine triphosphate 
B nucleobase 
BCH-189 dideoxy thiacytidine 
BCl3 boron trichloride 
BF3·Et2O boron trifluoride diethyl etherate 
BH3 borane 
Bn benzyl 
BnBr benzyl bromide 
BnNH2 benzylamine  
Boc t-butyloxycarbonyl  
Boc2O di-t-butyl dicarbonate  
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BSA N,O-bis(trimethylsilyl)acetamide  
Bu buthyl 
BVDV bovine viral diarrhea virus 
Bz benzoyl 
Bz2O benzoic anhydride 
BzCl benzoyl chloride 
C6H5 phenyl 
C6H5SeCl phenylselenenyl chloride 
CaCO3 calcium carbonate 
CAN ceric ammonium nitrate 
CBr4 carbon tetrabromide 
CBz benzyloxycarbonyl  
Cbz carboxybenzyl  
CbzCl benzyl chloroformate  
CbzCl benzyl chloroformate  
CCR5 C-C chemokine receptor type 5 
CD4 cluster of differentiation 4  
CDCl3 deuterated chloroform 
CH2(CN)CO2Et ethyl cyanoacrylate  
CH2(CN)CO2Et ethyl cyanoacrylate  
CH2Cl2 dichloromethane 
CHCl3 chloroform 
ClCO2Me methyl chloroformate 
CO carbon monoxide 
CO2Me methoxy carbonyl 
CoA coenzyme A 
COSY correlation spectroscopy 
Cp2TiCl2 bis(cyclopentadienyl)titanium(IV) dichloride 
Cp2TiMe2 Petasis reagent 
CRIs co-receptor inhibitors  
Cs2CO3 caesium carbonate 
CsF caesium fluoride 
CuCl copper(I) chloride 
CuI copper(I) iodide 
CuOOH cumene hydroperoxide 
CXCR4 C-X-C chemokine receptor type 4 
Cy cyclohexyl 
d4T stavudine 
DAB 1,4-dideoxy-1,4-imino-D-arabinitol 
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene  
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DCC N,N'-dicyclohexylcarbodiimide 
dCK deoxycytidine kinase  
DCM dichloromethane 
ddc zalcitabine 
ddI didanosine 
DDQ 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
DEAD diethyl azodicarboxylate  
DET diethyl tartrate 
DIBAH diisobutylaluminium hydride  
DIBAL-H diisobutylaluminium hydride 
DIPEA N,N-diisopropylethylamine 
DMAP 4-dimethylaminopyridine 
DMDP 2,5-dideoxy-2,5-imino-D-mannitol 
DME dimethoxyethane 
DMF dimethylformamide 
DMP Dess-Martin periodinane 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DNJ 1-deoxy-nojirimycin 
dNTP deoxynucleotide triphosphates 
dr diastereoisomeric ratio 
EC50 half maximal effective concentration 
EDCI 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
ee enantiomeric excess 
env envelope 
ERG electron releasing group  
ESI electrospray ionization mass spectrometry 
Et ethyl 
Et2O diethyl ether 
Et3N triethylamine 
Et3SiH triethylsilane 
Et3SiI triethylsilyl iodide 
EtOAc ethyl acetate 
EtOH ethanol 
E-TP emtricitabine triphosphate 
EWG electron withdrawing group  
FDA Food and Drug Administration  
FIs fusion inhibitors  
FTC emtricitabine 
FT-IR Fourier transform infrared spectroscopy 
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gag group-specific antigen 
GBA glucocerebrosidase 
GCase lysosomal β-glucosidase 
GCS glucosyl ceramide synthase 
GlcCer glucosylceramide 
GM monosialodihexosylganglioside 
gp glycoprotein 
GSL glycosphingolipid 
H2 hydrogen 
H2NNH2 hydrazine  
H2O2 hydrogen peroxide solution (30 wt. % in H2O)  
H2SO4 sulfuric acid 
HAART highly active anti-retroviral therapy  
HBr hydrobromic acid 
HBV hepatitis B virus 
HC≡CCH2Br 3-bromoprop-1-yne 
HCHO formaldehyde 
HCl hydrochloric acid 
HCO2H formic acid 
HCONH2 formamide 
HCV hepatitis C virus 
Hg(OCOCF3)2 mercury(II) trifluoroacetate 
HI hydroiodic acid 
HIV human immunodeficiency virus 
HMPA hexamethylphosphoramide 
HNJ homonojirimycin 
HOBt hydroxybenzotriazole 
HPLC high performance liquid chromatography 
HRMS high-resolution mass spectrometry 
HSAB hard and soft acids and bases 
HSQC heteronuclear single quantum coherence 
HWE Horner-Wadsworth-Emmons 
HWE-SGM Horner-Wadsworth-Emmons Still-Gennari modification 
I2 iodine 
IC50 half maximal inhibitory concentration 
IN integrase 
INIs integrase inhibitors  
i-Pr2EtN N,N-diisopropylethylamine  
i-PrMgCl isopropylmagnesium chloride 
IUPAC international union of pure and applied chemistry 
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K2CO3 potassium carbonate 
K2HPO4 dipotassium phosphate 
KEX potassium ethyl xanthate 
KHCO3 potassium bicarbonate 
KHMDS potassium bis(trimethylsilyl)amide 
KMnO4 potassium permanganate 
KOH potassium hydroxide 
LDA lithium diisopropylamide 
LiAlH4 lithium aluminium hydride 
LiBH4 lithium borohydride 
LiBr lithium bromide 
LiCl lithium chloride 
LiHMDS lithium bis(trimethylsilyl)amide 
LiOH litium hydroxide 
m.p. melting point 
Mbs p-methoxybenzenesulfonyl 
m-CPBA m-chloroperoxybenzoic acid  
Me methyl 
Me methyl 
Me2S dimethyl sulfide 
Me3P trimethylphosphine 
MeC(OMe)3 1,1,1-trimethoxyethane 
MeCN acetonitrile 
MeCO2Cl methyl chloroformate 
Me-DNJ N-methyl-1-deoxy-nojirimycin 
MeLi methyllitium 
MeNHOMe·HCl N,O-dimethylhydroxylamine hydrochloride  
MeOD deuterated methanol 
MeOH methanol 
MePPh3Br methyltriphenylphosphonium bromide 
MeSO3H methanesulfonic acid 
MgSO4 magnesium sulfate 
MOM methoxymethyl 
MOMCl chloromethyl methyl ether 
Ms mesyl 
MS mass spectra 
MsCl methanesulfonyl chloride 
N3 azide 
Na2S2O3  sodium thiosulfate 
Na2SO4 sodium sulfate 
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NaBH(OAc)3 sodium triacetoxyborohydride  
NaBH3CN sodium cyanoborohydride 
NaBH4 sodium borohydride 
NaCl sodium chloride 
NaH sodium hydride  
NaHCO3 sodium bicarbonate 
NaHMDS sodium bis(trimethylsilyl)amide 
NaI sodium iodide 
NaIO4 sodium periodate 
NaN3 sodium azide 
NaOAc sodium acetate 
NaOEt sodium ethoxide 
NaOH sodium hydroxide 
NaOMe sodium methoxide 
Napht naphtalene 
NAs nucleoside analogues 
NB-DNJ N-butyl-1-deoxy-nojirimycin 
n-BuBr 1-bromobutane 
n-BuLi n-butyllithium 
NCCH2CO2H cyanoacetic acid  
NH2OCH2Ph O-benzylhydroxylamine 
NH2OH·HCl hydroxylamine hydrochloride 
NH3 ammonia 
NH4Cl ammonium chloride 
NH4OH ammonium hydroxide 
NJ nojirimycin 
NMO N-methylmorpholine oxide 
NMR nuclear magnetic resonance 
NN-DNJ N-nonyl-1-deoxy-nojirimycin 
NNRTIs non-nucleoside reverse transcriptase inhibitors 
NRTIs nucleoside reverse transcriptase inhibitors 
Ns nosyl 
NsCl nosyl chloride 
NtRTIs nucleotide reverse transcriptase inhibitors  
Nu- nucleophile 
o-(OH)C6H4CHO salicylaldehyde 
o.y. overall yield 
o-C6H4(CH2OH)2 1,2-benzenedimethanol 
OH hydroxyl 
OsO4 osmium tetroxide  
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P2O5 phosphorus pentoxide 
Pb(OAc)4 lead(IV) acetate 
p-BrC6H4SO2Cl 4-bromobenzenesulfonyl chloride 
PCC pyridinium chlorochromate  
Pd(dba)2 bis(dibenzylideneacetone)palladium(0)  
Pd(OCOCF3)2 palladium(II) trifluoroacetate 
Pd(OH)2 palladium hydroxide 
Pd/C palladium on carbon 
Pd2dba3·CHCl3 tris(dibenzylideneacetone)dipalladium(0)-chloroform adduct 
PDC pyridinium dichromate 
PdCl2 palladium(II) chloride 
Ph phenyl 
Ph3P triphenylphosphine  
Ph3PCH3Br methyltriphenylphosphonium bromide 
PhI(OAc)2 (diacetoxyiodo)benzene 
PhSH thiophenol 
PhthNH phthalimide 
PIs protease inhibitors  
PMB 4-methoxybenzyl 
PMB cells primary human lymphocytes 
PMBCl 4-methoxybenzyl chloride 
PMe3 trimethylphosphine 
PMHS polymethylsiloxane 
pol polymerase 
pol γ DNA polimerase γ 
PPh3 triphenyl phosphine 
PPTS pyridinium p-toluenesulfonate  
PR protease 
p-TsOH 4-toluenesulfonic acid 
py pyridine 
PyBOP (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate  
RCM ring-closing metathesis 
rev regulator of expression of virion proteins 
Rf retardation factor 
RNA ribonucleic acid 
Rnase ribonuclease 
RT reverse transcriptase  
rt room temperature 
SAP sphingolipid activator protein 
SES trimethylsilylethylsulfonyl 
261 
 
SiO2 silicon dioxide 
SN2 bimolecular nucleophilic substitution 
SnCl4 tin(IV) tetrachloride 
SOCl2 thionyl chloride 
SRT substrate reduction therapy 
tat trans-activator of transcription 
TBAF tetra-n-butylammonium fluoride 
TBAI tetrabutylammonium iodide 
TBDMS tert-butyldimethylsilyl 
TBDMSCl t-butyldimethylsilyl chloride 
TBDMSOTf t-butyldimethylsilyl trifluoromethanesulfonate  
TBDPS tert-butyldiphenylsilyl 
TBDPSCl tert-butyldiphenylsilyl chloride 
t-BuCO2H pivalic acid 
t-BuOK potassium t-butoxide 
t-BuOMe methyl tert-butyl ether 
TEA triethylamine 
Teoc 2-(trimethylsilyl)ethoxycarbonyloxy 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
Ti(Oi-Pr)4 titanium(IV) isopropoxide  
TiCl3 titanium(III) chloride 
TiCl4 titanium(IV) chloride 
TIPS triisopropylsilyl 
TLC thin-layer chromatography 
TMS trimethylsilyl  
TMSCl chlorotrimethylsilane  
TMSI trimethylsilyl iodide 
TMSOTf trimethylsilyl trifluoromethanesulfonate  
TosMIC p-toluenesulfonylmethyl isocyanide 
TsCl 4-toluenesulfonyl chloride 
ZDV zidovudine 
ZrCl4 zirconium(IV) chloride 
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